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ABSTRACT
Work has been undertaken to characterise an amplicon on 
chromosome 17 in a non-small cell lung carcinoma cell line, CALU-3. There 
are a number of different genes in this region which have been implicated in 
tumorigenesis. These include topoisomerase I la  (TOPO Ila ) , ERBB2, 
NM23H1 and retinoic acid receptor alpha (RARa) genes. Topoisomerase I la  
is also a target for numerous anti-cancer drugs, such as VP16 and doxorubicin. 
Changes in the expression of topoisomerase I la  have been seen to have an 
effect on the response of cells to such topoisomerase II inhibitors, with 
overexpression causing sensitivity and reduced expression causing resistance 
to these agents. Therefore, CALU-3 is of interest as a model to study the 
genetic changes which have occurred around the topoisomerase I la  locus.
Southern hybridisation was initially used to investigate which 
genes were within the amplicon. From this analysis it was confirmed that the 
TOPO Ila  and ERBB2 genes were amplified and discovered that the RARa 
and G-CSF genes were also involved in the amplicon. Fluorescence in situ 
hybridisation (FISH) has subsequently been performed with CALU-3 to 
visualise the extent and structure of amplification for the different genes and 
to find any other cytogenetic changes which may have occurred to 
chromosome 17. New cosmid probes for TOPO Ila , RARa, NM23H1 and 
NFI genes have been developed from an Imperial Cancer Research Fund 
Reference Library-Database chromosome 17 library, for use in FISH analysis. 
By using a flow-sorted whole chromosome 17 paint, seven regions of 
hybridisation were observed in CALU-3. None of these regions covered an 
entire chromosome. Five chromosome 17-specific centromere sequences 
were also detected in CALU-3. It has been discovered that CALU-3 carries 
three large regions of TOPO I la  and ERBB2 gene amplification, residing on 
three separate chromosomes. The RARa gene has also been found to be 
amplified on the same three regions, although not as highly as TOPO I la  or 
ERBB2. Counts of hybridisation signals indicate that CALU-3 has at least 
eight copies of RARa. A cosmid containing sequences thought to be in the 
region of the BRCA1 gene has been used and this appears to be amplified in 
CALU-3 at a similar level to RARa. Five copies of both NFI and NM23H1 
genes were also found, each associated with a chromosome 17 centromere 
sequence. The NM23H1 gene also appears to be inverted since it is seen in 
close association to the centromere. Therefore, in CALU-3 there appears to 
have been some gross changes to chromosome 17, including numerous
x
translocations, as well as the formation of an amplicon involving at least five 
genes on 17q.
Expression analysis using W estern b lo tting  and 
immunofluorescence has confirmed that amplification of TOPO I la  and 
ERBB2 genes in CALU-3 can be correlated with the high expression of 
topoisomerase Ila  and erbB2 proteins. No alterations were found to the 
expected location of either of these proteins in CALU-3, as shown by 
immunofluorescence, with topoisomerase I la  present in the nucleoplasm and 
erbB2 detected in the cell membrane. Flow cytometry has shown that the 
topoisomerase I la  protein from CALU-3 still appears to be cell cycle 
regulated. The topoisomerase II enzyme in CALU-3 is also still sensitive to 
inhibition, as has been demonstrated by the addition of VP16 to biochemical 
assays of topoisomerase II activity. More specifically, the topoisomerase II a  
isozyme is still capable of being stabilised in a drug/enzyme/DNA complex by 
VP 16, as shown by band depletion assay.
CALU-3 is very sensitive to treatment with topoisomerase II 
inhibitors and it seems likely that this is as a result of amplification and 
overexpression of the topoisomerase I la  gene. There is an obvious clinical 
interest in this relationship since topoisomerase II inhibitors are commonly 
used in the treatment of a variety of cancers. However, resistance to these 
agents is a major problem in tumour treatment. Therefore, a resistant cell line 
was derived by exposure to VP16, from a sensitive CALU-3 clone (clone 4) 
and analysed for possible mechanisms of drug resistance. A cell line was 
subsequently derived which was resistant to 10~^MVP16, as well as being 
cross-resistant to doxorubicin and vincristine. Western analysis of CALU- 
3/10‘^ M VP16 showed no difference in topoisomerase I la  expression when 
compared to the parental clone. Subsequent biochemical assays also found no 
difference in catalytic activity between the CALU-3 clone 4 and CALU-3/10' 
VP16. Row cytometry was then performed to analyse P-glycoprotein 
expression levels in the two cell lines. No expression of this drug efflux pump 
was found in either parental or resistant lines. Expression of the atypical drug 
resistance associated protein, MRP, was then investigated using a polyclonal 
antiserum from Dr. Melvin Center. By Western blot analysis it appeared that 
CALU-3/ lO'^M VP16 overexpressed MRP when compared to the parental 
cell line. This result was confirmed by independent analysis of a Western blot 
with a monoclonal antibody against MRP by Dr. Susan Cole in Ontario, 
Canada. Therefore, it appears that MRP may play a role in the mechanism of 
drug resistance in CALU-3/10‘^ M VP16.
xi
CHAPTER 1
GENERAL INTRODUCTION
Cell division and gene expression both involve alterations to 
the topological nature of the DNA helix. For example, during chromosome 
segregation, recombination products must be resolved through breakage and 
rejoining of the double helix, thus allowing strand passage. Also, to allow 
gene expression, sister DNA strands must be separated to create access for 
transcription machinery. In eukaryotic cells, changes in DNA topology 
through strand breakage and reunion are regulated by topoisomerase enzymes. 
Mammalian topoisomerases are classified into two groups, based on their 
mechanism of action and referred to as type I and type II reviewed in Wang, 
1985. Both classes of topoisomerase are also targets for a number of anti­
cancer agents (Liu, 1989; Smith, 1990;Takano eta l., 1992).
Topoisomerase I
Topoisomerase I is a lOOkD protein, encoded by a gene that 
has been mapped to chromosome|20qll.2-ql3.1(Kunze et al., 1989). This 
enzyme only cleaves a single strand of the DNA duplex, without the 
requirement of ATP, and is thought to be involved in the relaxation of DNA 
supercoils, such as might occur ahead of replication forks(Wang, 1991). 
Topoisomerase I has been found associated with the nucleoli of cells 
(Fleischmann et al., 1984; Muller et al., 1985), which is the site of 
transcription by RNA polymerase I. Therefore, it has been proposed that 
topoisomerase I is somehow involved specifically in the transcription of 
ribosomal RNA genes (Muller et al., 1985). Topoisomerase I has also been 
found to be associated with active regions of DNA transcription, as observed 
in heat-shock induced DNA puffs in the giant polytene chromosomes from 
iDrosophila salivary glands (Fleischmann et al., 1984). The structure of the 
promoter of the topoisomerase I gene (TOPO I) has been characterised (Kunze 
et al., 1990; Kunze et al., 1991). The promoter region is found to be rich in 
GC content, a feature often associated with housekeeping genes, and lacks 
TATA and CCA AT elements which are usually present in promoter regions of 
regulated genes. Binding sites for a number of transcription factors, such as 
Spl and octamer transcription factor 1, have been localised to the 5'-flanking 
region of the TOPO I gene. In addition to these binding sites, a putative
1
cAMP-responsive element was also found (Kunze et al., 1990; Kunze et al.,
1991). The importance of these regulatory elements was seen in CAT reporter 
gene assays as most of the in vitro transcriptional activity from the TOPO I 
gene was abolished when the region containing these binding sites was deleted 
(Kunze et al., 1991). It has also been found that purified topoisomerase I can 
be activated by protein kinase C phosphorylation (Pommier et al., 1990).
Topoisomerase II
Two forms of topoisomerase II have been reported, alpha (a) 
and beta (p) (Chung et al., 1989; Drake et al., 1987; Wang, 1985). The two 
topoisomerase II isoforms are coded for by separate genes, TOPO Ila  on 
chromosome 17q (Tsai-Plugfelder et al., 1988) and TOPO II (3 on chromosome 
3p (Jenkins et al., 1992; Tan et al., 1992). The TOPO I la  gene encodes a 
170kD protein, whereas the TOPO Up gene encodes a 180kD protein. At the 
protein level, the isoforms exhibit a 72% homology (Jenkins et al., 1992). 
More details concerning the expression, cell cycle regulation and the 
subcellular localisation of the topoisomerase lip isozyme are given in Chapter 
5. The topoisomerase Ila  isoform is known to be cell cycle regulated, with an 
increased expression of the enzyme being observed at the G2/M phase of the 
normal cell cycle (Kaufmann et al., 1991; Prosperi et al., 1994; Prosperi et al.,
1992). The following section on the role, mechanisms of regulation and 
catalytic cycle of topoisomerase II all refer to the Ila  form, although this does 
not necessarily exclude the possibility that the same applies to the beta 
enzyme.
The Catalytic Cycle of Topoisomerase II
An outline of the topoisomerase II catalytic cycle is shown in 
Figure 1A. The initial stage of the cycle involves recognition and binding of 
topoisomerase II molecules to a region of the DNA duplex. Two 
topoisomerase II molecules bind as a homodimer to supercoiled DNA. The 
actual binding properties of topoisomerase II are poorly understood, although 
it has been observed that the enzyme appears to bind preferentially to 
supercoiled DNA (Zechiedrich & Osheroff, 1990), especially in the region of 
DNA crossovers. It has also been shown that topoisomerase II recognises 
specific regions of secondary structure in DNA duplexes (Froelich-Ammon et 
al., 1994). Using transcriptional footprinting, topoisomerase II was observed 
to protect a 28 bp region of RNA, with a more strongly protected central 22 bp
2
Figure 1A
The Catalytic Cycle of Topoisomerase II
This diagram shows the basic steps in the catalytic cycle of 
topoisomerase II, beginning with recognition and binding of a 
topoisomerase II homodimer to a region of dsDNA. 
Topoisomerase II cleaves the DNA (pre-strand passage 
cleavage/religation) creating a gate through which the sister DNA 
molecule can pass (strand passage). The gap in the DNA backbone 
is then sealed by the topoisomerase (religation), following which 
the enzyme is turned over and is capable of releasing the dsDNA 
and binding to another region (enzyme turnover).
See text for full details of the catalytic cycle.
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region (Thomsen et al., 1990). It was therefore hypothesised that the two 
topoisomerase II protein molecules bind to DNA with a 3 bp displacement at 
either end, as shown:
3bp
Following binding of the topoisomerase homodimer to the 
DNA duplex, an reaction equilibrium is established between cleavage and 
religation of the DNA. The equilibrium favours the religation reaction. For 
the pre-strand cleavage stage of the catalytic cycle to occur there is an 
absolute requirement for a divalent cation, such as magnesium (Osheroff, 
1987). This study demonstrated that magnesium ions were required for 
relaxation and cleavage of DNA by Drosophila topoisomerase II, as well as 
being necessary for ATP hydrolysis with this enzyme. No evidence was 
found for the involvement of magnesium ions in the initial binding reaction. 
When the availability of magnesium ions is limited by inclusion of excess 
EDTA in the reaction, or other divalent ions such as calcium or cobalt are 
substituted for magnesium, the enzyme is found to only cleave one strand of 
DNA rather than two (Lee et al., 1989). Therefore, it appears that DNA 
cleavage involves the topoisomerase II nicking each strand (Zechiedrich et al., 
1989) thus creating a staggered double-strand break, with a 5'-end 4 base-pair 
overhang. The topoisomerase II molecule becomes covalently linked to the 
5'-phosphoryl end of the DNA at this stage (Wang, 1985). Observation of 
topoisomerase II cleaved linear DNA using electron microscopy has shown 
association of individual topoisomerase II subunits with the ends of DNA 
molecules (Zechiedrich et al., 1989), thus it was proposed that the individual 
subunits each create a nick in the duplex thus producing the double-stranded 
gap for passage of the sister DNA duplex. Numerous experiments have been 
carried out to investigate consensus sequences for topoisomerase II cleavage 
(Capranico et al., 1990; Fosse et al., 1991; Freudenreich & Kreuzer, 1993; 
Pommier et al., 1991; Sander & Hsieh, 1985). From these investigations, 
cleavage consensus sequences have been suggested, but no one sequence 
agrees with all the others. These studies did find, however, that there appear 
to be two types of cleavage site, strong and weak, with the stronger sites 
showing more homology with the consensus than weak sites. It is notable that 
all consensus sequences which have been suggested are asymmetric and
3
would therefore require the topoisomerase enzyme to cleave between different 
nucleotides on each of the sister strands of the DNA duplex. It also appears 
that the enzyme can distinguish between the sequences of the two strands 
(Andersen et al., 1989), with the non-coding strand being preferentially 
cleaved over the coding strand. It should be pointed out, however, that most 
of the cleavage studies using mammalian topoisomerase II have been 
performed in the presence of drug since the actual cleavage reaction is 
extremely transient. Therefore, it is not known whether the consensus 
sequences that have proposed would act as such under normal cellular 
conditions.
Once the topoisomerase II enzyme has created a double-strand 
gap in the DNA backbone, passage of the sister DNA molecule can occur 
through this gap. This strand passage event is entirely dependent on the 
presence of magnesium and ATP, although hydrolysis of ATP does not occur 
at this stage of the cycle since non-hydrolysable analogues of ATP will allow 
one cycle of strand passage (Osheroff, 1987; Osheroff et al., 1991). Although 
it was known that type II topoisomerases required ATP for their action almost 
from the moment of their discovery (Hsieh & Brutlag, 1980; Liu et al., 1980) 
it was not known what function the ATP performed, or when it was bound. 
Recently it has been proposed that the ATP molecule actually causes a 
conformational change in the topoisomerase homodimer (Lindsley & Wang, 
1991). This finding has led to a model suggesting that topoisomerase II acts 
as an ATP-dependent protein clamp (Roca & Wang, 1992), as depicted below.
 ►
+ ATPCleaved DNA Strand
Transported DNA Strand
from Roca & Wang, 1992
This model was based on the finding that binding of topoisomerase II to a 
non-hydrolysable analogue of ATP triggers conformational change in the 
homodimer which limits the enzymes' binding to only linear and not circular 
DNA forms. Therefore, prior to the binding of ATP, it is proposed that the 
topoisomerase II molecule exists as an open complex ready to accept a second 
DNA duplex . On binding of the ATP, however, the molecule closes, trapping 
the second strand, which can then be passed through the gate in the cleaved
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strand. The problem still exists, however, as to how the transported DNA 
strand escapes from being held by the topoisomerase II. Recent experiments 
using a non-hydrolysable analogue of ATP, which seals the DNA strand-entry 
gate because it cannot be hydrolysed, have shown that relaxed DNA can still 
exit from the topoisomerase II molecule (Roca & Wang, 1994). This suggests 
that there is a second gate, at the opposite end of the topoisomerase II 
homodimer to the strand entry gate, through which transported DNA duplexes 
can be released.
Following strand passage, the post-strand passage religation 
must occur to seal the gate created in the DNA duplex. Again, an equilibrium 
exists at this stage between cleavage and religation. This phase of the 
catalytic cycle has been difficult to study due to the lack of means for isolating 
intermediates following strand passage and before enzyme turnover. Use of 
non-hydrolysable ATP analogues, however, which will support strand passage 
but not enzyme turnover, has enabled some study of this step (Robinson & 
Osheroff, 1991). The equilibrium at this stage has been found to/slightly more 
in favour of cleavage, although it is not clear why this should be so. It may be 
that the stability of the cleaved DNA at this stage allows release of the second 
DNA duplex prior to religation of the bound DNA duplex.
The final stages of the topoisomerase II catalytic cycle involve 
hydrolysis of the bound ATP and turnover of the enzyme. Topoisomerase II 
has intrinsic ATPase activity, but this activity is seen to be stimulated 
approximately 20-fold by the presence of DNA (Lindsley & Wang, 1993). As 
has already been hinted at, ATP hydrolysis is required for enzyme turnover. It 
appears that enzyme turnover regenerates the active conformation of the 
topoisomerase II molecule, and also allows the enzyme to dissociate from the 
DNA (Osheroff etal., 1991).
Role of Topoisomerase II in the Cell
Mammalian topoisomerase II was previously identified as a 
major component in the metaphase chromosome scaffold (Boy de la Tour & 
Laemmli, 1988; Earnshaw & Heck, 1985; Gasser & Laemmli, 1986), 
representing l%-2% of the total mitotic chromosomal protein. In particular, 
the enzyme was found to be associated at or near the base of chromatin loops 
(Earnshaw & Heck, 1985; Gasser et al., 1986). The findings of these early 
experiments pointed to the idea that topoisomerase II may be involved in the 
organisation of the higher order structure of the chromatin. The base of 
chromatin loops are thought to be defined by specific sequences, known as
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scaffold-associated regions (or SARs). These sequences are found to be A-T 
rich, and have a high frequency of potential topoisomerase II binding sites 
(Cockerill & Garrard, 1986; Gasser & Laemmli, 1986). It was subsequently 
shown in vitro that topoisomerase II did bind specifically to these SAR 
sequences (Adachi et al., 1989). Recently, topoisomerase II cleavage sites 
have been found in an SAR from the Drosophila histone gene repeat (Kas & 
Laemmli, 1992). This discovery thus strengthened the idea that 
topoisomerase II plays some kind of structural role in the organisation of 
mitotic chromosomes. Indeed when decondensed mitotic chromosomes are 
incubated with anti-topoisomerase II antibodies the scaffold can be clearly 
seen in a helical array (Boy de la Tour & Laemmli, 1988), with the sister 
chromatids related by mirror-symmetry. A recent study of metaphase 
chromosome structure (Saitoh & Laemmli, 1994) also found that staining with 
anti-topoisomerase II antibodies produced a helical banding pattern which 
appeared to be localised to A-T rich regions of DNA.
One of the first observed roles for topoisomerase II in vivo was 
that of the segregation of daughter molecules at the end of DNA replication 
(DiNardo et al., 1984). This was discovered by using a temperature-sensitive 
budding yeast mutant which was defective in topoisomerase II activity when 
grown at 37°C. At this temperature, the mutant yeast cells were observed to 
arrest during nuclear division. The nucleus in the arrested cells was seen to be 
located in the neck between the parent cell and the daughter bud. This arrest 
at cell division pointed to the requirement of topoisomerase II for separation 
of the newly synthesised daughter DNA molecules. Further experiments 
using temperature sensitive topoisomerase II yeast mutants have confirmed 
this hypothesis (Holm et al., 1989) and have also suggested a role for 
topoisomerase II in preventing the breakage and nondisjunction of 
chromosomes.
Experiments involving the reconstitution of nuclei in vitro 
showed that topoisomerase II appeared to be involved in the condensation of 
DNA (Newport, 1987). In this study, cytoplasmic nuclear reformation 
extracts were prepared from Xenopus oocytes. Deproteinised lambda DNA 
added to these extracts were seen to be packaged into replica eukaryotic 
nuclei, which were subsequently capable of replication. Topoisomerase II 
inhibitors added to the system prevented the formation of highly condensed 
chromosome structures. The same result was observed when eukaryotic 
interphase nuclei were added to the reformation extract (Newport & Spann, 
1987). It is not clear, however, if this blockage is due to specific inhibition of 
topoisomerase II, or a non-specific effect of the drug treatment. The role of
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topoisomerase II in chromosome condensation has also been shown in 
temperature-sensitive yeast mutants (Uemura et al., 1987) with growth at the 
non-permissive temperature resulting in production of long, entangled 
chromosomes. Condensation of chromosomes was seen to occur if cells were 
transferred to the permissive growth temperature. This study also showed the 
requirement for topoisomerase II at chromosome separation by only allowing 
the expression of topoisomerase II at certain stages after chromosome 
condensation. By using a double mutant of spindle formation and 
topoisomerase II, it was shown that even if spindle formation was allowed and 
topoisomerase II was inactivated, abberant chromosomes were still produced 
(Uemura et al., 1987). Even if topoisomerase II was active in short pulses 
during chromosome separation, chromosome disjunction was still seen. It has 
also been shown in chick erythrocyte cells that the degree of condensation of 
interphase nuclear material correlates with topoisomerase II level (Wood & 
Earnshaw, 1990). In a different study using Xenopus mitotic extract, HeLa 
cell nuclei and chick erythrocyte nuclei (Adachi et al., 1991), the degree of 
chromosome condensation was analysed in topoisomerase II-depleted 
extracts. The chick erythrocyte nuclei, which have a low endogenous level of 
topoisomerase II, failed to produce condensed chromosomes in the depleted 
extracts. Chromosome condensation did occur, however, when purified 
topoisomerase II was added.
Therefore, from data on the role of topoisomerase II in vivo, it 
would appear that this enzyme is involved in the higher structural organisation 
of chromosomes. There is also good evidence that the processes of 
chromosomal segregation and condensation require topoisomerase II. It has 
also been shown that topoisomerase II appears to play a role in illegitimate 
recombination (Bae et al., 1988; Sperry et al., 1989) and the stability of 
regions of DNA encoding ribosomal genes (Kim & Wang, 1989). The 
involvement of topoisomerase II in these processes indicates that intimate 
topological manipulation of the DNA is required in order for them to occur 
normally. Thus it is now known that topoisomerase II is vital for certain 
cellular functions, particularly at cell division.
Phosphorylation of Topoisomerase II
Phosphorylation is one way of post-translational processing of 
proteins that can be used to regulate enzymatic activity. In vitro experiments 
have shown that topoisomerase II can be phosphorylated by casein kinase II, 
protein kinase C, Ca2+ /calmodulin-dependent protein kinase and p34cdc2
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kinase (Ackerman et al., 1985; Cardenas et al., 1992; Sahyoun et al., 1986). 
The phosphorylated enzyme was found to have an approximate 3-fold 
stimulation of relaxation activity compared to dephosphorylated (Ackerman et 
al., 1985). It was later shown that topoisomerase II existed as a 
phosphoprotein in vivo in phorbol-stimulated dissociated sponge cells 
(Rottmann et al., 1987) and in Drosophila (Ackerman et al., 1988). In 
Drosophila it appeared as if casein kinase II was the main phosphorylating 
enzyme of topoisomerase II, whereas in Geodia cells, protein kinase C 
appeared to be responsible for the topoisomerase II phosphorylation. In the 
sponge system, phosphorylated topoisomerase II was found to be 2.5-fold 
more active in relaxation assays than non-phosphorylated enzyme (Rottmann 
et al., 1987). It is now thought that casein kinase II is the major kinase 
responsible for phosphorylation of topoisomerase II in vivo since this kinase 
has been co-purified with yeast topoisomerase II (Bojanowski et al., 1993; 
Cardenas et al., 1993) and is capable of re-activating dephosphorylated 
enzyme. Also, yeast mutants which have temperature-sensitive casein kinase 
II activity show little phosphorylation of topoisomerase II when grown at the 
nonpermissive temperature (Cardenas et al., 1992). Dephosphorylated yeast 
topoisomerase II has also been shown to be unable to decatenate kinetoplast 
DNA (Cardenas et al., 1993). In yeast, it has been demonstrated that casein 
kinase II sites are more highly modified in metaphase than in G1 (Cardenas et 
al., 1992). A study of topoisomerase II phosphorylation in mammalian cells 
has shown that topoisomerase II is phosphorylated maximally at M-phase 
which was also shown to be the stage at which topoisomerase II had maximal 
cleavage activity (Burden et al., 1993). It has been proposed that prior to 
phosphorylation the topoisomerase II homodimer exists in a negative 
conformation which requires phosphorylation of particular C-terminal 
residues to possibly alter the conformation of the enzyme thus making it 
active (Cardenas & Gasser, 1993).
Genetic Regulation of Topoisomerase II Expression
Until recently, little was known about the how the expression 
of mammalian topoisomerase II genes was regulated. It has now been 
discovered that the 5'-flanking region of the human TOPO Ila  gene exhibits 
promoter activity (Hochhauser et al., 1992). A number of potential 
transcription factor binding sites were found upstream of the translation start 
site, including two Spl factor binding sites, a consensus site for ATF binding 
and five inverted CCA AT boxes (Hochhauser et al., 1992). Such sequences
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have also been found in the 5' regions of other proliferation-controlled genes, 
including the gene for thymidine kinase and DNA polymerase a  (Knight et 
al., 1987; Pearson et al., 1991). The pattern of transcription produced by 
deletion fragments in CAT assays also indicated that negative regulatory 
elements are found towards the 5'-end of the isolated promoter fragment 
(Hochhauser et al., 1992). Recent analysis of the topoisomerase II promoter 
region has shown that there may be a phorbol regulatory region present 
(Loflin et al., 1994). Initial evidence for phorbol regulation of topoisomerase 
Ha expression came from the discovery that topoisomerase I la  mRNA was 
down-regulated in a human leukaemia cell line, HL-60 when cells were 
treated with the phorbol ester phorbol 12-myristate 13-acetate (PMA) 
(Zwelling et al., 1988). This down-regulation was not observed in a cell line 
derived from HL-60 which is refractory to differentiation using PMA 
(Zwelling et al., 1990a). Analysis of the topoisomerase I la  promoter in the 
parent and derived cell line, however, has shown that there are no mutations of 
this region, but that there is an alteration in methylation pattern of the 
promoter region between differentiation-sensitive and resistant cells (Loflin et 
al., 1994). This methylation may be specific to a phorbol-regulatory region 
and therefore have an effect on topoisomerase I la  transcription in the 
differentiation-resistant cell line.
Drug Interactions with Topoisomerase II
The topoisomerase II enzyme has been identified as the target 
for a number of commonly used chemotherapeutic agents (Liu, 1989; Smith, 
1990; Takano et al., 1992). There are two major types of topoisomerase 
inhibitors, those that intercalate with DNA and those that do not. Intercalative 
agents include drugs such as the acridine mAMSA, non-intercalators include 
the epipodophyllotoxins VP16 and VM26. These three drugs all appear to 
cause topoisomerase II inhibition by stabilisation of the cleavable complex by 
forming a nonproductive drug-enzyme-DNA complex. Studies investigating 
topoisomerase II cleavage in the presence of mAMSA or VM26 show that 
there are DNA base sequence preferences for the binding of each of these 
particular drugs (Pommier et al., 1991) which suggests that the drugs may 
intercalate into the DNA backbone flanking the cleavage site. It is still not 
clear, however, how the presence of these complexes actually brings about 
cell death. A new class of inhibitors has also recently been discovered, bis(2, 
6-dioxopiperazine) derivatives, which appear to inhibit the catalytic activity of
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topoisomerase II without forming a stabilised drug-enzyme-DNA complex 
(Ishida etal., 1991;Tanabe etal., 1991).
Once it was known that anti-tumour agents targeted the 
topoisomerase II enzyme, people began to investigate whether topoisomerase 
II levels in cells corresponded to response of those cells to anti-tumour drugs 
(Davies et al., 1988; Fry et al., 1991; Potmesil et al., 1988; Webb et al., 
1991). The take-home message from all these studies was that low levels of 
topoisomerase II in cells corresponded to resistance to topoisomerase II 
inhibitors and high levels of topoisomerase II led to increased sensitivity to 
inhibitors. It could therefore be postulated that, since not all tumours respond 
to treatment with topoisomerase II inhibitors, some of the resistance to anti- 
tumour agents seen in the clinic may be due to alterations in topoisomerase II 
expression in tumours. There have been many studies of in vitro derived drug 
resistant cell lines (Beck et al., 1993a; Beck et al., 1993b; Bugg et al., 1991; 
de Jong et al., 1993; Friche et al., 1992; Hinds et al., 1991; Long et al., 1991; 
Ritke et al., 1994) in which both alterations in expression and mutations of the 
topoisomerase II molecule have been found. Other mechanisms of drug 
resistance, such as P-glycoprotein and MRP, have also been detected in cell 
lines which are resistant to topoisomerase II inhibitors (Cole et al., 1992; 
Kamath et al., 1992). Therefore, resistance to topoisomerase II inhibitors, at 
least in vitro, may be due to a variety of mechanisms.
Cell Death
As mentioned previously, it is not clearly established how the 
topoisomerase II inhibitors bring about cell death. Recently it has come to 
light that both topoisomerase I and II inhibitors appear to cause apoptosis in 
cells (Bertrand et al., 1991; Solary et al., 1993). When cells are treated with 
topoisomerase II inhibitors, the complex of enzyme-DNA and drug become 
stably bound to the DNA. This leaves the DNA with many double- or single- 
strand breaks which obviously appear as DNA damage to the nuclear 
machinery. Alternatively, it has been suggested that travelling replication 
forks may collide with topoisomerase/drug complexes which are trapped on 
the DNA, and thus cause irreversible stalling of the replication fork (Zhang et 
al., 1990). This may leave exposed regions of single-stranded DNA which 
could appear as DNA damage One possible response to DNA damage in the 
cell is the induction of the p53 protein (Kastan et al., 1991). It has recently 
been shown that the cytotoxicity of various anti-tumour agents, including 
etoposide, is modulated by p53 (Lowe et al., 1993). Interestingly, one of the
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first indications of apoptosis in cells is the appearance of large fragments of 
DNA which result from endonuclease activity within the nucleus 
(Oberhammer et al., 1993). It is thought that these fragments are chromatin 
loops which have been released from the scaffold. Therefore, since there is 
strong evidence that topoisomerase II binds to the base of these loops 
(Cockerill & Garrard, 1986; Gasser & Laemmli, 1986), it would not seem 
unlikely for there to be some co-operation of topoisomerase II in this pathway 
of cell death. Recent studies of drug-sensitive and resistant cells show that c- 
JUN, involved in the response to DNA damage, is activated when drug- 
sensitive cells are treated with VM-26 (Kim & Beck, 1994). Intemucleosomal 
DNA ladders are also observed in the treated cells. Cells resistant to VM-26, 
however, showed an attenuation of both c-JUN induction and formation of 
DNA laddering. Therefore, some features associated with apoptosis are 
observed following topoisomerase II inhibition.
The apoptotic pathway is extremely complex, involving the 
collaboration of many genes (Levine etal., 1994; Williams & Smith, 1993). It 
appears from what has been said above that the inhibition of topoisomerase II 
by drugs such as VP16, indirectly triggers the DNA damage response in cells 
and ultimately programmed cell death. Many of the genes involved in 
apoptosis also participate in the tumorigenic process, by mutation or 
amplification.
Multistage Tumorigenesis
The development of a tumour is known to be a complex 
multistep process involving numerous complex changes to the genome 
(Vogelstein & Kinzler, 1993; Weinberg, 1989). The growth of a normal cell 
is thought to be balanced by two distinct mechanisms. Firstly, cellular 
proliferation is promoted by proto-oncogenes. When a proto-oncogene is 
activated, by mutation or amplification for example, it becomes an oncogene 
which can drive the growth of a tumour cell. In a number of cases these 
oncogenes have been shown to encode growth factors, receptor tyrosine 
kinases and other proteins vital to cell signalling pathways, reviewed in 
Aaronson, 1991. Secondly, the growth-promoting effects of proto-oncogenes 
are counter-balanced in normal cellular proliferation by the effects of tumour 
suppressor genes. These are genes which impose growth constraints on cells, 
possibly by controlling growth-inhibitory signals between cells (Weinberg, 
1991). Inactivation of tumour suppressor genes, which can occur by deletion 
or mutation, will also result in deregulated cell growth. Therefore, an
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alteration in either of these pathways allows a cell to escape from the growth 
controls which are normally imposed on it. Once such changes have occurred 
the cell has the potential to become tumorigenic.
Thus in a number of tumour types, mutation, deletion or 
amplification at specific loci have been observed. For example, inactivation 
of the retinoblastoma susceptibility gene, RB, by deletion is found in most 
cases of retinoblastoma (Horowitz et al., 1990) and amplification of the N- 
MYC gene is seen in a high percentage of aggressive neuroblastomas (Schwab 
& Amler, 1990). Despite the fact that there are obviously specific gene targets 
for these alterations, often larger areas around the target genes are found to be 
deleted or amplified. For example, a large deletion of chromosome 6q is 
commonly observed in malignant melanoma (Trent et al., 1989), and 
amplifications involving large regions of chromosome 20q and l lq  are 
commonly observed in breast cancers (Tanigami et al., 1992; Tanner et al., 
1994). This leads to the situation where genes unrelated to the target gene 
become deleted or amplified.
In the case of gene amplification, a number of amplicons have 
been analysed in tumours where such co-amplified genes may have an affect 
on the response of the tumour to certain chemotherapeutic agents. One of 
these regions is the aforementioned amplification of chromosome llq l3 ,  
found in up to 18% of breast tumours and 48% of head and neck tumours 
(Brison, 1993). A number of genes have been mapped to this region including 
CCND1 (or PRAD1), EMS1, FGF4 (or HSTF1), FGF3 (or INT2), BCL1 and 
GSTjt (Lammie & Peters, 1991). Expression analyses of the genes within 
1 lq l3  have shown that FGF3 and FGF4 are rarely expressed by cells carrying 
the amplicon (Schuuring et al., 1992) and thus are probably not the target 
genes of the amplification. It appears that there are two possible oncogene 
targets within l lq  13, these being CCND1 which has been found to encode a 
D-type cyclin (Motokura et al., 1991; Xiong et al., 1991) and EMS1, the gene 
product of which is thought to be involved in the invasive potential of cells 
(Schuuring et al., 1993). Interestingly, co-amplification of the GSTji gene has 
also been observed with FGF3 and FGF4 gene amplification in breast tumours 
(Saint-Ruf et al., 1991). The glutathione-S-transferase enzymes are a family 
of drug-detoxifying enzymes which have been associated with drug resistance 
in tumours (Tew, 1994). Specifically, GSTjt expression has been seen to be 
increased in a number of different tumour types (Moscow et al., 1989) with 
high expression found in head and neck tumour samples (Moscow et al., 
1989) where, as previously mentioned, l lq l3  amplification is relatively
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common. It is not known, however, if any correlation exists between GSTjt 
amplification, GSTjt expression and possible drug resistance in these tumours.
Of particular relevance to the work presented in this thesis is 
the amplification of genes on 17q. Among the genes localised to this region 
are ERBB2 (Fukushige et al., 1986), RARa (Mattei et al., 1988), TOPO Ila  
(Tsai-Plugfelder et al., 1988) and NM23H1 (Varesco et al., 1992). These 
genes are all of interest with respect to the process of carcinogenesis and drug 
resistance. ERBB2 is found to be amplified in up to 30% of breast and 
ovarian tumours (Hynes, 1993; Iglehart et al., 1990; Liu et al., 1992; Slamon 
et al., 1987; Slamon et al., 1989) and expression of this gene has also been 
correlated with poor prognosis of breast cancer patients (Press et al., 1993; 
Tetu & Brisson, 1994; Varley etal., 1987; Winstanley etal., 1991). Analysis 
of genetic changes in acute promyelocytic leukaemia patients has found that 
there are often changes to the RARa gene, with it often being found re­
arranged and fused to a gene on chromosome 15, PML (Chang et al., 1991; de 
The et al., 1990). This gene fusion results in the production of a fusion 
protein which is thought to play a key role in leukaemogenesis. The TOPO 
Da gene is important with respect to the expression levels of topoisomerase II 
alpha enzyme in the cell, since it has already been mentioned that the levels of 
topoisomerase I la  within a cell can affect the drug sensitivity of a tumour. 
The NM23H1 gene is also of interest since the product of this gene is 
proposed to have an effect on the metastatic potential of tumour cells (Leone 
etal., 1993a; Leone etal., 1993b; Steeg etal., 1988b; Wang etal., 1993), with 
loss of the protein associated with greater metastatic ability of cells. In certain 
cases of amplification of ERBB2 in breast tumours, it has been observed that 
there is co-amplification of the TOPO I la  gene (Keith et al., 1993; Smith et 
al., 1993). In some of these cases there was also amplification of the RARa 
gene (Keith etal., 1993).
The observation of ERBB2 and TOPO I la  co-amplification is 
extremely interesting because of the role that topoisomerase II plays in drug 
resistance and sensitivity. It is likely that the co-amplification of these genes 
has arisen due to their proximity on chromosome 17q, of which the same is 
probably true for the co-amplification of GSTjt with other genes on llq . 
Whatever the reason for the co-amplification of TOPO Ila  and GSTjt genes, 
the fact remains that any alteration to the expression of these genes may have 
an effect on the response of the tumour to certain anti-tumour drugs. The 
finding that genes such as GSTjt and TOPO I la  can be affected in this way, 
and thus perhaps affect tumour response, makes clear the importance of 
studying the full extent of amplicons in human tumours. In addition to the
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role that topoisomerase II plays in drug resistance, this enzyme may also 
participate in tumour progression. This suggestion has arisen since 
topoisomerase II has been proposed to mediate illegitimate recombination 
(Bae et al., 1988; Sperry et al., 1989) and possible binding sites for 
topoisomerase II have also been detected at the breakpoints of chromosomal 
translocations (Dong et al., 1993). In addition to this, in patients being treated 
for tumours with topoisomerase II-targeting agents, secondary myeloid 
leukaemias involving l lq  chromosomal abnormalities have been observed 
(Pui et al., 1991). Thus it is inferred that targeting topoisomerase II somehow 
has a knock-on effect to cause instabilities of chromosome 11.
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CHAPTER 2 
MATERIALS & METHODS
2.1 Materials
The following section lists all routinely used materials. Less 
frequently used materials are described within the appropriate Methods' 
section.
2.1.1 Chemicals
All chemicals were obtained from the following 
manufacturers unless otherwise stated; BDH Chemicals Ltd., GIBCO BRL, 
Pharmacia LKB Biotechnology or Sigma Chemicals.
2.1.2 Radiochemicals
The a-32p-dCTP used in random prime labelling 
reactions of Southern and Northern probes and y-^p.dA T P used in 5' end- 
labelling reactions were obtained from Amersham International pic.
2.1.3 Restriction Endonucleases and other Enzymes
The majority of restriction endonucleases were obtained 
through the Wolfson Laboratories of Molecular Pathology from GIBCO BRL, 
Northumbria Biologicals Ltd. or Pharmacia LKB Biotechnology.
Other enzymes were obtained as follows:
Pepsin (P6887) Sigma Chemicals
RNAse A Boehringer Mannheim
Restriction digests were run out on 1% agarose/TBE 
gels containing ethidium bromide, visualised under UV illumination and 
photographed using either a Polaroid MP4 land camera with Type 57 Kodak 
film or an Appligene "Imager" CCD camera with supplied software. In the 
latter case, images were printed on thermal paper or stored on 3 V2 " Verbatim 
MF2-HD diskettes.
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2.1.4 Size Markers 
DNA size markers
(a) Hind III digested phage X
(b) EcoRI/BamHI digested Adenovirus 
Protein size markers
Prestained protein standards, 15300-206,450
2.1.5 Media, Solutions and Buffers
2.1.5.1 General Solutions
20 x SSC
3M NaCl
0.3M Tri-sodium citrate
Brought to pH 7.0 with NaOH
TBE (x 1)
89mM Tris borate 
89mM Boric acid 
2.5mMEDTA
For TBE with ethidium bromide, use at final concentration of 
0.5mg/ml
TAE (x 1)
40mM Tris base 
2mM EDTA 
20mM NaCl 
20mM Na Acetate
Brought to pH 8.15 with glacial acetic acid
PBS
Per 2 litres distilled water:
20 PBS (Dulbecco 'A') formulated tablets (OXOID, Unipath Ltd.)
For PBST (PBS with 0.05% Tween) add 2mls 25% Tween 20 
per litre
IBI Ltd. 
IBI Ltd.
BRL
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2.1.5.2 Tissue Culture Solutions
Medium for CALU-3, L-DAN and SK-MES-1
50:50 Hams' F10 (ICN Biomedicals):Dulbecco's Modified Eagle's
Medium
0.075% sodium bicarbonate 
2mM L-glutamine
10% foetal calf serum (GlobePharm or GIBCO BRL) 
in autoclaved distilled water
to pH 1.2-1 A  with 1M NaOH
For the resistant CALU-3 cell line, F10/DMEM medium was 
supplemented with 10'^M VP-16. Cells were exposed to drug for 24 
hours once a month.
Medium for GLC4 , GLC4 /Adr, A2780 and A2780/Adr
RPMI 1640 with:
0.075% sodium bicarbonate 
ImM sodium pyruvate 
2mM L-glutamine 
10% foetal calf serum (as above) 
in autoclaved distilled water
to pH 1.2-1 A  with 1M NaOH
For GLC4/Adr and A2780/Adr, 400/d of a 40/<g/ml doxorubicin 
solution was added per 25mls of medium.
Trypsin
0.25% trypsin 
ImM EDTA 
in autoclaved PBS
Phosphate Buffered Saline
140mM NaCl 
lOmM Na2HP04 
2mM KC1 
ImM KH2PO4
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2.1.5.3 Southern and Northern solutions
Northern Gel
1.2% agarose solution in distilled water
microwaved to dissolve and cooled to room temp.
1 x MOPS 
0.5% formaldehyde
MOPS (x 10)
200mM MOPS 
lOmMEDTA 
50mM Na Acetate
to pH 7 with glacial acetic acid and then autoclaved
RNA Loading Dye
95% formamide
20mM EDTA
0.05% bromophenol blue
0.05% xylene cyanol
1/10^ volume of 50% glycerol
Southern Gel
0 .8 % agarose in distilled water
DNA Lysis Buffer
0.3M sodium acetate, pH 8.0 
0.5% SDS 
5mM EDTA
DNA Loading Dye
0.25% bromophenol blue 
0.25% xylene cyanol FF 
30% glycerol
20 x Genescreen
0.5M Na2HPC>4 
0.5M NaH2P04
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Denaturation Solution
2.5M NaOH 
7.5M NaCl
Neutralisation Solution
1M Tris base (pH 7.4)
1.5M 1 NaCl I
Southern and Northern Hybridisation Buffer
50m M PIPES 
50mM NaH2P04.2H20 
50mM Na2HPC>4 
lOOmM NaCl 
ImM EDTA 
5% SDS
Filter sterilised before use
Southern and Northern Hybridisation Wash Buffer
1 x SSC 
5% SDS
2.1.5.4 Fluorescence In Situ Hybridisation 
Solutions
70% Hybridisation Solution for Centromeric Probes
70% formamide 
2 x  SSC
5% dextran sulphate 
500/^g/ml salmon sperm DNA
50% Hybridisation Solution for Single-Copy Probes
50% formamide
2 x SSC
10% dextran sulphate 
500pig/ml salmon sperm DNA
Hypotonic Solution
0.075M KC1
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Fix
3 volumes methanol: 1 volume glacial acetic acid 
Post-Fix
Streck Tissue Fixative (Alpha Labs)
Denaturation Solution
70% formamide in 2 x SSC at 70-80°C
10% Block Solution Stock
10% Boehringer Mannheim blocking reagent in maleic acid buffer
Microwave until solution becomes yellow and turbid and then 
autoclave to dissolve.
Used at a concentration of 0.5% in maleic acid buffer/Tween, 
4 x SSC-T orPN-T buffer
4 x SSC-T Wash Solution
4 x  SSC
0.05% Tween 20
Maleic Acid Buffer
0.1M maleic acid 
0.15MNaCl 
0.35M NaOH
pH to 7.5 with NaOH 
For maleic acid buffer with 0.05% Tween, add 2 mis of 25% Tween 20 
per litre
PN buffer
Mix of 0.1M NaH2P0 4  and 0.1M Na2HF0 4
(a) 0 .1M Na2HP0 4 : 35.6g in 2 litres distilled water
(b) 0.1M NaH2P0 4 : 13.7g in 1 litre distilled water
Add solution (b) to 2 litres of solution (a) until pH 8.0 is 
reached
PN-T Buffer
PN buffer 
0.05% Tween 20
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2.1.5.5 Protein and Western Blotting Solutions
Nucleus Buffer
ImM KH2PO4  
5mM MgCl2 -6H2 0  
ImM EDTA, pH6.4 
2.5% SDS
Store at 4°C
Immediately prior to use various protease inhibitors were added, to the 
following final concentrations:
0.2 mM DTT (from ImM stock kept at -20°Q
IpiM pepstatin
ImMPMSF
Protease Inhibitors (stock concentrations)
lOmM PMSF in isopropanol 
lmg/ml pepstatin in ethanol 
lOmg/ml leupeptin in distilled water 
500mM benzamidine in distilled water
Sample Lysis Buffer
2% SDS
25% spacer gel buffer
5mMEDTA
10% glycerol
2.5% p-mercaptoethanol
Protease inhibitors added before use
Running Buffer
1.5M Tris base 
0.4% SDS
pH to 8.9 with conc. HC1
Spacer Gel Buffer
0.5M Tris base 
0.4% SDS
pH to 6.7 with conc. HC1
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5 x Tank Buffer
0.25M Tris base 
0.5M glycine 
0.5% SDS
Transfer Buffer
48mM Tns-base 
39mM glycine 
0.038% SDS
8% Polyacrylamide Gel
8ml running buffer
8.5ml 30% acrylamide, 0.8% bis-acrylamide (Severn Biotech Ltd)
3.2ml 1% polyacrylamide
12.2ml distilled water
120/d 10% APS
15/d TEMED
15% Polyacrylamide Gel
8ml running buffer
16ml 30% acrylamide, 0.8% bis-acrylamide
3.2ml 1% polyacrylamide
4.8ml distilled water
180/d 10% APS
15/d TEMED
4% Spacer Gel
3ml spacer gel buffer
1.6ml 30% acrylamide, 0.8% bis-acrylamide
1.2ml 1% polyacrylamide
6 .2ml distilled water
250/d 10% APS
20/d TEMED
Wash Buffer (PBST)
PBS
0.05% Tween 20
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Blocking Solution
5% Marvel (Premier Beverages) in PBST
Western Loading Dye
4% SDS
50% spacer gel buffer 
lOmM EDTA 
20% glycerol 
5% p-mercaptoethanol 
0.25% bromophenol blue
Gel Stain
90% methanol/H20 (1:1)
10% glacial acetic acid
0.25% Coomassie Brilliant Blue R250
Destain
25% methanol 
7% glacial acetic acid
2.1.5.6 Topoisomerase II Assay Buffers
Assay Buffer 
50mM Tris-HCl, pH8 
120mM KC1 
lOmM MgCl2 
0.5mM ATP 
0.5mM DTT 
30]4g/m\ BSA
Stop Buffer/Loading Dye
5% Sarkosyl
0.0025% bromophenol blue 
25% glycerol
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2.1.5.7 Immunofluorescence Solutions
Blocking Solution
Same as that for FISH
Used at a concentration of 0.05% in PBS-T
PBS-T Wash Solution
PBS
0.05% Tween 20
2.1.5.8 Flow Cytometry Solutions
Same as those for immunofluorescence plus:
PBT
PBS containing 0.5% bovine serum | albumin and 0.1% Tween 20
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2.1.6 Table of Primary Antibodies used in 
Immunofluorescence, Flow Cytometry and Western Blotting
Antibody Supplier
Anti-Topoisomerase Ila  
(Polyclonal, IM, FACS)
TopoGEN, U.S.A.
Anti-Topoisomerase Ila  
(Polyclonal, FACS, W)
Cambridge Research 
Biochemicals
Anti-Topoisomerase II (3 
(Monoclonal, IM, W)
Negri et. al.
Anti-ErbB2, NCL-CB11 
(Monoclonal, IM, FACS)
Novocastra
Anti-nm23Hl/H2 
(Polyclonal, IM, FACS, W)
Cambridge Research 
Biochemicals
Anti-P-glycoprotein, JSB-1 
(Monoclonal, FACS)
Monosan 
(via Bradsure Biologicals Ltd)
Anti-P-glycoprotein, MRK-16 
(Monoclonal, FACS)
Tsuruo et al., Cancer 
Chemotherapy Centre, Tokyo
Anti-Retinoic Acid Receptor 
Alpha 
(Polyclonal, W)
Affinity BioReagents
Anti-bromodeoxyuridine 
(Monoclonal, FACS)
DAKO
Anti-Human Nucleolar Control 
(Polyclonal, IM)
ImmunoConcepts 
(via Alpha Labs)
FACS: Used in flow cytometry
IM: Used in immunofluorescence analysis
W: Used in Western analysis
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2.1.7 Table of Antibodies used for Fluorescence In Situ
Hybridisation
Antibody Supplier
Sheep anti-digoxigenin Boehringer Mannheim
Mouse anti-biotin Boehringer Mannheim
Donkey anti-sheep-FITC Jackson ImmunoResearch 
(via Stratech Scientific)
Goat anti-mouse-FITC Jackson ImmunoResearch 
(via Stratech Scientific)
Donkey anti-rabbit-FTTC Jackson ImmunoResearch 
(via Stratech Scientific)
Donkey anti-sheep-Cy5 Jackson ImmunoResearch 
(via Stratech Scientific)
Goat anti-mouse-Cy ^ Jackson ImmunoResearch 
(via Stratech Scientific)
Avidin-FTTC DCS Vector Laboratories
Biotinylated anti-Avidin D Vector Laboratories
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2.2 Methods
2.2.1 Cell Lines and Tissue Culture
Details o f all growth media used in tissue culture are given in Section 2.1.5.2
The human non-small cell lung carcinoma cell lines CALU-3 
and SK-MES-1 were obtained from the American Type Culture Collection 
(ATCC, Rockville, MD). L-DAN is a squamous lung cancer cell line 
established in the Department of Medical Oncology in Glasgow. All three cell 
lines are adherent lines and were tested monthly for mycoplasma 
contamination. Cells were passaged 1:10 once a week.
A VP16 resistant clone of CALU-3 was derived in the 
Department of Medical Oncology by Dr. Jane Plumb. A sensitive clone (ID 50 
for VP16=0.2/<M) was selected for derivation of the resistant cell line from 
the heterogeneous population of CALU-3. Cells were exposed to between 
0.1//M and 1//M VP16 for 24 hours following which they were allowed to 
regrow. Cells which grew through the highest concentration (lyiM) were then 
re-exposed to this concentration of VP16 twice (cells frozen down at this 
stage, CALU-3/10"^M VP16). After six months the cells were tested for 
sensitivity to VP16 and reselected in between 1 and 10 yiM of the drug. Cells 
which survived 9/<M drug (CALU-3/9xlO“^ M VP16) were reselected in 
10^M VP16 and these cells were then tested for sensitivity to VP16, 
doxorubicin, vincristine and cisplatin. This cell line, CALU-3/10"^M VP16 is 
the resistant clone which has been studied as part of this work. When 
culturing this cell line, 10"^M VP16 was added to the growth medium.
Human lung cell lines GLC4  and GLC4/Adr were cultured 
briefly (< 7 days) for use as controls in Western analysis, as were the A2780 
and A2780/Adr ovarian cell lines.
2.2.2 Southern Analysis
Details o f solutions used in Southern analysis are given in Section 2.1.5.3
2.2.2.1 DNA Extraction (from Keith etal., 1992)
Genomic DNA was harvested independently from the three 
lung cancer cell lines mentioned above for use in the preparation of Southern 
blots. Extraction of DNA was achieved by addition of 10 mis of equilibrated
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phenol to cells growing in a 75 cm  2 tissue culture flask. Cells were scraped 
from the bottom of the flask using a Costar disposable cell scraper and the 
mixture left, shaking gently at 37°C for 10 minutes. Ten mis of DNA lysis 
buffet were then added and the flask again incubated, shaking gently at 37°C 
for 10 minutes. Once this incubation was complete the contents of the flask 
were emptied into a 50 ml Falcon "Blue Max" tube (Becton Dickinson) and 10 
mis of chloroform/isoamyl alcohol (25:1) was added. The tube was then 
incubated at 37°C on a rotating rack for 10 minutes. After this time the 
solution was centrifuged for 15 minutes at 3500 rpm, 22°C, following which 
the supernatant was removed and the genomic DNA precipitated using an 
equal volume of isopropyl alcohol. This solution was placed at -20°C for 
approximately 30 minutes prior to centrifugation, which was performed as 
detailed above. The DNA pellet was air-dried for approximately 10 minutes 
and resuspended in 100-200/d of distilled water. All genomic DNA samples 
were stored at 4°C.
2.2.2.2 Southern Blotting
See Sambrook et al. , 1989 for review of technique.
Twenty micrograms of genomic DNA were used in digestions 
for Southern blotting. DNA was digested overnight at 37°C in a 150/d 
volume with 100U of the required restriction enzyme according to 
manufacturers instructions. Digested DNA was precipitated using 0.1 volume 
3M sodium acetate (pH 8) and 2 volumes absolute alcohol and incubated at 
-20°C overnight. DNA was pelleted at 13,000 rpm for 25 mins, air-dried for 
30 mins and resuspended in 50/d distilled water. Resuspension was carried 
out at 37°C overnight. Five /d of DNA loading dye was then added and 
samples were run on a 0.8% agarose/TAE gel overnight at approximately 50V 
using gel tanks from IBI Ltd., Cambridge. jry\ y c c\
Following electrophoresis, the digested DNA was ^  stained^ 
for 45 mins with ethidium bromide (0.5/^g/ml) and then photographed using 
Kodak Type 57 film under UV illumination with a Polaroid MP4 land camera 
in order to check levels of DNA loading. DNA on the gel was then denatured 
by 2 x 15 min washes in denaturation solution and neutralised by 2 x 30 min 
washes in neutralisation solution. Gels were then blotted overnight onto nylon 
filters (HyBond Nfp, Amersham, U.K.) using 1 x Genescreen buffer. Filters 
were then rinsed briefly in Genescreen and dried. DNA was subsequently 
cross-linked to the filter by a 5 minute exposure to a UV light source.
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Hybridisation and washing of filters was carried out as 
described in Section 2.2.5.
2.2.2.3 Chromosome 17 Cosmid Library Filters
Two duplicate cosmid library filters were obtained from the 
ICRF, through Dr. Donny Black at the Beatson Institute. The filters consisted 
of approximately 20000 bacterial clones each having been spotted in 3 x 3 
colony grids on the filter. Each of the individual clones contains a cosmid 
incorporating some sequence from chromosome 17. In order to find a cosmid 
probe for the RARa gene for use in FISH, 40mer oligos from part of the 
RARa gene were obtained from Oncogene Science, end-labelled using a 
Promega 5'-end labelling kit (according to manufacturers instructions) and 
hybridised as detailed in section 2.2.4. An RARa plasmid, p63, acquired from 
the ATCC was ^P-labelled using a Stratagene random prime kit (see section 
2.2.6.3) and hybridised independently from the oligo probe to the filters. 
Following autoradiography, x and y grid co-ordinates of positive colonies 
were taken, provided the colony was positive on both filters, and these co­
ordinates sent back to the ICRF. The requested clones were then kindly 
supplied in the form of an agar stab.
2.2.3 Northern Analysis
See Sambrook et al., for a review of Northern blotting 
Details o f solutions used in Northern analysis are given in Section 2.1.53
RNA was harvested from 75 cm^ tissue culture flasks of 
CALU-3, L-DAN and SK-MES-1 cells according to the RNAzol 'B' method 
(Cinna/Biotecx Laboratories, Texas, USA). Twenty micrograms of total 
cellular RNA was used per cell line for Northern analysis. Samples, 
containing 20 pig RNA (made up to 12.5 pt\ with autoclaved, distilled water), 
1 yi\ ethidium bromide (1 mg/ml stock), 4.5 ]A 5 x MOPS, 4.5 ]A 37% 
formaldehyde and 22.5 jA formamide, were denatured at 55°C for 15 minutes 
before addition of 5 ]A RNA loading dye.
Gels were electrophoresed at 50V overnight, in IBI gel tanks, 
in 1 x MOPS, photographed as for Southern gels and then blotted for 7-8 
hours in 0.05M NaOH onto Hybond Nfp nylon membrane (Amersham, U.K.).
Hybridisation and washing of filters |were carried out as 
described in the following section.
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2.2.4 Hybridisation and Washing of Membranes
(previously detailed in Keith etal., 1992)
Hybridisation and washing of filtersfwere carried out using the 
Hybaid rotisserie system and oven set at 65°C. Filters were rolled in 20 x 
20cm squares of nylon mesh (Hybaid) and placed in glass hybridisation 
bottles. Bottles were then incubated in the oven. Filters were prehybridised 
for 1-2 hrs in approximately 20 mis of hybridisation solution before the 
addition of radiolabelled probe. Labelled probes were applied to filters in a 10 
ml volume of hybridisation buffer and hybridisation was then carried out for 
18-24 hours at 65°C in the Hybaid oven. Filters were subsequently washed in 
20-30 mis of wash solution for several hours also in the rotisserie oven with 
repeated changes of solution.
2.2.5 Autoradiography
Probed filters were exposed to Kodak XAR 5, or FUJI RX 
autoradiography film in sealed film cassettes with fast tungstate intensifying 
screens at -70°C for varying lengths of time depending on the signal intensity.
2.2.6 Southern and Northern probes
2.2.6.1 Probes Used
The human topoisomerase II a  gene probe used was SP1 
(Chung et a l 1989). ERBB2 was detected by the probe pCER204, RARa by 
the probe p63 and PKCa by pHPKC-alpha 7 (Parker et a l 1986). All these 
gene probes were obtained from the ATCC. The nm23 gene probe was kindly 
provided by Dr. Patricia Steeg (N.I.H., Bethesda). pHJi, a genomic clone of 
the human immunoglobulin heavy chain locus, was used to quantify DNA 
loading in Southerns (Erickson et a l 1982). The same probe for 
topoisomerase I la  was used in Northern analysis and the SP12 probe used to 
detect topoisomerase II p. Topoisomerase I was detected by the pScl70 probe 
(Sunde et al. , 1989) and a 7S RNA probe was used as a loading control. The 
probe for G-CSF was obtained from Dr. I Pragnell, Beatson Institute.
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2.2.6.2 Preparation of Probes for Labelling
For SP1 and SP12yinserts were cut from whole plasmids for use 
as Southern and Northern probes. The appropriate digests were performed 
with plasmids in order to release inserts. Digested plasmid was run on 1.5% 
TBE gel so as to obtain well separated bands. The required band was excised 
from the gel and put into a "Spin-X” column with 100/d distilled water. The 
gel fragment was mashed using a sealed glass pipette and then spun at 13,000 
rpm for 25 mins. Solution pushed through the filter unit was re-applied to the 
gel remains above, a further 100/d of water was added and the column left at 
4°C to elute overnight. The next morning the column was spun again, 
solution re-applied to filter and left for 30 mins following which the column 
was re-spun. This process was repeated 6-7 times before a 10/d aliquot was 
taken and run on a test gel with a known amount of marker to ensurqffequired 
fragment had been purified and to estimate probe concentration. Purified 
insert was stored at -20°C.
2.2.6.3 Random Labelling of dsDNA
32p-iabelled dsDNA probes (used for Southerns and 
Northerns) were prepared using the Stratagene "Prime-It" kit and lOOng of 
template DNA. The labelling protocol was carried out according to 
manufacturer’s instructions. Following labelling, probes were purified using 
Sephadex-containing NICK columns (Pharmacia) and chemically denatured 
before being applied to filters in 10 mis of hybridisation buffer.
2.2.7 Re-probing of Southern and Northern Membranes
Filters were re-probed with a number of probes for different 
genes. In order to remove previous hybridisation signal, filters were placed in 
boiling 0.1% SDS solution and left until cooled to room temperature.
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2.2.8 Fluorescence In Situ Hybridisation (FISH)
All protocols listed below are variations from the following published 
methods: Kallioniemi etal., 1992b, Coutts etal., 1993, Gosden etal., 1992.
Details o f all solutions used in FISH are given in Section 2.1.5.4
The individual stages of FISH, preparation of chromosomes and slides, 
hybridisation and post-hybridisation washing, have been separated for ease of 
understanding.
2.2.8.1 Preparation of Chromosomes from Lymphocytes
Chromosomes were prepared using a small amount of fresh 
blood from a willing volunteer and "chromosome medium 1A" bought from 
GIBCO Life Technologies. 200/d of blood was added to each 5ml tube of 
medium and incubated for 72 hrs at 37°C. Tubes were agitated daily to 
prevent settling of the contents. Seventy-one hours after the blood had been 
seeded, colcemid (GIBCO) was added to each tube to a final concentration of 
0.1/<g./ml. Tubes were then agitated gently and left for 1 hr at 37°C. 
Following this incubation the blood culture was transferred to 15ml Falcon 
tubes, spun down (2500 rpm for 5 mins) and the supernatant poured off. Cells 
were resuspended in the small amount of remaining medium and 10 mis of 
warmed (37°C) hypotonic solution added slowly. Tubes were incubated at 
37°C for 10 mins before being spun, as detailed previously. The hypotonic 
solution was then poured off, leaving a very small amount remaining above 
the cell pellet in which the cells were then resuspended. At this stage it is 
crucial that the cells are well resuspended and not at all clumpy. Ten mis of 
fix was added to the cell suspension very slowly dropwise, with the tube 
constantly being agitated by the fingers. Once the fix was all added the cells 
were left at room temperature for 15 mins to allow penetration of the fix into 
the cells. Tubes were then spun as before. The fix solution was poured off, 
leaving a small amount remaining in which cells were resuspended and a 
second lOmls of fix solution was added. Cells were then spun immediately.
This process of fixing and spinning samples was continued 
until the resuspended solution became clear and there was no trace of 
haemoglobin from the lysed red blood cells, usually 5-6 repetitions. A sample 
of the fixed cells was then dropped onto a slide to check for the presence of 
metaphase spreads and also for determination of cell density. Final 
lymphocyte preparations were stored in fix at -20°C.
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2.2.8.2 Preparation of Chromosomes from Cell Lines
Chromosomes were prepared from 75cm2 tissue culture flasks 
of sub-confluent cell lines. Different concentrations of colcemid were used 
for the three different cell lines with 0.2/<g/ml being added to L-DAN and SK- 
MES-1 cultures and 0.25/^g/ml added to CALU-3 cultures. L-DAN and SK- 
MES-1 were then incubated for 2 hours and CALU-3 for 3 hours at 37°C. 
Medium was then removed, cells were rinsed with PBS and trypsinised to 
remove them from the base of the flask. Cells were washed in PBS, spun 
down ( 2500 rpm for 5 mins) and the PBS poured off leaving a small amount 
covering the cells. The cell pellet was resuspended in this small amount of 
PBS and 10 mis of warmed hypotonic solution added, as for the lymphocyte 
preparation. All cell lines were incubated for 15 mins with hypotonic solution 
at 37°C and then spun, as before. The chromosome preparation then 
continued as outlined for lymphocytes with fix and spin cycles being repeated 
4-5 times.
2.2.8.3 Probes Used for FISH
A number of different probes from chromosome 17 were used, 
as outlined in the following table:
Probe Name Region of Chr.17 
Detected
Supplied By
Chromosome 17 paint Whole chromosome Cambio
17-specific centromere Centromere only Home-made via PCR
pC5 TOPO Ila  gene Dr.Ian Hickson, ICRF
ICRFc 105B041155 TOPO Ila  gene ICRF RLDB
ICRFcl05H01119 TOPO Ila  gene ICRFRLDB
ICRFc 105C0861 NF1 gene ICRFRLDB
ICRFcl05H12160 NM23H1 gene ICRFRLDB
ICRFc 105F1255 RARa gene ICRF RLDB
C05123 BRCA1 region Dr. Donny Black, 
CRC
Neu 1 ERBB2 gene White & Leppert, Utah
Neu4 ERBB2 gene White & Leppert, Utah
ICRF RLDB: Imperial Cancer Research Fund Reference Library-DataBase
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2.2.8.4 Isolation of Cosmids
Cosmids were usually supplied in bacterial agar stabs. A 
sample of the stab was taken using a sterile wire loop and grown in a 10 ml 
culture of L-broth and the relevant antibiotic (either kanamycin or ampicillin, 
both used at a final concentration of 20/ig/ml) overnight at 37°C in a shaking 
incubator. This overnight culture was seeded into either 100 or 500 mis of L- 
broth/antibiotic and grown for a further 24 hours. The cosmid DNA was 
isolated from these cultures using the Qiagen system (Hybaid).
Following the Qiagen isolation protocol, DNA pellets were 
resuspended in 100-400/d of distilled water. A 2/d sample of cosmid was 
digested with EcoRI and run on a 0.8% TBE/EtBr gel in order to check 
cosmid size and 1 and 5/d undigested samples were also run on these gels to 
check DNA concentration. The remaining cosmid preparation was stored at 
-20°C.
In order to confirm that cosmids contain inserts from a 
particular gene, approximately Iptg of cosmid was digested using EcoRI and 
then run on a 0.8% agarose/TAE gel. Gels were stained, photographed and 
blotted according to Southern blot protocol (section 2.2.2.2) and 
hybridisations were then performed using the appropriate probe 
(topoisomerase II alpha, retinoic acid receptor alpha or nm23Hl), as described 
previously.
Occasionally cosmids were received as samples of DNA, in 
which case it was necessary to package them into bacteria. This was achieved 
using a GigaPack Gold II packaging kit from Promega and by following the 
supplied manufacturers instructions.
2.2.8.5 Labelling of Probes for FISH
Probes were labelled with either biotin or digoxigenin. In order 
to label the cosmid probes with biotin a "Bio-Nick" nick translation kit from 
GIBCO was used. For incorporation of digoxigenin a Boehringer Mannheim 
nick translation kit was used. For each of these kits, l//g of cosmid DNA was 
labelled. The chromosome paint used was purchased already labelled with 
biotin and the centromere sequence could be labelled with either hapten 
during the initial PCR reaction.
Nick translation reactions were performed at 16°C for 2-3 
hours following which DNA was precipitated by the addition of 1/d glycogen, 
1/d 0.5M EDTA, 5/d 3M NaAc, pH8.0, 25-75/d human Cotl DNA and 300/d 
ethanol and incubated at -20°C overnight or in a dry ice/ethanol bath for 30
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mins. DNA was pelleted by centrifugation at 13,000 rpm for 25 mins, washed 
in 70% ethanol and then vacuum dried for 15 mins at 56°C in a Howe 
GyroVap. The DNA pellet was resuspended in 50/d of 50% hybridisation mix 
(for single-copy gene cosmids) or 70% hybridisation mix (for repetitive 
probes) and left to resuspend at 37°C for an hour.
2.2.8.6 Preparing Slides for Hybridisation
The first step in preparing slides for hybridisation was to drop a 
small quantity of the required chromosome preparation onto a clean glass 
slide. Slides and coverslips (for final mounting) were kept in 100% ethanol 
with a few drops of concentrated hydrochloric acid added to it. Chromosomes 
were dropped from a couple of feet above the slide using a short-form glass 
pipette. Slides were then rinsed with a pipette-full of fixative and air-dried.
A 1 hour fixation in 3:1 methanol/acetic acid followed, after 
which slides were rinsed in 2 x SSC and incubated in 100//g/ml RNAse in 2 x 
SSC for 1 hour at 37°C. Slides were rinsed in PBS and then incubated in 
0.01% pepsin in 0.01M HC1 for 10 mins at 37°C. Following a rinse in 2 x 
SSC, the post-fix stage was performed using Streck tissue fixative, in which 
slides were left for 10 mins at room temperature. Slides were then dehydrated 
by passing twice through 70% ethanol (2 mins each time) and twice through 
100% ethanol (2 mins each time).
Denaturation of slides was performed just prior to hybridisation 
and was achieved by incubation of the slides for 5 mins in 70% formamide at 
75°C. The formamide solution was heated to 1°C higher than 75°C for each 
slide to be denatured. Ice-cold 70% ethanol was then used to rinse the slides 
at least 5 times (1 min each time) following which dehydration in 100% 
ethanol was carried out, as detailed above and slides were air-dried.
Slides were then ready to be hybridised with the required
probe.
2.2.8.7 Hybridisation of Slides
Before hybridising, all probes were denatured to single- 
stranded DNA by incubation at 70°C for 5 mins (unless otherwise instructed 
by the manufacturers) followed by an hours' incubation at 37°C to enable 
competing out of any repetitive sequences in the probe by the Cotl DNA. Ten 
microlitres of denatured probe was then added to slides, as prepared above, 
covered with a coverslip and sealed round the edges of the coverslip with Cow 
Gum, rubber adhesive using a 1 or 2 ml syringe. Slides were then incubated
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in a humidified chamber overnight at 37°C. Where double hybridisations 
were performed using a centromere probe and a single-copy gene probe, 3/d 
of the centromere probe was mixed with 9/d of single-copy probe after both 
had been denatured. This entire mixture was then applied to the slide. For 
doubles with two single-copy probes, 5/d of each was taken, mixed and 
applied to the slide.
2.2.8.8 Washing and Detection of Probes
The washing procedure was always the same, irrespective of 
which detection method was used. The Cow Gum sealant was removed 
carefully from the slides by dipping slides in 2 x SSC and peeling off using a 
pair of curved, pointed forceps. The coverslips were then gently prised off by 
holding a corner of the coverslip. Slides were then washed twice in 50% 
formamide/1 x SSC at 42°C and twice in 2 x SSC at 42°C in Coplin jars. 
Blocking and detection then proceeded according to one of the following 
protocols. All antibodies were diluted in block solution with 100/d of diluted 
antibody being applied per slide. Parafilm coverslips were then placed over 
the antibody on the slide to ensure even coverage of the area previously 
hybridised.
Different detection methods were used dependent on which 
hapten the probe was labelled with and which fluorochrome one wished to use 
to detect that hapten.
Version I, for Biotin or Digoxigenin labelled probes
(i) Rinse slides briefly in maleic acid/Tween buffer
(ii) Block for 30 mins at 37°C in 0.5% block solution in 
maleic acid/Tween buffer
(iii) Incubate with first antibody for 1 hour at 37°C in a 
humidified box.
Either mouse anti-biotin (for biotin probes) or sheep anti- 
digoxigenin (for digoxigenin probes). Both antibodies were used at 1:200 
dilution in 0.5% blocking solution.
(iv) Rinse slides for 10 mins in large glass slide holder on 
stirrer with maleic acid/Tween buffer.
(v) Incubate with second antibody for 30 mins at 37°C in a 
humidified box.
Either goat anti-mouse-FITC or donkey anti-sheep-FITC, both 
at 1:500 dilution in block solution.
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(vi) Rinse slides for 30 mins in large glass slide holder on
stirrer with maleic acid/Tween buffer.
(vii) Dehydrate, as detailed in Section 2.2.5.5, Version I
Version II, for Biotin labelled probes
(i) Rinse slides briefly in 4 x SSC-T buffer
(ii) Block for 10 mins at room temperature in 4 x SSC-
T/0.5% block (4 x SSC-TB).
(iii) Incubate with FITC-Avidin DCS at 1:200 dilution in 4
x SSC-TB for 45 mins in humidified box at room temperature.
(iv) Rinse slides for 10 mins, in large stirrer in 4 x SSC-T
{keep for use again in steps (vi) and (viii)}.
(v) Incubate with Biotinylated anti-avidin D at 1:100
dilution in 4 x SSC-TB for 45 mins in humidified box at room temperature.
(vi) Rinse slides, as above.
(vii) Incubate again with FITC-Avidin DCS 4 x SSC-TB, as
above {Step (iii)}
(viii) Rinse slides in 4 x SSC-T for 20 mins in large stirrer.
(ix) Dehydrate, as detailed in Section 2.2.5.5, Version I
Version III, for double hybridisations with biotin and digoxigenin
probes
(i) Rinse slides briefly in 4 x SSC-T
(ii) Block for 10 mins at room temperature in 4 x SSC-
T/0.5% block.
(iii) Incubate with FITC-Avidin DCS at 1:200 dilution in 4
x SSC-TB for 45 mins in humidified box at room temperature.
(iv) Wash slides in 4 x SSC-T in large glass stirrer for 10 
mins at room temperature.
(v) Transfer slides to PN-T buffer for 2 mins.
(vi) Block slides for 10 mins in PN-T buffer/0.5% block at 
room temperature.
(vii) Incubate with biotinylated anti-avidin D at 1:100 and 
sheep anti-digoxigenin at 1:200, both in PN-T buffer/0.5% block solution for 
45 mins at room temp in a humidified box.
(viii) Wash in PN-T buffer for 10 mins in large glass stirrer at 
room temp (keep for later use).
(ix) Incubate slides with FITC-Avidin DCS at 1:200 and 
anti-sheep Cy^ at 1:400 in PN-T buffer/0.5% block for 45 mins at room temp.
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(x) Wash slides in PN-T buffer for 20 mins in large glass
stirrer.
(xi) Dehydrate, as detailed in Section 2.2.5.5, Version I.
Following dehydration slides were mounted in 10/d of 
Vectashield anti-fade mountant H-1000 (Vector Labs) with propidium iodide 
(1:5000 dilution) and DAPI (1:2000 dilution) added as counterstains. Clean 
coverslips were then applied and sealed with clear nail varnish. Slides were 
stored in darkness at 4°C.
Analysis of slides was performed on a Bio-Rad MRC-600 laser 
scanning confocal microscope equipped with a krypton/argon ion laser. For 
FITC and PI, 488/568 nm line excitation and dual channel 522 and 585 nm 
emission filters were used. For Cy5, 647 nm line excitation and a 680 EF-32 
emission filter were used. Image analysis was performed using Bio-Rad 
software.
2.2.9 Protein Analysis
Details o f solutions used for the isolation o f proteins are given in Section
2.1.5.5
2.2.9.1 Preparation of Crude Nuclear Extracts
(from vanderZee etal., 1991)
Subconfluent flasks of cells were washed with approximately 
10 mis of ice-cold phosphate buffered saline solution (PBS) and cells scraped 
off the base of the flask using a disposable cell scraper. This solution was 
centrifuged at 2500rpm for 10 minutes. The resulting cell pellet was 
resuspended in 200/d of nucleus buffer in a 1.5ml eppendorf tube and freeze- 
thawed twice in a dry ice/ethanol bath. One-tenth volume of 3.5M NaCl was 
then added to give a final concentration of 0.35M NaCl. The cell solution was 
vortexed briefly and incubated on ice for 1 hour, mixing after 30 mins. Cells 
were then spun at 15000 rpm for 20 mins at 4°C.
The resulting supernatant was removed and split three ways; (i) 
20 /d for protein estimation, (ii) 50/d for activity assays (diluted with an equal 
volume of 87% glycerol), (iii) remainder used for Western blotting (diluted 
with an equal volume of Western loading dye). Protein estimation was 
performed using Bio-Rad protein assay dye and doubling dilutions of the 
unknown extract. The standard curve was produced using lmg/ml BSA
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solution. Readings were taken using a Perkin Elmer Lambda 2 
spectrophotometer.
2.23.2 Preparation of Whole Cell Extracts
For adherent cell lines, cells were counted using a Coulter 
counter and seeded at a concentration of 1 x 10^ per well in 6-well plates and 
left at 37°C, 2% CO2 for approximately 24 hours. Medium was then removed 
and cells were washed briefly with PBS before being lysed by the addition of 
100/d of protein loading dye (with added protease inhibitors). Non-adherent 
cells were counted and diluted to a concentration of 1 x 10^ cells per ml. One 
ml aliquots of cells were then spun down (3000 rpm, 5 minutes), washed with 
PBS and resuspended in 100/d loading dye. Samples were stored at -20°C, 
unless used immediately.
2.2.10 Western Analysis (as shown in Keith etal., 1993)
Details o f solutions used in Western analysis are given in Section 2.1.5.5
2.2.10.1 Gel Running and Electroblotting
Samples containing either 50/<g of protein or 1 x 10^ cells were 
run using the Bio-Rad Protean II system on 8% or 15% non-denaturing gels in 
depending on the size of protein being analysed. Gels were run for 4-6 hours 
at 35-40mA, or at 10mA overnight.
Dot-blotting was also performed on a couple of occasions using 
a dot-blot manifold from BRL. For this technique, 50/ig of protein was used 
in the first column from which seven doubling dilutions were made stepwise 
down the filter. Each sample was applied in triplicate to the dot-blot 
manifold.
Proteins were transferred to membranes using a Millipore 
semi-dry electroblotter. Millipore Immobilon-P membrane was used, which 
required pre-wetting in methanol, then water and finally transfer buffer before 
being used. Six sheets of 3MM Whatman filter paper were sandwiched 
between the anode and cathode of the blotter with the gel and filter layered in 
the middle. Transfer was performed at 200mA for 45 mins following which 
the gel was stained with Coomassie Brilliant Blue dye. The filter was rinsed 
in methanol, water and finally PBS-T before detection was performed.
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2.2.10.2 Immunodetection
All steps were carried out at room temperature unless otherwise 
stated. Filters were blocked at for at least 1 hour in 5% Marvel before 
application of any antibodies. All antibody dilutions were performed in this 
block solution. Filters were incubated with primary antibodies overnight on a 
rocking table at room temperature sealed in plastic files. Anti-topoisomerase 
Ha antibody was used at 1:1000 dilution, anti-topoisomerase lip  at 1:50, anti- 
retinoic acid receptor alpha (RARa) antibody at 1:500 and anti-nm23Hl/H2 
antibody also used at 1:500. Blocking peptides for nm23Hl/H2 and RARa 
antibodies were used to try and prevent antigen binding. Four microlitres of 
RARa primary antibody and 4/d of its' blocking peptide (Affinity 
Bioreagents) were incubated overnight at 4°C in a 20/d volume and made up 
to 2 mis with 5% Marvel prior to use. For nm23Hl/H2 blocking, 4/d of 
antibody was incubated with 2/d of blocking peptide (Cambridge Research 
Biochemicals) under the same conditions as for RARa. These blocked 
primary antibodies were then incubated with filters in the same way as normal 
primary antibodies.
Following exposure to primary antibody, filters were rinsed 
briefly in PBS-T and then incubated with 10 mis of diluted secondary 
antibody, protein A-horseradish peroxidase (Amersham) for 30 mins. This 
antibody was used at 1:5000 dilution in 5% Marvel. Filters were then rinsed 
for 30 mins in PBS-T with the solution being changed every 5-10 mins.
Signal was detected by chemiluminescence using either 
Amersham ECL reagents or Boehringer Mannheim reagents (for detection of 
POD labelled antibodies). Protocols for detection were followed according to 
the manufacturers' instructions. Filters were exposed to ECL fluid for 1 
minute, blotted on Whatman 3MM paper and wrapped in SaranWrap. 
Stratagene GloGos stickers were used to aid in sizing bands after 
autoradiography. Films were initially exposed for 1-5 mins with a second film 
being exposed for longer, as required.
2.2.10.3 Band Depletion Assay
(adapted from Zwelling etal., 1989)
Cells from the three cell lines were seeded at a concentration of 
105 cells per well in 6 -well plates. Plates were allowed to grow in a 2% 
gassing incubator at 37°C for 24 hours before being treated with VP-16. 
Concentrations of VP-16 used were 5 x lO^M , 5  x 10"^M, 5 x lO ^M  and 5 x
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10“7m  in growth medium. One well was kept untreated as a control. Cells 
were incubated with drug for 2 hours in the incubator following which the 
medium was removed, cells were washed briefly with PBS and then lysed 
with western loading buffer. Extracts were then loaded onto an 8% western 
gel and run and electroblotted as detailed in Section 2.2.10.1. Resultant filters 
were incubated with anti-topoisomerase I la  antibody and horseradish 
peroxidase conjugated second antibody, as described previously. Detection of 
signal was achieved as described in Section 2.2.10.2. A more in-depth 
explanation of this technique will be given in Chapter 4.
2.2.11 Biochemical Assay for Topoisomerase II
Details o f solutions used in biochemical assays are given in Section 2.1.5.6
This assay was performed according to manufacturers 
instructions (TopoGEN Inc., Ohio). Activity of topoisomerase II is observed 
through the enzymes' ability to decatenate kinetoplast DNA (kDNA), as 
shown below.
Catenated kDNA networks
GD
oo
Decatenated kDNA 
monomers
K
M
Kinetoplast DNA is mitochondrial DNA from Crithidia 
fasciculata and consists of networks of 2.5kb rings catenated together. 
Topoisomerase II can monomerise these rings via its catalytic, ATP- 
dependent cycle of cleavage, strand passage and religation. The amount of 
topoisomerase II within a cell will therefore determine how much of the
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kDNA is decatenated. When reactions are resolved on an agarose gel, the 
monomeric circles of DNA migrate much faster than catenated circles and 
therefore move further within the gel. Any remaining networks of kDNA stay 
in the wells as they are not able to migrate. Three situations may arise in this 
experiment, which are depicted above. Lane 1 indicates the result if an extract 
containing high topoisomerase II activity is used. Almost all of the kDNA (K) 
has been monomerised (M). Low activity of an extract is shown in lane 2, 
where most of the kDNA remains catenated. An extract containing no activity 
would give the result seen in lane 3.
The assay involves incubating a known amount of nuclear 
extract (see Section 2.2.9.1), in doubling dilutions from 5pig down to 
0.0375/^g of protein, with 300ng of kDNA in assay buffer (see Section
2.1.5.6). Samples are then incubated at 37°C for 30 mins, following which 
they are placed on ice and I /5 volume of stop buffer/loading dye (see Section
2.1.5.6) is added. Activity was resolved in 1% agarose/TBE gels containing 
0.05% ethidium bromide. TBE with 0.05% ethidium bromide was also used 
as the running buffer. Gels were run at 50-150 V until the dye front had 
moved approximately 5cm and then photographed using Type 55 film.
Inhibition of activity was performed using differing 
concentrations of VP16: 5 x lO^M, 5 x 10‘^ M, 5 x 10"^M and 5 x 10"7M, 
incubated with samples. The drug was dissolved in DMSO with the final 
concentration of DMSO being 2%. This amount of DMSO was also added to 
no drug controls to ensure that it did not affect decatenation. Samples for 
inhibition assays were set up at room temperature and incubated with drug for 
30 mins at 37°C.
2.2.12 Immunofluorescence (as used in Coutts etal., 1993) 
Details o f solutions used in immunofluorescence are given in Section 2.1.5.7
Cells were trypsinised from flasks and resuspended in fresh 
medium at a concentration of 2 x 10^ cells per ml. One ml of these diluted 
samples was then seeded per chamber of a Nunclon 4-well chamber slide. 
Slides were placed in a 37°C, 2% CO2 incubator overnight. Coverslips and 
chambers were removed prior to hybridisation with special care being taken to 
remove all silicon sealant from the slides (usually achieved with the aid of a 
scalpel). A number of slides were set up at once using L-DAN, CALU-3 and 
SK-MES-1, and those not used immediately in experiments were rinsed in 
PBS, air-dried, wrapped in Parafilm and frozen at -20°C.
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Remaining slides were also rinsed in PBS and then fixed for 1 
minute in acetone/methanol (1:1). Blocking was performed in 3% BSA/PBST 
or 0.5% Boehringer Mannheim blocking reagent in PBST for 10 mins at room 
temperature, following which slides were washed briefly in PBST and 
incubated in primary antibody for 1-2 hours at 37°C in a humidified container.
Section 2.1 .6  ou tlines all an tibod ies  used in 
immunofluorescence and who they were supplied by. All primary antibodies 
were used at 1:50 dilution in block solution. The nucleolar control antibody 
obtained was part of a fluorescent ana test system kit from ImmunoConcepts, 
Sacramento and both primary, human anti-nucleoli and secondary anti-human- 
FITC antibodies came ready to use. Blocking peptides for topoisomerase I la  
and nm23Hl/H2 antibodies were used to abolish antigen binding. For 
antibody blocking, 1/d of peptide was incubated with 1/d of primary antibody 
in a total volume of 10/d (8/d PBS) overnight at 4°C. The volume was made 
up to 50/d with blocking solution prior to use and used on one slide.
Following incubation with primary antibody, slides were 
washed in a large volume (approximately 400 mis) of PBST for 10 mins at 
room temperature. For detection of mouse monoclonal primary antibodies, 
anti-topoisomerase lip and anti-ErbB2, a goat anti-mouse-FITC conjugated 
second antibody was used (Jackson Immunoresearch). For detection of rabbit 
polyclonal primary antibodies, anti-topoisomerase I la  and anti-nm23Hl/H2, a 
donkey anti-rabbit-FITC conjugated second antibody was used (Jackson 
Immunoresearch). For co-localisation studies using topoisomerase lip and 
nucleolar control antibodies, the topoisomerase lip antibody was detected with 
an a n ti-m o u s e -C y ^  conjugated second antibody. Slides were incubated with 
secondary antibodies at 1:100 dilution in blocking solution for 30 mins to 1 
hour at room temperature. A final wash of 30 mins was performed in PBST 
as before and slides were then dehydrated and mounted as for FISH studies 
(Section 2.2.8.7), except slides were mounted under 22 x 32 cm coverslips. 
Slides were analysed as for FISH studies. In order to gain quantitative, 
comparative data, important when using blocked primary antibodies and 
normal antibodies in the same experiment, parameters used during image 
acquisition were set and remained unaltered during image collection by the 
scanning confocal microscope.
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2.2.13 Flow Cytometry
(adapted from Kaufmann etal., 1991 and Prosperi et al., 1992)
Details o f solutions used in FACS analysis are given in Section 2.1.5.8
2.2.13.1 Cell Cycle Analysis using Bromodeoxyuridine 
(BrdUrd) and Propidium Iodide (PI)
Cells were seeded at around 5 x 10^ cells per flask, in duplicate 
for each cell line. Approximately 3 days after seeding, well before cells were 
confluent, the medium was removed from the flasks and replaced with fresh 
medium containing IOjaM freshly made BrdUrd. Cells were then incubated at 
37°C for 4 hours to allow incorporation of the BrdUrd. Following this time 
the medium was removed and cells trypsinised as for normal tissue culture. 
The trypsin/cell solution was added to 5mls of medium and spun down at 
1200rpm for 5 min. The cell pellet was fixed by the addition of 5ml ice-cold 
70% ethanol while vortexing and kept at 4°C for at least 1 hour before 
continuing with the protocol to allow full penetration of the fixative. After 
this time, cells were washed twice in PBS, transferred to eppendorf tubes and 
each pellet resuspended in 1ml 2N HC1. Cells were left in acid for 30 mins at 
room temperature in order to partially denature the DNA. Centrifugation was 
then performed at 5000rpm for 5 min, the acid removed and each pellet 
resuspended in 1ml PBS. Cells were washed twice with this volume of PBS, 
once with PBT and then centrifuged as before. Each cell pellet was incubated 
with 100/<1 of mouse anti-BrdUrd at 1:40 dilution in PBT for 1 hour at room 
temperature and then washed twice with PBT. Following these washes, cells 
were incubated with 100/d of goat anti-mouse FITC at 1:40 dilution in PBT 
for 30 mins at room temperature. Samples were then washed once with PBT 
and once with PBS. It was at this point that a sample was dropped onto a 
clean glass slide, dried and mounted as for FISH analysis, to be examined 
under fluorescence microscopy. Remaining samples were stained with 
10/<g/ml PI for 30 mins at room temperature or overnight at 4°C. Samples 
were centrifuged as described previously, resuspended in 0.5-lm l PBS 
depending on the cell number and analysed with a flow cytometer. Samples 
were stored in the dark at 4°C.
2.2.13.2 FACS for Topoisomerase I la
Cells were trypsinised from 75 cm^ flasks of subconfluent 
cells, fed the night prior to harvesting and pelleted at 2,500 rpm for 5 mins.
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Cell pellets were then washed in PBS to remove any traces of medium and 
resuspended thoroughly in a small amount (100-200/d) of PBS. Five mis of 
1:1 methanol/acetone was then added slowly to each sample and left at room 
temperature for 10-15 mins to ensure cells are infused with fixative. Cells 
were then spun as detailed above and the fixing and pelleting step repeated. 
All fix was removed from cell pellets using a P200 Gilson pipette and pellets 
resuspended in 1-2 mis of 0.5% Boehringer Mannheim blocking reagent in 
PBST. Cells were blocked at room temperature for 10 mins, spun down and 
resuspended in 50-100/d of primary antibody.
Three different topoisomerase Ila  antibodies were used, these 
being a rabbit polyclonal from Cambridge Research Biochemicals (CRB) and 
a rabbit polyclonal and a mouse monoclonal from TopoGEN. The CRB 
antibody was used at 1:100 dilution and the TopoGEN antibodies were used at 
1:50 dilution. Cells were incubated with primary antibody for 1 hour at room 
temperature, following which they were spun down and washed twice with 3 
mis of PBST. Secondary antibodies were used at 1:100 dilution with an anti- 
mouse-FITC antibody used for detection of the monoclonal topoisomerase I la  
antibody and anti-rabbit-FITC antibody used for detection of the polyclonal 
primary antibodies. One hundred microlitres of secondary antibody dilution 
was used per sample of cells and left for 1 hour at room temperature. Samples 
were again spun down and washed twice with PBST as before.
At this point, a drop of each sample was put on a clean glass 
slide, dried and mounted with anti-fade mountant, as for FISH samples. This 
enabled samples to be examined under the fluorescence microscope as well as 
by FACS. Following the final wash, cells were resuspended in 1 ml of PBS to 
which 10 /d of a lOmg/ml propidium iodide was added. Cells were left to 
stain overnight at 4°C and were then spun down and resuspended in 
approximately 500/ri of PBS, depending on the number of cells per sample. 
FACS analysis was performed using a Coulter flow cytometer.
2.2.13.3 FACS for P-Glycoprotein and MRP
CALU-3, CALU-3/10-5M VP16, A2780, A2780/Adr, GLC4  
and GLC4/Adr were analysed by flow cytometry for P-glycoprotein and MRP 
status. Two different antibodies for P-glycoprotein were used, JSB-1 and 
MRK-16, as shown in Section 2.1.6 (kindly provided by Dr. Fiona Scott, 
MRC, Edinburgh). All antibodies were diluted to required strength in PBS 
with 3% BSA and 0.05% sodium azide. JSB-1 was used at l//g/ml and MRK- 
16 was used at 0.2/<g/ml. Three different dilutions of polyclonal anti-MRP
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serum (kindly provided by Professor Melvin Center) were used, 1:5, 1:25 and 
1:50. Cells were used in 1 x 10^ aliquots, obtained from trypsinised flasks. 
Samples of cells used for MRK-16 incubation were not fixed since this 
antibody recognises an external epitope of P-glycoprotein.
Cells were pelleted at 1500 rpm for 5 min at 4°C and then 
fixed in 70% ethanol in PBS at 4°C, if required. Samples were then washed 
twice in PBS at 4°C and incubated with 20/d of rabbit or goat serum for 
monoclonal or polyclonal primary antibodies respectively. Serum was 
incubated with cells for 10 mins at 4°C, following which samples were spun 
at 1500 rpm for 5 mins and serum removed. Cell pellets were then 
resuspended in 25/d of primary antibody and left on ice for 30 mins. Samples 
were then spun as before and washed three times in PBS/BSA/sodium azide. 
Following the final wash, the cell pellet was resuspended in 50/d of the 
appropriate secondary antibody and again incubated for 30 mins on ice. Cells 
were then washed for a further three times in PBS/BS A/sodium azide and 
finally resuspended in 500/d of PBS/BSA/sodium azide solution with 1 mg/ml 
propidium iodide.
Samples were analysed on a Becton-Dickinson FACScan 
machine using Hewlett Packard software. Data was acquired using Consort 30 
and analysed using LYSYS.
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CHAPTER 3
CHARACTERISATION OF A 17q AMPLICON 
IN THE NON-SMALL CELL LUNG 
ADENOCARCINOMA CELL LINE, CALU-3
3.1 Introduction
From previous work on the non-sm all cell lung 
adenocarcinoma cell line, CALU-3 it is known that this cell line has 
amplification of ERBB2 and TOPO Ila  genes (Keith et al., 1992). The 
ERBB2 gene has been found to be amplified in a variety of human 
adenocarcinomas including breast (Slamon et al., 1987; van de Vijver et al., 
1987; Varley et al., 1987), ovarian (Berchuck et al., 1990; Slamon et al., 
1989; Zheng et al., 1991) stomach (Park et al., 1989) and lung (Kern et al., 
1990; Schneider et al., 1989; Shi et al., 1992). ERBB2 amplification and 
overexpression has also been associated with tumour development and poor 
prognosis in breast cancer (Gullick et al., 1991; Lovekin et al., 1991; Muss et 
al., 1994; Slamon etal., 1989; Winstanley eta l., 1991; Wright eta l., 1992). 
Cases of ERBB2 and TOPO I la  co-amplification have previously been 
described in breast tumours (Keith et al., 1993; Murphy et al., in press; Smith 
et al., 1993). This co-amplification is thought to arise because the two genes 
are situated in close proximity on chromosome 17q, both having been mapped 
previously to 17q21-22 (Fukushige et al., 1986; Tan et al., 1992; Tsai- 
Plugfelder et al., 1988). Therefore, the situation of TOPO II a  and ERBB2 co­
amplification observed in CALU-3 appears to mimic that seen in a certain 
subset of breast tumours.
The co-amplification of ERBB2 and TOPO I la  genes is also of 
interest from a clinical point of view since cell lines found to have this co­
amplification appear to be more sensitive to topoisomerase II inhibitors than 
those lacking TOPO Ila  amplification (Keith et al., 1993; Smith et al., 1993). 
This could lead one to postulate that those tumours which have ERBB2 and 
TOPO I la  co-amplification may be more sensitive to treatment with 
topoisomerase II inhibiting agents. The CALU-3 cell line has also been found 
to be very sensitive to the topoisomerase II targeting agents VP16 and 
doxorubicin (Merry et al., 1987) and so may be a viable model for the study of 
changes around chromosome 17q which occur in breast cancer. There are a 
number of interesting genes on 17q including NF1, G-CSF, NM23H1, RARa
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and PKCa as well as the BRCA1, familial breast cancer gene region. Thus, 
the aim of the work presented in this chapter was to further characterise the 
17q amplicon in CALU-3 by investigating whether any of the above genes 
were also co-amplified.
Initial studies were performed using cDNA probes for the 
various genes in Southern blotting of CALU-3, L-DAN and SK-MES-1 DNA. 
Using this technique, the intensity of bands detected on an autoradiograph is 
indicative of the gene copy number of the probe used. However, Southern 
blotting does not provide any information on the chromosomal localisation of 
gene copies. In order to find out more structural information on the 17q 
amplicon in CALU-3, fluorescence in situ hybridisation (FISH) was 
performed. Using this technique, whole chromosomes, chromosome-specific 
centromeres and single-copy genes can be detected, as depicted in Figure 3A. 
Chromosome painting (Carter, 1994; Lichter et al., 1988) was used with a 
flow-sorted chromosome 17 paint to specifically detect chromosome 17 
sequences in metaphase spreads from L-DAN, CALU-3 and SK-MES-1. This 
particular kind of probe is extremely useful for detecting gross abnormalities 
of chromosomes, such as translocations. As shown in Figure 3A, 
chromosome-specific centromere probes are also available, or can readily be 
synthesised using PCR from alpha satellite arrays present at chromosome 
centromeres (Willard, 1990; Haaf & Willard, 1992). Such centromere probes 
are useful in checking that single-gene probes are hybridising to the correct 
chromosomes. Multiple single gene probes can also be used in the same 
hybridisation (Heppell-Parton et al. , 1994; Inazawa et al. , 1994). This is 
particularly useful for investigating possible co-localisation of genes on a 
chromosome and also for ordering of gene probes.
All FISH experiments performed in this chapter utilised 
chromosomes isolated from either normal lymphocytes or the three non-small 
cell lung cancer cell lines, L-DAN, CALU-3 or SK-MES-1, but FISH can also 
be performed on frozen or paraffin sections of tissue (Murphy et al., in press) 
and in isolated interphase nuclei (Amoldus eta l., 1991; Bar-Am etal., 1992; 
Devilee et al., 1988; Kallioniemi et al., 1992b). Whatever the target material 
is, the basic methodology for FISH is the same. This is outlined in Figure 3B, 
using chromosomes as the target material. In this technique, chromosomes are 
isolated from cells by treatment of the cells with colcemid. This drug blocks 
cells at the metaphase stage of the cell cycle by interfering with spindle 
formation. Cells are then swollen with a hypotonic solution and fixed. Drops 
of the fixed cell suspension are dropped from a height onto clean glass slides.
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Figure 3A
General uses of fluorescence in situ hybridisation (FISH)
This figure depicts the different chromosomal regions which can 
be detected using FISH and the uses of the different probes.
Black areas indicate normal, unhybridised chromosome sequence. 
Red or blue areas indicate hybridisation of probe.
Whole chromosome paints will hybridise to sequences along the 
entire length of a particular chromosome. These probes are 
extremely useful for analysis of chromosomal translocations. 
Centromere probes that are specific for individual chromosomes 
are also available and can be used to ensure that a single-copy gene 
probe is hybridising to the correct chromosome.
Cosmids carrying sequences from single copy genes can be used to 
check actual gene copy number. Multiple single-copy gene 
cosmids can be used in hybridisations, provided different 
fluorochromes are used for their detection. This technique is 
useful when studying the co-localisation and order of genes.
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Figure 3B
Basic methodology for FISH
This figure depicts the basic protocol for FISH experiments using 
chromosomes as the target material.
Cells are treated in culture with colcemid which interferes with the 
spindle production during mitosis and thus traps cells at 
metaphase. Hypotonic treatment of these cells causes them to 
swell at which point cells are fixed in a mixture of methanol and 
acetic acid. When cells are then dropped onto clean glass slides, 
they burst and release the chromosomes to which probes can then 
be hybridised. Slides are then subjected to a further
fixation step, RNase treatment (to digest any RNA present) and 
mild protease treatment, which aids probe penetration of the DNA. 
A short post-fixation step is then performed following which slides 
are treated with hot 70% formamide which denatures the dsDNA 
to ssDNA.
The required gene probe is labelled with either biotin or 
digoxigenin (DIG), achieved through a nick translation reaction 
using biotin or digoxigenin-conjugated nucleotide/' The probe is 
also denatured by heat treatment prior to hybridisation.
The denatured probe is then applied to the denatured chromosomes 
and incubated overnight at 37°C in a humidified chamber. 
Following this, numerous washes are performed to remove 
unhybridised probe and the probe can then either be detected using 
antibodies (in the case of DIG probes or biotin probes) or cycles of 
avidin-FITC/anti-biotin detection (only for biotin probes). Various 
different fluorochromes can be conjugated to the second antibody 
such as FITC, Texas Red or Cy^.
Samples are then analysed by confocal laser scanning microscopy.
•  •
CELLS
PROBE
V
<yV CHI
LABELLING
REACTION
ROMOSOMES
y
TARGET
DENATURE 
TO ssDNA
DENATURE
TO ssDNA
i
/
Chromosomes
HYBRIDISATION
DETECTION
The force of the cells hitting the slide causes them to burst thus the 
chromosomes are released from the nucleus. Once slides have been prepared 
they are fixed again, treated with RNase to digest any RNA which may cause 
background in the hybridisation and given a mild protease treatment. 
Following another fixation step the samples are denatured in hot 70% 
formamide solution. This treatment causes the dissociation of dsDNA to form 
ssDNA. The probe which is to be used in the hybridisation is labelled with a 
hapten, usually either biotin or digoxigenin. This is achieved by nick 
translation of the probe with biotin- or digoxigenin-conjugated nucleotides. 
Human Cotl DNA is usually added to single-copy gene probes in order to 
compete out any repetitive DNA sequences which may be present (Lichter et 
at., 1988). Labelled probe is resuspended in a formamide-based hybridisation 
solution. This solution can be made more or less stringent for probe binding 
depending on the concentration of formamide used (usually 50% for single­
copy gene probes and 70% for repetitive sequence probes). Denaturation of 
the probe is then carried out, followed by a period of incubation at 37°C to 
allow reannealing of the repetitive sequences. Hybridisation of probe and 
sample is performed overnight at 37°C in a humidified chamber.
Probe detection can be achieved using antibodies, or 
biotin/avidin reactions with secondary antibody or avidin being conjugated to 
a fluorochrome. Multiple fluorochromes are required if more than one probe 
is used. Commonly used fluorochromes are fluorescein isothiocyanate 
(FITC), which produces green fluorescence, and Texas Red and Cy^ which 
both produce red fluorescence. Once detected, samples can be analysed using 
conventional fluorescence microscopy or a laser scanning confocal 
microscope. Analysis by confocal microscopy enables use of fluorochromes 
which are not excited by ultra-violet light, such as Cy5.
As well as characterisation of genes involved in the 17q 
amplicon in CALU-3, the process of amplification is also of interest in this 
study. As mentioned in Chapter 1, amplification of genes is one mechanism 
whereby cells can override the growth restrains which are normally imposed 
on them. Thus the mechanism by which this amplification occurs is also 
extremely important. FISH analysis can be extremely informative in this 
respect since the location of genes are visualised on the chromosomes, and 
this technique has been used to previously to investigate mechanisms of 
amplification (Smith et al. , 1990; Trask & Hamlin, 1989; Windle et al., 
1991). Amplified DNA can be visualised either as extended chromosomal 
regions (ECRs), also referred to as homogeneously staining regions (HSRs), 
or as extrachromosomal elements, such as episomes or double minutes (DMs).
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Double minutes are small, paired circular DNA molecules which lack 
centromeres, j Replication of double minutes, initiated from replication origins 
(Carroll et d . , 1993), has been found to occur at approximately the same time
as that of the j corresponding sequences in the genome (Carroll etal., 1991).
Double minutes carrying the c-MYC oncogene 
have been found in cases of acute myeloid leukaemia (Slovak et al., 1994) and 
the P-glycoprotein encoding gene, MDR1, has also been localised to DMs in 
colchicine-selected cells (Schoenlein et al., 1992). It is thought that double 
minutes are formed via deletion of gene sequences from chromosomes (Hahn, 
1993; Wintersberger, 1994). Although DMs appear to be stable once formed, 
integration of DMs into chromosomes (to form HSRs) has been observed 
(Carroll et al., 1988) and it has been proposed that double minutes are the 
precursors to HSRs in cells (Wahl, 1989). More details concerning 
characterisation and importance of DMs in gene amplification can be found in 
the recent review by (Hahn, 1993).
Homogeneously staining regions are a common source of 
amplified genes in mammalian cells. Analyses of such HSRs has been 
performed on drug-resistant rodent, and particularly hamster, cell lines since it 
has been discovered that certain genes become amplified on exposure to 
particular drugs (Flintoff et al., 1984; Hyrien et al., 1988; Kaufman & 
Schimke, 1981; Smith et al., 1990; Trask & Hamlin, 1989). Chinese hamster 
ovary (CHO) cell lines appear to be particularly amenable to such gene 
amplification. When'CHO cells are exposed to increasing concentrations of 
| methotrexate (MTX), they become resistant to this drug via over-production 
of the enzyme dihydrofolate reductase (DHFR), which is the target of MTX. 
Therefore, the excess enzyme in the cell neutralises the MTX whilst enough 
DHFR is present to continue its normal role in the cell. Chinese hamster cells 
over-producing adenylate deaminase (AMPD) have also been isolated 
following exposure of the cells to coformycin, an inhibitor of AMPD 
(Debatisse et al., 1986; Hyrien et al., 1988). These cells were found to 
possess 150 copies of an amplicon containing the gene for AMPD. Another 
model system utilised is that of amplification of the carbamoyl-P synthetase, 
aspartate transcarbamylase, dihydro-orotase (CAD) gene in Syrian hamster 
cells (Smith et al., 1990; Smith et al., 1992) which can be induced by 
exposure to the inhibitor N-phosphonoacetyl-L-aspartate (PALA). The CAD 
gene encodes a tri-functional protein involved in UMP biosynthesis. In the 
Syrian hamster cells, the amplified CAD genes are found in multiple copies of 
large regions of DNA, with each of these regions being tens of megabases in 
length.
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The fact that the systems outlined above can be manipulated in 
vitro to produce these extended chromosomal regions means that they are also 
extremely useful for investigating mechanisms of DNA amplification. Many 
different models for mechanisms of gene amplification have been proposed 
recently reviewed in (Stark, 1993; Wintersberger, 1994). These proposed 
mechanisms can be divided into two groups based on the initial cause of the 
amplification, these being either over-replication from a replication origin or 
recombination between sister chromatids or chromosome homologues.
The earliest model proposed for gene amplification was the 
"onion-skin" model, depicted in Figure 3C. This mechanism was initially 
proposed to account for SV40 virus excision in transformed cells (Botchan et 
al., 1979) but had also been extended to account for amplification in 
mammalian cells (Roberts et al., 1983; Varshavsky, 1981; Schimke et al., 
1986). The mechanism proposes that a replication origin is initiated more 
than once per cell cycle. This causes "runaway" replication of the replicon 
resulting in the layered effect of replication bubbles, similar to the layers of an 
onion skin, hence the name. This final structure is thought to be very unstable 
and can break down to produce numerous structures including episomes and 
DNA duplexes containing amplified DNA sequences (Stark et al., 1989). 
However, later experiments on gene amplification in mammalian cells 
attempting to repeat data already published implied that this mechanism may 
not be the basis for the genetic changes seen with gene amplification (Hahn et 
al., 1986). It is now thought that this mechanism does not play a major role in 
the amplification of mammalian genes. This onion-skin model is used to 
explain amplification of developmentally regulated genes in Drosophila and 
Sciara (Delidakis & Kafatos, 1989; Kafatos et al., 1985; Liang et al., 1993).
Mechanisms of gene amplification in mammalian cells have 
been analysed mainly using the numerous hamster cell line models outlined 
previously. The mechanism of formation of an amplicon can only really be 
deduced, however, from the early stages of amplification (Ma et al., 1993; 
Smith eta l., 1990; Trask & Hamlin, 1989; Windle eta l., 1991) since further 
amplification may be caused by additional mechanisms only permitted 
because of the resulting DNA structure after the initial genetic change. The 
four papers referred to above all conclude that the genetic changes observed in 
early gene amplification are most likely due to unequal sister chromatid 
exchange and subsequent bridge/breakage/fusion cycles. This mechanism for 
gene amplification is shown in Figure 3D (adapted from Wintersberger, 
1994). This figure shows the possible pathways leading to gene amplification 
starting with a normal chromosome. The normal chromosome is shown with
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Figure 3C
"Onion-skin" model for gene amplification by over-replication
(adapted from Stark etal., 1989)
This figure shows one of the first models proposed for gene 
amplification.
The red lines show origins of replication and the arrowed lines 
represent replication forks moving in the direction of the 
arrowhead.
The model begins with normal replication proceeding from a 
replication origin. This produces a bubble of DNA consisting of 
the two parental strands and two newly replicated, daughter 
strands. Some obstruction in replication then occurs which 
prevents this structure from being resolved and causes the 
replication origin to fire again, resulting in the replication of the 
daughter strands. This cycle could be repeated many times, thus 
forming layers of partially replicated DNA duplexes. This 
structure is extremely unstable and could resolve by intra- or inter- 
duplex DNA recombination to produce episomes or large arrays of 
amplified genes, respectively.
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Figure 3D
Sister chromatid exchange and bridge/breakage/fusion model
of gene amplification
(adapted from Wintersberger, 1994)
This figure shows the most popular proposed model for 
mammalian gene amplification.
The model begins with a normal chromosome depicted as having 
orange and green sister chromatids, for ease of distinction of 
chromatids. The black circle represents a centromere and the blue 
circle represents the gene to be amplified.
There are three possible pathways which this chromosome can 
follow in order to produce gene amplification:
Pathway A is a simple telomere breakage-fusion model where a 
break occurs by the telomere region of each sister chromatid. This 
creates frayed chromosome ends which are healed by sister 
chromatid fusion. A dicentric chromosome is thus produced which 
breaks during the next round of DNA replication to produce one 
chromosome with two copies of the gene and one lacking any 
copies.
Pathway B also results in the formation of a dicentric chromosome, 
but in this pathway it is formed by unequal sister chromatid 
exchange occurring between the gene and the telomere followed by 
DNA breakage. An acentric chromosomal fragment is also formed 
which will probably be lost during the following round of DNA 
replication.
Pathway C results in the formation of two monocentric 
chromosomes via unequal sister chromatid exchange occurring 
above the gene in one chromatid and below the gene in the other. 
Therefore, one chromosome carries both copies of the gene and the 
other lacks any copies.
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orange and green sister chromatids (for ease of distinction of chromatids), the 
blue circle is the gene to be amplified and the black circle is the centromere. 
In pathway A, frayed telomeres are created, presumably by incorrect DNA 
replication or repair causing DNA breakage, and the sister chromatids then 
fuse at the free ends. This process creates a dicentric chromosome which will 
break at the next round of replication to produce one chromosome with two 
copies of the gene and a chromosome fragment, which retains a centromere. 
Both of these molecules will only have one intact telomere, thus the cycle of 
bridge/fusion and breakage could continue into the next round of replication. 
Pathway B results in the same dicentric chromosome as pathway A, but this 
arises through unequal sister chromatid exchange rather than telomere loss. 
Pathway C again shows a method involving non-homologous recombination, 
but the end results of this exchange are two monocentric chromosomes, one of 
which lacks the gene in question and one of which has both copies.
Abnormalities of telomeres have been observed in a variety of 
different tumour types, such as renal (Holzmann et al., 1993; Mehle et al., 
1994), brain (Sawyer et al., 1993), melanoma (Melzter et al., 1993) and 
colorectal (Hastie et al., 1990). The most common abnormality appears to 
involve shortening of the telomere which makes the telomere unstable and 
creates a "sticky” end to which other chromosomes may associate. It has also 
been shown using Chinese hamster ovary cells that telomeric DNA sequences 
are more likely to break following exposure to ionising radiation than any 
other part of the total genome (Alvarez et al., 1993). This evidence lends 
more weight to the suggested telomere-breakage model of gene amplification 
previously proposed. Indeed, when the early steps of gene amplification are 
studied, chromosomal changes which could be explained by the unequal sister 
chromatid exchange and bridge/breakage/fusion model are found (Ma et al., 
1993; Smith et al., 1990; Smith et al., 1992; Toledo et al., 1992; Trask & 
Hamlin, 1989; Windle et al., 1991). The general chromosomal changes 
observed in all the above studies include the formation of dicentric 
chromosomes and the discovery that the original copy of the gene appears to 
remain associated with the amplified region. Also, inverted duplication of 
sequences is commonly observed which would be indicative of telomeric 
fusion of sister chromatids.
The work presented in this chapter uses various methods of 
genetic analysis to further characterise the chromosome 17q amplicon found 
in the NSCLC cell line CALU-3. Initial detection of amplified genes from 
chromosome 17 was achieved using Southern analysis. More detailed genetic
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analysis has been performed using the technique of fluorescence in situ 
hybridisation.
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3.2 Results
In this chapter, genetic changes to chromosome 17 have been 
analysed by Southern blot hybridisation and fluorescence in situ hybridisation 
(FISH) in the three non-small cell lung cancer cell lines L-DAN, CALU-3 and 
SK-MES-1. Previous work by Keith et al. has shown CALU-3 to have 
amplified TOPO Ila  and ERBB2 genes (Keith et al., 1992). The results 
shown here demonstrate the use of other gene probes from the 17q region, as 
well as those for ERBB2 and TOPO Ila  genes, in a more detailed study of the 
chromosome 17 amplicon in CALU-3. L-DAN and SK-MES-1 were included 
as examples of NSCLC cell lines which show no evidence of amplification of 
chromosome 17q.
Characterisation of the 17q Amplicon by Southern Analysis
Southern blot hybridisation was performed using DNA isolated 
from CALU-3, L-DAN and SK-MES-1 in order to detect amplified gene 
sequences from the long arm of chromosome 17. Figures 3.1 and 3.2 show 
the results of Southern analysis of L-DAN, CALU-3 and SK-MES-1 with a 
number of different probes from genes on 17q. Figure 3.1 shows the same 
Southern filter re-probed with 4 different 17q gene probes (TOPO Ila , 
ERBB2, RARa and NM23H1). An immunoglobulin probe from chromosome 
14, pHJi, was also used to assess samples. From the results of the pHJi 
probing, all the lanes appear to be relatively equal in signal and are therefore 
equally loaded. Thus the amplified signal seen in the CALU-3 lanes (1, 4, 7 
and 10) in those panels showing results of TOPO I la , ERBB2 and RARa 
gene probings is not due to overloading of CALU-3 DNA. The amplification 
of TOPO I la  and ERBB2 seen in CALU-3 in Figure 3.1 also agrees with the 
results previously obtained by Keith et al., as mentioned above. From the 
NM23H1 probed filter it can be seen that there does not appear to be 
amplification of this gene in any of the three cell lines. Figure 3.2, panel (a) 
demonstrates that there is also low level amplification of the G-CSF gene in 
CALU-3 (lanes 1, 4, 7, 10, 13 and 16). Panel (b) shows pHJi probing of the 
same filter from panel (a). It can therefore be seen that the CALU-3 lanes are 
not overloaded, thus the amplification seen in panel (a) is genuine. Panels (c) 
and (d) in Figure 3.2 show the results of PKCa and pHJi probing of a filter 
with CALU-3 DNA present in lanes 3, 6 ,9  and 12. Panel (d) shows that there 
is equal DNA loading of the samples. Therefore, as seen in the NM23H1
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Figure 3.1
Southern blot analysis of L-DAN, CALU-3 and SK-MES-1.
The same blot was probed with SP1 (TOPO Ila), 
pCer204 (ERBB2), p63 (RARa), nm23Hl (NM23H1)
The pHJi probe was used as a loading control
Marker sizes in kilobases are shown on the right of each panel
Lanes 1, 4 ,7 & 10: CALU-3 , Lanes 2 ,5 ,8  & 11: L-DAN, 
Lanes 3 ,6 ,9  & 12: SK-MES-1
DNA loaded in lanes 1-3 was digested with TaqI 
DNA loaded in lanes 4-6 was digested with EcoRI 
DNA loaded in lanes 7-9 was digested with PstI 
DNA loaded in lanes 10-12 was digested with BamHI
In the panels which show the results of TOPO Ila, ERBB2 and 
RARa probings, a more intense signal can be seen in the CALU-3 
lanes (1,4,7 and 10) than in the L-DAN or SK-MES-1 lanes.
The signal observed in the NM23H1-probed blot is very similar 
between all the samples.
DNA loading is almost equal between the samples, as can be seen 
from the pHJi-probed blot.
Therefore,by Southern blotting the CALU-3 cell line appears to 
have amplification of TOPO Ila, ERBB2 and RARa genes. The 
NM23H1 gene is not amplified in CALU-3.
No differences are observed in digest patterns between L-DAN, 
CALU-3 and SK-MES-1, thus there do not appear to be any 
rearrangements within those genes amplified in CALU-3.
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Figure 3.2
Further Southern blot analysis of L-DAN, CALU-3 and
SK-MES-1.
Panels (a) & (b) show the same blot probed with G-CSF and pHJi probes,
respectively
Lanes 1 ,4 ,7 ,10,13 & 16: CALU-3, Lanes 2 ,5 ,8 ,11 ,14  & 17: L-DAN 
Lanes 3, 6,9 ,12,15 & 18: SK-MES-1 
DNA loaded in lanes 1-3 was digested with XmnI 
DNA loaded in lanes 4-6 was digested with PstI 
DNA loaded in lanes 7-9 was digested with TaqI 
DNA loaded in lanes 10-12 was digested with Bglll 
DNA loaded in lanes 13-15 was digested with BamHI 
DNA loaded in lanes 16-18 was digested with EcoRI
Panels (c) & (d) show the same blot probed with PKCa and pHJi probes,
respectively
Lanes 1,4, 7, & 10: SK-MES-1, Lanes 2,5, 8, & 11: L-DAN 
Lanes 3 ,6 ,9  & 12: CALU-3 
DNA loaded in lanes 1-3 was digested with TaqI 
DNA loaded in lanes 4-6 was digested with EcoRI 
DNA loaded in lanes 7-9 was digested with PstI 
DNA loaded in lanes 10-12 was digested with BamHI
pHJi was used as a loading control 
Marker sizes are shown in kilobases on the right of each panel
In panel (a), which shows the result of G-CSF gene probing, the strongest 
signal is observed in lanes containing CALU-3 DNA. DNA loading is fairly 
consistent between L-DAN, CALU-3 and SK-MES-1, as can be seen from 
panel (b). Therefore, CALU-3 also appears to have amplification of the G- 
CSF gene.
Panel (c) shows the result of PKCa gene probing. The strongest signals on 
this filter appears to be in the lanes containing SK-MES-1 DNA. From panel 
(d) these lanes are also found to have the highest DNA loading. Therefore, the 
PKCa gene is not amplified in CALU-3.
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probed blot in Figure 3.1 there does not appear to be any amplification of this 
gene in CALU-3, L-DAN or SK-MES-1. Various enzyme digests were 
performed on the samples in order to detect any possible rearrangement of the 
genes to be analysed. However, no differences in banding patterns were 
observed between CALU-3, L-DAN and SK-MES-1, thus none of the genes 
analysed appear to be rearranged in CALU-3.
Thus, in CALU-3 an amplicon exists which contains the TOPO 
Ha, ERBB2, RARa and G-CSF genes, as detected by Southern analysis. The 
NM23H1 and PKCa genes are outside this region of amplification in CALU- 
3. None of the genes analysed in this section by Southern blot analysis are 
amplified in L-DAN or SK-MES-1.
Isolation of Cosmid Probes for NM23H1, RARa, TOPO Ila  and NF1
Cosmid probes for genes on 17q were required for fluorescence 
in situ hybridisation (FISH) studies. Cosmid probes for NM23H1, RARa, 
TOPO I la  and NF1 were all obtained from the Imperial Cancer Research 
Fund Reference Library-DataBase (ICRF RLDB) (Lehrach, 1990). The 
retinoic acid receptor alpha cosmids (digests of which are shown in Figure 
3.3) were obtained through screening of chromosome 17 library filters with 
both a-32P-dCTP-labelled oligos from the RARa gene and the p63 RARa 
plasmid probe used in Southern analysis. Positive clones were identified, co­
ordinates calculated and these co-ordinates sent back to the ICRF RLDB. 
Agar stabs of positive clones were then received and the cosmids isolated as 
outlined in Section 2.2.8.4. Cosmids for NM23H1, TOPO Ila  and NF1 genes 
were also requested from the ICRF RLDB.
Panel (a) in Figure 3.3 shows an ethidium bromide stained 
Southern gel on which digested DNA of TOPO Ila  , RARa and NM23H1 
cosmids has been run. Panel (b) shows the autoradiograph which resulted 
from probing of the filter from this gel with the NM23H1 gene probe, 
previously used in Southern analysis. Thus it can be seen that only lanes (a) 
and (b), which contain undigested and digested DNA from the NM23H1 gene 
cosmid, respectively, show positivity following this probing. The smear seen 
in one of the lanes containing TOPO I la  cosmid DNA was caused by 
detection of repetitive DNA sequences and is not specific. Therefore, the 
ICRFcl05H12160 cosmid is specific for the NM23H1 gene.
Panel (c) shows an ethidium stained Southern gel of undigested 
and digested TOPO I la  cosmids received from the ICRF RLDB. The filter 
produced from this gel was hybridised with the SP1, TOPO I la  gene probe,
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Figure 3.3
Confirmation of identity of ICRF NM23H1 and TOPO I la  
cosmids by Southern analysis.
Panel (a): Ethidium bromide stained Southern gel showing undigested and 
digested TOPO Ila  (as marked), RARa (as marked) and NM23H1 cosmid
(lanes a and b).
Panel (b): Autoradiograph resulting from incubation of filter from gel in 
panel (a) with NM23H1 Southern probe.
Lane a: ICRFcl05H 12160, undigested 
Lane b: ICRFcl05H12160, EcoRI digested
Panel (c): Ethidium bromide stained Southern gel showing undigested and 
digested ICRF TOPO I la  cosmids.
Panel (d): Autoradiograph resulting from incubation of filter from gel in 
panel c with TOPO I la  (SP1) Southern probe.
Lanes 1&  2: ICRFcl05G0847, Lanes 3 &4: ICRFcl05G01101,
Lanes 5 & 6: ICRFcl05C0867, Lanes 7 & 8: ICRFcl05C0913,
Lanes 9 & 10: ICRFcl05H01119, Lanes 11 & 12: ICRFcl05C1056, 
Lanes 13 & 14: ICRFcl05B04155, Lanes 15 & 16: ICRFcl05A09111, 
Lanes 17 & 18: ICRFcl05A07140 
Lanes 19 & 20: ICRFcl05C0967,
Lanes 21 & 22: ICRFcl05E1029,
Lanes 23 & 24: ICRFcl05G1239.
M: Lambda x Hindlll Marker
Odd numbers: Undigested cosmid DNA 
Even numbers: EcoRI digested cosmid DNA
Marker sizes in base pairs are shown on the right of panels (a) and (c)
Panel (b) shows that only the NM23H1 cosmid, ICRFcl05H12160, hybridises 
with the NM23H1 gene probe.
Panel (d) shows that all the TOPO I la  cosmids hybridise with the SP1 probe.

and the resulting autoradiograph is shown in panel (d). Therefore, all TOPO 
Ha cosmids received from the ICRF hybridise to this probe. From panels (c) 
and (d), the largest clones were chosen for use in FISH analysis, these being 
ICRFcl05B04155 and ICRFcl05H01119. All eight RARa cosmids received 
from the ICRF were used in FISH analysis and ICRFcl05F1255 was chosen 
for use in further experiments due to its1 hybridisation efficiency.
Investigation of Gross Genetic Changes to Chromosome 17 in L-DAN, 
CALU-3 and SK-MES-1 by FISH
Initial FISH experiments with L-DAN, CALU-3 and SK-MES- 
1 were performed using whole chromosome 17 paints andj[chromosome 17- 
specific centromere probe. These probes enable any gross changes to 
chromosome 17 to be investigated since the paint probe will identify 
sequences from anywhere along the length of chromosome 17, thus making it 
possible to detect translocations involving this chromosome.
Figure 3.4 shows the results of using both the whole 
chromosome 17 paint and chromosome 17-specific centromere probe on 
normal lymphocyte (panels a & e), CALU-3 (panels b & f), L-DAN (panels c 
& g) and SK-MES-1 (panels d & h) metaphase chromosome spreads. In 
lymphocytes, two copies of chromosome 17 are observed (panel a), as shown 
by the two chromosomes which are visualised in green. Two copies of 
chromosome 17 centromere are also observed in normal lymphocytes (panel 
e), as shown by the two green spots on two of the chromosomes in the spread. 
When these probes are used on CALU-3 chromosomes, the results appear to 
be very different from those seen in lymphocytes. No single chromosome 
within the CALU-3 metaphase spread hybridises in its entirety to chromosome 
17 paint (panel b). Instead, there appear to be seven different chromosomal 
regions to which the paint hybridises. When chromosome 17-specific 
centromere probe was used (panel f), five chromosomes were seen to react 
with this probe. This indicates that not all of the chromosome 17 regions 
detected by chromosome 17 paint are associated with a chromosome 17 
centromere sequence.
When L-DAN chromosomes were hybridised with 
chromosome 17 paint and centromere probes (panels c and g respectively) it 
was discovered that this cell line appears to have three copies of chromosome 
17, and three chromosome 17 centromeres. Therefore, it appears that these 
three chromosomes still possess chromosome 17 centromeres. However, it 
cannot be said that these chromosomes are normal copies of chromosome 17,
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Figure 3.4
Detection of chromosome 17 and chromosome 17 centromere 
in lymphocytes and lung tumour cell lines by FISH.
Panels (a) & (e): Normal lymphocytes 
Panels (b) & (I): CALU-3 
Panels (c) & (g): L-DAN 
Panels (d) & (h): SK-MES-1
Chromosomes were visualised with PI (pseudocoloured red). 
Chromosome 17 and chromosome 17-specific centromere signals 
wer6 visualised with FITC (pseudocoloured green).
Chromosome 17 paint from Cambio was used to detect 
chromosome 17 sequences. Our own PCR-produced centromere 
17-specific alpha satellite probe was used to detect chromosome 17 
centromere sequences.
In lymphocytes, two copies of chromosome 17 (panel a) and 
chromosome 17 centromere (panel e) are observed, as would be 
expected in a normal cell.
CALU-3 appears not to have any intact chromosome 17s\ but has 
7 major regions of hybridisation to the chromosome 17 paint 
(panel b). Panel f shows CALU-3 to have 5 chromosome 17 
centromere sequences.
L-DAN appears to have three copies of chromosome 17 and 
chromosome 17 centromere (panels c and g, respectively). 
SK-MES-1 appears to have six regions of hybridisation to the 
chromosome 17 paint (panel d) and three chromosome 17 
centromere sequences (panel h).

since this analysis can only detect gross changes to chromosomes. Panels (d) 
and (h) show the results of whole chromosome 17 painting and chromosome 
17 centromere detection in SK-MES-1. This cell line appears to have six 
regions of chromosome 17 paint hybridisation (panel d) and three 
chromosome 17 centromere sequences (panel h). Therefore, as in CALU-3, 
some of the chromosome 17 detected regions are not associated with 
chromosome 17 centromeres.
Co-hybridisation of Single-Copy Gene Cosmids with Chromosome 17- 
Specific Centromere Probe in Lymphocytes
To confirm the co-localisation of gene cosmids to particular 
chromosomes, single-copy gene cosmids can be co-hybridised with 
chromosome-specific centromere probes. Figure 3.5 shows double 
hybridisation of all single-copy gene cosmids used in FISH analysis with the 
chromosome 17-specific centromere probe in lymphocytes. Green signal 
indicates hybridisation of single-copy probe and red signal indicates 
hybridisation of chromosome 17 centromere probe. In all panels, four single­
copy gene signals can be seen on each metaphase spread. This is a result of 
the gene being detected on both chromatids of each chromosome 17. Thus it 
can be seen that all the cosmids used do hybridise to chromosome 17 in 
lymphocytes.
Three different TOPOII a  gene cosmids were available for use 
in FISH, pC5, ICRFcl05H01119 and ICRFcl05B041155. To discover if 
there was any difference in results obtained from using the different probes in 
FISH, counts were made of hybridisation signals from 20 lymphocyte 
metaphase spreads. These counts are shown in Table 3.1. In each case 20 
metaphase spreads were counted and it was assumed that the maximum total 
number of hybridisation counts possible was 80 (four per metaphase spread). 
Therefore, the final percentage hybridisation frequency was calculated as total 
counts from that experiment divided by 80 and multiplied by 100. 
Hybridisation frequencies in Table 3.1 show that the ICRFcl05B04155 
cosmid has the highest frequency and thus is the most efficient at detecting the 
TOPO II a  gene. Hybridisation frequencies were also calculated for NF1, 
NM23H1, RARa and C05123 cosmids on lymphocyte metaphase spreads. 
These frequencies are shown in Table 3.2.
Since all the gene probes used were all situated around the 
same region of chromosome 17, it was very difficult to deduce an order for the 
probes by eye. Therefore, photographs of hybridisations in lymphocytes were
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Figure 3.5
Double hybridisation of single-copy gene cosmids and 
chromosome 17 centromere probe in lymphocytes.
Each panel shows a different single copy gene cosmid (from the 
17q region) hybridised in conjunction with the PCR-produced 
chromosome 17-specific centromere probe to metaphase spreads 
prepared from normal lymphocytes.
Single gene cosmids used: ICRFcl05B041155 (TOPO Ila)
C05123 (BRCA1 region)
ICRFcl05C0861 (NF1)
Neul and Neu4 (ERBB2) 
ICRFcl05F1255 (RARct) 
ICRFcl05H12160 (NM23H1)
Chromosomes were visualised with PI (pseudocoloured blue), 
single gene cosmids were visualised with FTTC (pseudocoloured 
green) and chromosome 17 centromere sequence was visualised 
with Cy^ (pseudocoloured red).
In each panel two chromosome 17s are observed, both with single 
gene cosmid signal (green) and centromere signal (red). Two 
cosmid signals are seen on each chromosome (four per metaphase 
spread) due to detection of the single-copy gene gene on each of 
the chromosome arms.
Small panel within each picture shows close-up of a chromosome 
17 from that spread.
Therefore, this confirms that all of the single gene cosmids used do 
hybridise to chromosome 17 in normal lymphocytes.

Table 3.1
Relative hybridisation frequencies of the three TOPO II a  
cosmids, pC5, ICRFcI05H01119 and ICRFcl05B041155 on 
lymphocyte metaphase spreads.
Cosmid
Used
No. of chr. 
spreads 
counted
Total no. of 
chr. with 
signal
Total no. of 
signals
%age
hybridisation
frequency
pC5 20 34 63 78%
HOI119 20 38 72 90%
B041155 20 39 73 91%
Table 3.2
Hybridisation frequencies of NF1, NM23H1, RARa and 
C05I23 cosmids on lymphocyte metaphase spreads.
Gene
Locus
Cosmid
Used
No. of chr. 
spreads 
counted
Total no. 
of chr. 
with 
signal
Total no. 
of signals
%age
hybrid11
frequency
NF1 C0861 20 40 63 78%
NM23H1 H12160 20 39 67 83%
RARa F1255 20 40 77 96%
Unknown C05123 20 39 67 83%
Percentage hybridsation efficiency was calculated on the basis of 4 signals 
(doublets) being detected per metaphase spread.
used to obtain fractional length measurements for each of the single-copy gene 
cosmids (Tanner et al., 1994). The SigmaScan programme on PC was used to 
take these measurements. Measurements were taken from the tip of the p arm 
of chromosome 17 down to the single-copy cosmid signal (FL1), and then 
from the single gene signal down to the tip of the q arm (FL2). Fractional 
length measurement 1 (FL1) was then expressed as a fraction of the sum of 
FL1 and FL2.
FL2
FL1
Table 3.3 shows the mean, median and standard deviation of fractional length 
measurements taken for all the gene cosmids used in FISH. Figure 3.6 shows 
the distances of the genes from the p arm of chromosome 17 according to the 
mean fractional length measurement. Mann-Whitney analysis of all possible 
gene combinations was also performed using the median FL. Results of this 
analysis are shown in Table 3.4. These results show that the distances 
between almost all the gene pairs are significant if level of significance is set 
at 10% (p=0.1). Gene pairs analysed which give a p-value greater than or 
close to 0.1 are assumed to be located very close together on chromosome 
17q. Therefore, fractional length measurements enabled ordering of the gene 
cosmids used in FISH analysis.
Analysis of TOPO Ila  and ERBB2 gene copy number in L-DAN and 
SK-MES-1
Since Southern data has been accumulated on L-DAN and 
SK-MES-1, it was also of interest to perform FISH on these cell lines with 
TOPO Ila  and ERBB2 gene cosmids. This work was carried out prior to
receipt of the ICRF cosmids, thus the pC5 cosmid was used to detect TOPO 
Ha in these experiments. Figure 3.7 shows the results of detection of TOPO 
Ha and ERBB2 in L-DAN and SK-MES-1. Panels (a) and (c) show 
hybridisation of TOPO Ila  and ERBB2 cosmids, respectively in L-DAN. In 
panel (b) three copies of ERBB2 can also be seen in the interphase nuclei. Six 
signals are detected due to there being one gene copy per chromatid arm.
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Table 3.3
Table showing mean, median and standard deviation of 
fractional length measurements for all genes studied by FISH.
Gene No. of 
chromatids 
counted
Mean
Fractional
Length
Median
Fractional
Length
Standard
Deviation
NF1 22 0.40 0.41 0.042
ERBB2 25 0.47 0.47 0.043
TOPO Ila 22 0.49 0.50 0.034
RARa 16 0.52 0.52 0.060
C05123 21 0.55 0.55 0.047
NM23H1 17 0.59 0.60 0.055
Table 3.4
Table showing p-values from Mann-Whitney analysis for all 
gene pair combinations.
Gene Pair Tested p-value
NF1-NM23H1 0.00
NF1-C05123 0.00
NFl-RARa 0.00
NF1-TOPO Ila 0.00
NF1-ERBB2 0.00
ERBB2-NM23H1 0.00
ERBB2- C05123 0.00
ERBB2-RARa 0.00
ERBB2-TOPO Ila 0.14
TOPO IIa-NM23Hl 0.00
TOPO IIa-C05123 0.00
TOPO Ila-RARa 0.09
RARa-NM23Hl 0.00
RARa-C05123 0.12
C05123-NM23H1 0.02
Figure 3.6
Diagram showing positions of genes on 17q according to mean 
fractional length measurement (FLM)
Fractional length measurements were calculated from single gene 
cosmid hybridisations on lymphocytes (using SigmaScan) in order 
to obtain mapping data. Measurements were taken from the tip of 
the p arm to the gene signal and then from the gene signal to the tip 
of the q arm. The fractional length of the gene signal from 17p 
was then calculated from these measurements.
The cosmids used were: ICRFc 105B041155 (TOPO Ila)
This diagram shows the order of the above genes on chromosome 
17 according to the calculated mean fractional length of each 
cosmid hybridisation. Further statistical details of samples, such as 
number of chromatids counted and the standard deviation, are 
shown in Table 3.1.
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Figure 3.7
Analysis of TOPO Ila and ERBB2 copy number in L-DAN and
SK-MES-1 using FISH.
Panel (a): L-DAN chromosomes hybridised with TOPO Ila  gene
cosmid (pC5)
Panel (b): L-DAN chromosomes hybridised with ERBB2 gene 
cosmids (Neul and Neu4)
Panel (c): SK-MES-1 chromosomes hybridised with TOPO Ila
gene cosmid (pC5)
Panel (d): SK-MES-1 chromosomes hybridised with ERBB2 gene
cosmids (Neul and Neu4)
Chromosomes were visualised with PI (pseudocoloured red), 
single copy gene cosmids were visualised with FITC 
(pseudocoloured green).
Panels (a) and (b) show L-DAN to have three copies of the TOPO 
Ila and ERBB2 genes. Six signals are visualised since there is one 
copy of the gene on each chromatid. The finding of three copies of 
these genes correlates with the detection of the three seemingly 
intact chromosome 17s’ by chromosome 17 painting (Figure 3.4). 
Panels (c) and (d) show SK-MES-1 to have two copies of both 
TOPO Ila  and ERBB2. Therefore, there does not appear to be any 
changes in the copy number of these genes in SK-MES-1. 
However, it appears that one of the chromosomes on which signal 
is being detected is much larger than a normal chromosome 17. 
Thus it appears that a translocation may have occurred between a 
chromosome 17 and another chromosome in SK-MES-1.
L-DAN
Therefore, it appears that L-DAN has three copies of TOPO I la  and ERBB2 
genes. This data agrees with previous data showing that L-DAN has three 
copies of chromosome 17 and three chromosome 17 centromeres (Figure 3.4, 
panels c and g). Figure 3.7, panels (c) and (d) show the results of TOPO I la  
and ERBB2 cosmid hybridisation in SK-MES-1. Therefore, there does not 
appear to be any changes in the copy number of these genes in this cell line. 
However, although one pair of signals appears to be on a 'normal' 
chromosome 17, the other chromosome on which cosmid signals are detected 
is much larger. Thus it is proposed that a translocation has occurred in SK- 
MES-1 between one chromosome 17 and another chromosome.
Further Characterisation of the Chromosome 17 Amplicon in CALU-3 
using FISH
From previous work by Keith et aL, (1992) it is known that the 
TOPO Ila  and ERBB2 genes are co-amplified in CALU-3. One of the main 
aims of this project was to discover if there was amplification of any other 
genes from this region of chromosome 17. Figures 3.1 and 3.2 have 
demonstrated that the RARa and G-CSF genes are also contained within the 
chromosome 17 amplicon, whereas NM23H1 and PKCa genes are outside the 
region of amplification. However, the structure of the amplicon is still 
unknown. By FISH analysis, the precise location of these amplified genes can 
be observed on the chromosomes. Figure 3.4, panels (b) and (0 showed that 
CALU-3 has seven regions of chromosome 17 sequence and five chromosome 
17 centromeres. Figure 3.8 shows double hybridisation of the chromosome 
17-specific centromere probe and six single-copy gene probes (for TOPO Ila , 
ERBB2, RARa, NM23H1, NF1 genes and C05123 for the BRCA1 region) on 
CALU-3 metaphases. All these panels show that regions of hybridisation to 
the single gene probes (green signal) are associated with chromosome 17 
centromere sequences (red signal).
With the ERBB2 cosmids, three regions of amplification are 
observed. Three regions of TOPO I la  amplification are also observed, along 
with 2 single copies of the gene on the remaining two chromosomes which 
have chromosome 17 centromeres. The same finding of three amplified 
regions and 2 single gene copies was also seen when C05123 and RARa 
cosmids were hybridised to CALU-3 metaphases. NM23H1 and NF1 cosmid 
hybridisations resulted in the detection of 5 copies of each of these genes, one 
associated with each chromosome 17 centromere. Interestingly, it appears that 
there may have been an inversion of this region of chromosome 17 as well as
59
Figure 3.8
Double hybridisation of single-copy gene cosmids and 
chromosome 17 centromere probe in CALU-3.
Each panel shows a different single copy gene cosmid (from the 
17q region) hybridised in conjunction with the PCR-produced 
chromosome 17-specific centromere probe to metaphase spreads 
prepared from CALU-3.
Single gene cosmids used: ICRFcl05B041155 (TOPO Ila)
C05123 (BRCA1 region)
ICRFc 105C0861 (NF1)
Neul and Neu4 (ERBB2) 
ICRFcl05F1255 (RARa) 
ICRFcl05H12160 (NM23H1)
Chromosomes were visualised with PI (pseudocoloured blue), 
single gene cosmids were visualised with FITC (pseudocoloured 
green) and chromosome 17 centromere sequence was visualised 
with Cy^ (pseudocoloured red).
CALU-3 has 3 regions of amplification of ERBB2, all of which are 
associated with chromosome 17 centromere sequence. The TOPO 
Ila gene amplification is also found on three chromosomes, with 
two single copies of the gene present on the other chromosomes 
with 17 centromere signal. Both C05123 and RARa genes show 
amplification on three chromosomes, although not to the same 
extent as ERBB2 or TOPO Ila  genes. Single copies of these genes 
are also seen associated with the other two chromosome 17 signals. 
CALU-3 appears to have 5 copies of both the NM23H1 and NF1 
genes, all linked to chromosome 17 centromere signals.
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the amplification since the NM23H1 gene appears to be very close to the 
centromere. From fractional length measurements shown in Figure 3.6, 
NM23H1 should be located towards the | q ter of chromosome 17 below all 
the other genes. The close-up pictures of chromosomes with ERBB2 and 
TOPO Ila  hybridisation also show the laddering pattern of signal.
Figure 3.9 shows close up images of the three chromosomes on 
which the 17q amplicon is present following hybridisation of the six single 
gene cosmids. The laddered banding pattern of signal hybridisation is shown 
very clearly in the panels from ERBB2, TOPO Ila , RA Ra and C05123 
experiments. It can also be seen that RARa and C05123 genes are not 
amplified to the same extent as TOPO I la  and ERBB2 genes. Hybridisation 
frequencies were calculated from these experiments and are shown in Table 
3.5. Total number of hybridisation signals was not determined for TOPO II a, 
ERBB2, RARa or C05123 cosmids since resolution of hybridisation was not 
good enough to enable counting of individual signals.
Figure 3.10 shows co-hybridisation of the TOPO Ila  cosmid 
with ERBB2 and RARa cosmids (upper and lower panels, respectively) in 
CALU-3. In the upper panel (ERBB2/TOPO Ila  hybridisation), TOPO I la  
cosmid hybridisation is visualised in green and ERBB2 cosmid hybridisation 
is visualised in red. Where there is overlap of these colours, yellow signal is 
seen. In the lower panel (TOPO Ila/RARa hybridisation) RA Ra cosmid 
hybridisation is visualised in green and TOPO Ila  cosmid hybridisation is 
visualised in red. Again, overlap of red and green signal results in yellow. 
Both these images show that signals from the gene cosmids used are detected 
on the same distinct chromosomal regions in CALU-3. Clear laddering of 
cosmid signal can be seen in the TOPO IIa/ERBB2 panel. Figure 3.11 shows 
co-hybridisation of the TOPO I la  cosmid with NF1 and NM23H1 cosmids 
(upper and lower panels, respectively). In both these panels TOPO I la  
cosmid hybridisation is shown in red and NF1 and NM23H1 hybridisation is 
shown in green. Five copies of the NF1 and NM23H1 cosmids are detected in 
CALU-3, with TOPO I la  amplification associated with three of these gene 
copies.
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Figure 3.9
Hybridisation of single-copy gene cosmids in CALU-3.
Each panel shows a different single-copy gene cosmid (from the 
17q region) hybridised to CALU-3 chromosomes. Only the three 
chromosomes which carry the amplicon are shown in each panel, 
at a slightly higher magnification in order to show the structure of 
amplified genes in the 17q region.
Single gene cosmids used: ICRFc 105B041155 (TOPO Ila)
C05123 (BRCA1 region)
ICRFc 105C0861 (NF1)
Neul and Neu4 (ERBB2)
ICRFc 105F1255 (RARa)
ICRFcl05H12160 (NM23H1)
Chromosomes were visualised with PI (pseudocoloured red) and 
gene cosmids were visualised with FITC (pseudocoloured green).
These figures show a more detailed view of the gene amplification 
in CALU-3. Two stripes of green signal (indicating cosmid 
hybridisation) can clearly be seen in the panels showing ERBB2, 
TOPO Ila, RARa and C05123 hybridisations.
Only single copies of NF1 and NM23H1 appear to be present on 
these chromosomes.

Table 3.5
Hybridisation frequencies of TOPOII a , ERBB2, NF1, 
NM23H1, RARaand C05123 cosmids on CALU-3 metaphase
spreads.
Gene
Locus
Cosmid
Used
No. of chr. 
spreads 
counted
Total no. 
of chr. 
with 
signal
Total no. 
of signals
%age
hybrid11
frequency
Topo Ila B041155 20 85 ND ND*
ERBB2 Neul/Neu4 20 60 ND ND
NF1 C0861 20 99 145 72%
NM23H1 H12160 20 100 175 87%
RARa F1255 20 100 ND ND
Unknown C05123 20 100 ND ND
ND: Not Determined
*: Each spread was seen to have 1 or 2 single copies of the TOPO 
Ila gene on separate chromosomes from those carrying the 
amplification.
Percentage hybridisation efficiency was calculated on the basis of 4 signals 
(doublets) being detected per metaphase spread.
Figure 3.10
Double hybridisation of single-copy gene cosmids in CALU-3.
Upper panel shows double hybridisation of TOPO Ila and ERBB2 
gene cosmids to a metaphase spread from CALU-3 
Chromosomes were visualised with PI (pseudocoloured blue), 
TOPO Ila was visualised with FITC (pseudocoloured green) and 
ERBB2 was visualised with Cy^ (pseudocoloured red).
Lower panel shows double hybridisation of TOPO Ila  and RARa 
cosmids to a metaphase spread from CALU-3 
Chromosomes were visualised with PI (pseudocoloured blue), 
RARa was visualised with FITC (pseudocoloured green) and 
TOPO Ila was visualised with Cy^ (pseudocoloured red).
Inset boxes show close-up of chromosome with double 
hybridisation. Yellow signal denotes overlap of green and red 
colours.
Single gene cosmids used: ICRFcl05B041155 (TOPO Ila)
Neul and Neu4 (ERBB2) 
ICRFcl05F1255 (RARa)
These figures show the co-hybridisation of signals for ERBB2 and 
RARa with TOPO Ila on three distinct chromosomal regions in 
CALU-3.
TOPO I10C/ERBB2
TOPO lla /R A R a
Figure 3.11
Double hybridisation of single-copy gene cosmids in CALU-3.
Upper panel shows double hybridisation of TOPO Ila and NF1 
gene cosmids to a metaphase spread from CALU-3 
Chromosomes were visualised with PI (pseudocoloured blue), NF1 
was visualised with FITC (pseudocoloured green) and TOPO Ila 
was visualised with Cy^ (pseudocoloured red).
Lower panel shows double hybridisation of TOPO Ila  and 
NM23H1 cosmids to a metaphase spread from CALU-3 
Chromosomes were visualised with PI (pseudocoloured blue), 
NM23H1 was visualised with FITC (pseudocoloured green) and 
TOPO Ila was visualised with Cy^ (pseudocoloured red).
Inset boxes show close-up of chromosome with double 
hybridisation. Yellow signal denotes overlap of green and red 
colours.
Single gene cosmids used: ICRFcl05B041155 (TOPO Ila)
ICRFcl05C0861 (NF1) 
ICRFcl05H12160 (NM23H1)
These figures show the co-hybridisation of signals for NF1 and 
NM23H1 with TOPO Ila on three distinct chromosomal regions in 
CALU-3.
TOPO Ila/NFl
OPO a/NM23H
3.3 Discussion
The work presented in this chapter deals with further 
characterisation of the amplicon on chromosome 17 in the NSCLC cell line, 
CALU-3. As mentioned in the introduction to this chapter, co-amplification 
of TOPO Ila  and ERBB2 genes has been observed in certain cases of breast 
cancer (Keith et al., 1993; Murphy et al., in press; Smith et al., 1993). 
Amplification of the ERBB2 gene, however, has also been shown without 
involvement of the TOPO I la  gene (Keith et al., 1993; Smith et al., 1993). 
Thus one could propose that ERBB2 is the driving force for the amplification 
of this region of chromosome 17. This would seem to make sense since it is 
known that the product of the ERBB2 gene is a growth factor receptor and 
overexpression of such a receptor would be an obvious advantage to cellular 
growth, although amplification of a gene does not necessarily mean that the 
gene is being overexpressed (Lafage et al., 1990; Tsuda et al., 1989; van de 
Vijver et al., 1987). The study of expression of the ERBB2 gene in CALU-3 
is dealt with in Chapter 4.
Analysis of co-amplification of genes on 17q in breast cancer 
(Keith et al., 1993) indicates, however, that ERBB2 may not necessarily be 
the driver for amplification of genes in this region. In 3 tumours which 
demonstrated co-amplification of TOPO Ila , RARa and ERBB2 genes by 
Southern blot analysis, the RARa locus was seen to be amplified to a greater 
degree than ERBB2 in all 3 cases. Two of these tumours also showed higher 
amplification of TOPO I la  than ERBB2. Therefore, it may be that higher 
levels of RARa and TOPO I la  have been selected for during the process of 
carcinogenesis, since it is not clear what affect overexpression of these genes 
would have on a cell. It could also be that these differences in gene 
amplification levels are a result of the mechanism of amplification. As 
mentioned above, this investigation was performed using Southern blot 
hybridisation. Such analysis, however, does not give any information on the 
precise copy number of the genes studied, nor does it provide information on 
location of the genes. Also, perhaps more importantly, Southern analysis does 
not show possible relationships between genes. For example, in the above 
study there may be specific areas of the breast tumours where only TOPO II a  
and ERBB2 gene amplification are seen, with only certain cells having co- 
amplification of all three genes. This kind of information can be obtained, 
however, by performing FISH analysis on tumour sections, and such work has 
been carried out using repetitive and single-copy gene probes on both paraffin
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sections and touch preparations of tumours (Kallioniemi et al., 1992b; Kim et 
al., 1993; Murphy etal., in press; Persons etal., 1993; Stock etal., 1993).
Following the detection of amplified genes in CALU-3 by 
Southern analysis, a more detailed approach was taken using fluorescence in 
situ hybridisation. Since cosmid probes for some of the genes of interest on 
chromosome 17q were not commercially available, it was necessary to 
develop and map new cosmids. This was achieved for RARa, NM23H1 and 
NF1 genes. All cosmids used were shown to co-localise with chromosome 
17-specific centromere sequences (Figure 3.5) and mapping data was derived 
by taking fractional length measurements from cosmid hybridisations with 
lymphocyte chromosomes (Figure 3.6). There has been I a lot of interest 
generated in chromosome 17q because of the linkage of the early onset breast 
cancer gene to this region. Previous mapping data obtained for 17q (Abel et 
al., 1993; Anderson et al., 1993; Flejter et al., 1993) shows a very similar 
ordering of the ERBB2, TOPO I la  and NM23H1 (or NME1) genes, although 
mapping data for the RARa gene places it between the ERBB2 and TOPO Ila  
genes (Abel et al., 1993). In order to resolve these cosmids more accurately, 
FISH could be performed either on interphase cells or on stretched DNA 
(DIRVISH) using three colour mapping (Flejter et al., 1993; Parra & Windle, 
1993).
Differences in resolution between Southern and FISH analyses 
were also observed in this chapter. By Southern analysis, there did not appear 
to be any difference in TOPO I la  or ERBB2 gene copy number between 
L-DAN and SK-MES-1 (Figure 3.1). By FISH analysis, however, 3 copies of 
both TOPO I la  and ERBB2 were detected in L-DAN and 2 copies of each of 
these genes were detected in SK-MES-1 (Figure 3.7). This example 
highlights the usefulness of FISH in being able to visualise the exact copy 
number of a gene. The apparent translocation of chromosome 17 detected in 
SK-MES-1 would also have remained undetected by Southern analysis.
FISH analysis of CALU-3 (Figures 3.8,3.9,3.10 and 3.11) has 
shown that there is amplification of TOPO Ila , ERBB2 and RA Ra genes. 
The region of the C05123 cosmid was also found to be amplified. Therefore, 
the amplicon in CALU-3 encompasses five loci, ERBB2, TOPO Ila , RARa, 
G-CSF and C05123. It is interesting that the TOPO I la  and ERBB2 genes 
appear to be more highly amplified than RARa, G-CSF and C05123 
sequences. With RARa, the FISH data therefore agrees with Southern data 
which also showed lower levels of amplification of this gene (Figure 3.1). 
Therefore, there are three chromosomes carrying the amplified sequences in 
CALU-3, with two other chromosomes carrying single copy loci. Both the
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single copy regions and the regions of amplification in CALU-3 are still 
associated with chromosome 17 sequences, as is shown by the co­
hybridisation of chromosome 17-specific centromere sequence (Figure 3.8). 
Co-hybridisation of cosmids detecting the TOPO Ila , ERBB2 and RARa 
genes in CALU-3 indicates that these genes are truly co-amplified on the same 
region of the chromosome arm (Figure 3.10). There also appears to be an 
inversion of the region of amplification in CALU-3 since the NM23H1 gene is 
detected in close association with the centromere region (Figure 3.8). The 
exact copy number of TOPO Ila  and ERBB2 genes in CALU-3 could not be 
calculated due to the proximity of hybridisation signals within the amplicon. 
It would be of interest to obtain quantitative fluorescence measurements on 
these hybridisations, which compares to performing densitometry on 
autoradiographs. The advantage of measuring quantitative fluorescence is that 
measurement of a true single-copy signal can be taken and compared to the 
fluorescence of an amplified region.
It was previously published that CALU-3 was observed to have 
five copies of TOPO Ila , three of which were clustered on one chromosome 
(Coutts et al., 1993). The data presented in this chapter has shown much 
higher levels of TOPO I la  amplification in CALU-3. The most likely 
explanation for this is that there has been selection and outgrowth of a clone 
with higher levels of gene amplification. The amplicon described above, in 
CALU-3, appears to represent a stable genotype since a number of 
independent chromosome preparations have been used in this analysis and 
have produced the same results.
It is of interest to note the pattern of amplified genes in CALU- 
3 since there appear to be two distinct stripes of ERBB2, TOPO Ila , RARa 
and C05123 hybridisation. Such stripe patterns were also reported in the 
papers concerning mechanisms of amplification, and the unequal sister 
chromatid exchange model, in particular, as outlined in Figure 3D (Smith et 
al., 1990; Trask & Hamlin, 1989). Also noted in the paper by Trask and 
Hamlin are that single copies of the gene remain associated with the original 
locus. A similar phenomenon is noted in CALU-3 with single copies of the 
TOPO Ila , RARa and C05123 loci detected independently of the 
chromosomes carrying the amplicon. Since CALU-3 has now been passaged 
for many years in culture, it would be extremely difficult to deduce the initial 
mechanism of amplification. It would also be impossible to tell whether the 
inversion of this region occurred before or after the amplification. However, 
the genetic changes observed in CALU-3 could probably be accounted for by 
the unequal sister chromatid exchange and bridge/breakage/fusion model
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(Smith et al., 1990; Trask & Hamlin, 1989, Figure 3D). Figure 3E shows an 
extended version of this model, with a further cycle of bridge and breakage 
shown. The red and blue triangles in this diagram indicate two hypothetical 
genes and their orientation. Therefore, as the cycles of breakage and fusion 
occur, the changes to gene copy number and direction can be followed. This 
figure depicts formation of a bridge structure at D, thus at E head-to-tail arrays 
of the genes are observed. Alternatively, non-homologous exchange could 
occur between sister chromatids at D, as could breakage at a different 
telomere site which would possibly create a different outcome at E.
This theory of gene amplification could be tested in CALU-3 
by analysing the amplicon in more detail. In order to do this, the region of 
amplification would need to be microdissected and then PCR-amplified. A 
microclone library could then be generated from the PCR products. Clones 
could then be analysed by Southern blotting to check which gene or genes 
they contained. Clones positive for two genes would be very interesting to 
study since they would contain the joining regions, thus by sequencing the 
DNA it would be possible to deduce the orientation of the genes. This 
technique of microdissection and microcloning has been used to study 
amplicons found in melanoma cell lines (Zhang et al., 1993), neuroblastoma 
cell lines (Schneider et al., 1992) and drug-resistant lung cancer cell lines 
(Ray et al., 1994).
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Figure 3E
Extended model of gene amplification for CALU-3
This figure shows an extended version of Figure 3D, with the red 
and blue triangles representing two hypothetical genes and their 
orientation. The sister chromatids are depicted in orange and green 
and the centromere is shown as a black circle.
This pathway begins at A with a normal chromosome which 
undergoes chromosomal breakage near the telomeres. This creates 
frayed ends which are then healed by fusion of the two sister 
chromatids (B). Following replication, the chromosome shown in 
C is produced. At this stage it can be seen that the gene copies 
from the green sister chromatid have become reversed in 
orientation. Another breakage then occurs at the telomere of this 
chromosome which again is healed by telomere fusion (D). A 
further round of DNA replication results in the chromosome shown 
in E. Therefore, as the copy number of the two genes increases, it 
can be seen that their orientation is also being changed.
There does not necessarily have to be telomere breakage at C, 
however. The model could also be continued by non-homologous 
exchange between the sister chromatids which may result in 
different copy numbers or orientations of the genes from that 
depicted in E.
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CHAPTER 4
CHROMOSOME 17q AMPLICON: 
ANALYSIS OF GENE EXPRESSION
4.1 Introduction
This chapter will deal with expression of genes on chromosome 
17q in CALU-3, as analysed using a variety of techniques. As mentioned in 
Chapter 1, topoisomerase II is the target for a number of commonly used 
chemotherapeutic agents. Where treatment with such topoisomerase II 
inhibitors is used, the level of expression of topoisomerase II within the 
tumour may be an important factor in the success of that treatment. 
Resistance to topoisomerase II inhibitors is now a major problem in the clinic 
and numerous studies have attempted to investigate the relationship between 
topoisomerase II expression levels in cells and sensitivity to drugs such as 
amsacrine (mAMSA) and etoposide (VP16) (Davies et al., 1988; Fry et al., 
1991). Both of these studies report a correlation between topoisomerase II 
levels in cells and their chemosensitivity, with a higher level of topoisomerase 
II resulting in greater sensitivity of the cells to topoisomerase II inhibitors. It 
has also been shown in yeast cells that constitutive overexpression of a 
plasmid-borne TOP2 gene (encoding yeast topoisomerase II) leads to 
hypersensitivity of these cells to mAMSA and etoposide (Nitiss etal., 1992).
Conversely, low levels of topoisomerase II alone have been 
associated with drug resistance in both cell lines derived from tumours and 
those having undergone in vitro drug selection (Giaccone et al., 1992; 
Potmesil et al., 1988; Ritke et al., 1994; Webb et al., 1991). This mechanism 
of drug resistance may be extremely important in certain tumour types where 
traditional drug resistance mechanisms, such as P-glycoprotein are rarely 
observed. However, it is not only low levels of topoisomerase II expression 
which can lead to drug resistance. Alterations to the topoisomerase II protein 
have also been found in cells selected for drug resistance in vitro. Such 
alterations may be in the form of point mutations, which result in a single 
amino acid changes in the protein (Bugg et al., 1991; Danks et al., 1993; 
Hinds et al., 1991; Lee et al., 1992) These changes are most commonly found 
to occur between j  residues 1346 and 1555, the site of consensus sequences 
which are known to bind ATP in other proteins, although alterations have also 
been found around the active site tyrosine at amino acid position 804 (Danks
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et al., 1993; Patel & Fisher, 1993). This is an important region of the 
topoisomerase II molecule because it is known that this tyrosine residue binds 
covalently to DNA during the catalytic cycle. Gross alterations to 
topoisomerase II have also been reported in connection with drug resistance 
(Mirski et al., 1993). In this case a topoisomerase Ila-related protein was 
observed in the derived resistant cell line, with an apparent molecular weight 
of 160kD as opposed to the normal 170kD mass of topoisomerase Ila. A 
smaller mRNA molecule was also observed. Cell lines selected in vitro for 
resistance in VP16, VM26, adriamycin, mAMSA or mitoxantrone have 
sometimes been found to overexpress either P-glycoprotein or the multidrug 
resistance-associated protein MRP as well as having decreased levels of 
topoisomerase II (Cole et al., 1991; de Jong et al., 1993; Kamath et al., 1992; 
Schneider et al. , 1994).
Thus, it can be seen that topoisomerase II plays an important 
role in both drug sensitivity and resistance in a variety of cell lines and 
tumours. Work outlined above demonstrates that alteration of topoisomerase 
II expression by amplification, mutation or deletion during tumour 
development could determine the response of those cells to topoisomerase 
inhibitors. A paper by Keith et a l in 1992 demonstrated the co-amplification 
of TOPO Ila  with the ERBB2 gene in a non-small cell lung adenocarcinoma 
cell line, CALU-3 (Keith et al., 1992). It is presumed that this situation has 
arisen because of the proximity of TOPO I la  to ERBB2 on 17q. Results 
shown in Chapter 3 confirm this co-amplification and also demonstrate the 
amplification of RARa andjG-CSF genes in CALU-3. It is therefore of 
interest to study the expression of the topoisomerase I la  gene in CALU-3, to 
determine if amplification of this gene has led to increased levels of 
expression.
Some of the genes around this region of chromosome 17q have 
been implicated in the process of carcinogenesis, including ERBB2, RARa 
and NM23H1. The ERBB2 gene (mapped to chromosome 17q21 by 
Fukushige et al. in 1986) was originally discovered, in two independent 
studies, by its homology with the v-ERBB gene and its amplification in the 
tumours analysed (King et al. , 1985; Semba et al. , 1985). The same gene had 
previously been identified as the transforming oncogene, NEU, in a series of 
rat neuroblastoma cells (Schechter et al., 1984). The protein which ERBB2 
encodes (a tyrosine-specific kinase receptor, p l85neu) was found to display a 
strong homology to the epidermal growth factor (EGF) receptor (Coussens et 
al., 1985; Yamamoto et al., 1986) and its amplification and overexpression 
has been associated with tumour development and poor prognosis in breast
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cancer (Gullick et al., 1991;Lovekin et al., 1991; Muss et al., 1994;Slamon 
et al., 1989; Winstanley et al., 1991; Wright et al., 1992).
Retinoids (derivatives of vitamin A) are important molecules in 
terms of cellular development and differentiation see Holdener & Bollag, 
1993 and Leid et al., 1992 for reviews. Three members of the retinoic acid 
receptor family have so far been isolated, a, p and y (Elder et al., 1991; Zelent 
et al., 1989), with multiple isoforms found of RARa and y (Gaub et al., 1992; 
Lazega et al., 1993). The RARa gene (mapped to chromosome 17q21 by 
Mattei et al. in 1988) is commonly found to be rearranged and fused to a 
novel gene, PML, in acute promyelocytic leukaemia (APL) (Chang et al., 
1991; de The et al., 1990). It is thought that the PML gene product may be 
involved in RNA processing because of its speckled nuclear localisation and 
also some of the domains within the protein are found in components of 
ribonucleoprotein complexes (Kastner et al., 1992).* The RARa-PML gene 
translocation results in the production of two reciprocal fusion proteins, 
PML/RARa and RARa/PML (Kastner et al., 1992; Pandofli et al., 1991)^ 
with PML/RARa thought to play the primary role in leukaemogenesis, since 
this isoform contains the functional domains of both proteins and is found in 
all patients with t(15;17) translocation. The finding of this translocation was 
of great interest since APL patients were known to undergo complete 
remission after a few weeks of treatment with retinoic acid (Castaigne et al., 
1990; Meng-Er et al., 1988; Warrell et al., 1991; Gillard & Solomon, 1993). 
Retinoids are also used as adjuvant therapy in cancer chemotherapy due to 
their ability to cause cellular differentiation (Bollag & Holdener, 1992; Costa, 
1993; Holdener & Bollag, 1993).
The NM23H1 gene was initially discovered by Steeg etal. by 
differential colony hybridisation of a panel of related murine melanoma cell 
lines with varying metastatic potential (Steeg et al., 1988a). A second NM23 
gene was subsequently identified, having significant homology to NM23H1 
(Stahl et al., 1991). It is thought that the two genes are differentially regulated 
since RNA levels are seen to differ for each gene in the same tumour. 
Expression of the NM23H1 gene (mapped by Varesco et al., (1992) to 17q22) 
has been investigated in CALU-3 as the protein product is proposed to have an 
effect on the metastatic potential of certain tumour cells (Leone et al., 1993a; 
Leone etal., 1993b; Steeg etal., 1988b; Wang etal., 1993). Expression of the 
NM23H1 gene has been correlated with the proliferative stages of the cell 
cycle (Igawa et al., 1994). The nm23Hl and H2 proteins were recently 
identified as being nucleoside diphosphate (NDP) kinase A and NDP kinase 
B, respectively (Gilles et al., 1991; Wallet et al., 1990). Cellular NDP kinase
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is an oligomer of these individual NDP subunits. NDP kinases play major 
roles in the synthesis of nucleoside triphosphates (other than ATP), regulation 
of microtubule assembly and disassembly and are also found associated with 
GTP-binding proteins, so may be involved in regulation of some signal 
transduction pathways (Liotta & Steeg, 1990). Thus it can be seen how 
alterations in expression of these proteins could affect both cellular motility 
and proliferation.
Analysis of gene expression in CALU-3 has been performed 
using a variety of techniques on both amplified and non-amplified genes. 
Northern analysis was initially carried out to investigate any alterations in 
expression of the three topoisomerase genes, I, I la  and II p at the RNA level. 
A number of small cell lung cancer (SCLC) cell lines were screened on this 
Northern at the same time as the non-small cell lung cancer (NSCLC) cell 
lines. Western and immunofluorescence analysis has also been performed on 
CALU-3, L-DAN and SK-MES-1 using antibodies against the TOPO Ila, 
ERBB2, RARa and NM23H1/2 gene products. Western analysis enables 
quantitative measurement of topoisomerase I la  protein levels, whereas 
immunofluorescence shows cellular localisation of the enzyme, and any 
differences in expression amongst cells of the same population. Any 
qualitative differences in topoisomerase II between the three cell lines were 
detected using biochemical and band depletion assays. Row cytometry was 
used to investigate cellular proliferation in L-DAN, CALU-3 and SK-MES-1, 
and the cell cycle regulation of topoisomerase Ila , nm23Hl/H2 and erbB2 
expression in these cell lines. The possibility of alterations in the chromatin 
structure around the TOPO Ila  and TOPO lip genes was also investigated by 
analysis of methylation status of these genes.
The expression analyses undertaken in this chapter utilised the 
non-small cell lung cancer cell lines L-DAN and SK-MES-1 as examples of 
cell lines with no evidence of TOPO Ila  gene amplification.
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4.2 Results
In this part of the study, expression analysis of a number of 
genes in the 17q 12-telomere region has been undertaken. From Chapter 3 it is 
known that the loci for ERBB2, RARa, G-CSF and TOPO Ila  genes, are 
amplified in CALU-3. Southern data shows the NM23H1 and protein kinase 
C alpha (PKCa) genes are outside the amplicon in CALU-3. To investigate 
whether amplified genes are overexpressed in CALU-3, and to determine if an 
elevated level of the topoisomerase I la  enzyme is the cause of the sensitivity 
of CALU-3 to topoisomerase II inhibitors, a number of different techniques 
have been utilised.
Northern Blot Analysis of TOPO I la  Expression
Northern blotting was initially used to investigate TOPO I la  
expression in L-DAN, CALU-3 and SK-MES-1. Figure 4.1 shows an 
example of a Northern with these three non-small cell lung tumour cell lines 
plus a number of other cell lines derived from small cell lung tumours. The 
same blot was reprobed 4 times with cDNA probes for TOPO Ila  (panel a), 
TOPO II|3 (panel b), TOPO I (panel c) and 7S (panel d) genes. From Figure 
4.1 (lane 1) CALU-3 was seen to express high levels of TOPO I la  mRNA. 
No overexpression of TOPO lip or TOPO I was observed relative to L-DAN 
or SK-MES-1. SK-MES-1 (lane 3) was seen to express all three 
topoisomerases. L-DAN (lane 2) was underloaded so expression of TOPO II p 
and TOPO I genes was difficult to detect (panels b and c respectively). Thus, 
of these three non-small cell lung tumour cell lines, CALU-3 has the highest 
expression of topoisomerase I la  mRNA, which may be presumed to be a 
result of the amplification of the TOPO Ila  gene.
A number of small cell lung tumour cell lines were screened at 
the same time, although no further analysis was performed. Lanes 4-9 contain 
samples of RNA from these cell lines. LS263 (Lane 4) was developed from a 
post-therapy biopsy of a neck node metastasis which appeared to be 
intrinsically resistant to treatment in the clinic (3 cycles of cyclophosphamide, 
doxorubicin, vincristine, etoposide and verapamil). From blots a, b and c it 
can be seen that this tumour expresses very low levels of all three 
topoisomerases. LS277 (Lane 5) was derived from a pre-treatment biopsy of a 
chemosensitive small cell lung tumour. Blot a shows that this cell line has a 
relatively high level of TOPO I la  RNA expression. The samples in lanes 6
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Figure 4.1
Detection of topoisomerase RNA expression levels by Northern
blot analysis.
(a): TOPO Ila  (SP1), (b): TOPO lip (SP12),
(c): TOPO I (ScI70), (d): 7S
Lane 1: CALU-3, Lane 2: L-DAN, Lane 3: SK-MES-1, 
Lane 4: LS263, Lane 5: LS277, Lane 6: LS274,
Lane 7: LS310,Lane8: LS112,Lane9: LS112ST
Sizes of mRNA detected:
28S= ~5kb, 18S= ~2kb, TOPO Ha= 6.5kb, TOPO Iip= 6.5kb,
TOPO 1= 4.1 kb
CALU-3, L-DAN and SK-MES-1 are all non-small cell lung 
carcinoma cell lines. All other cell lines mentioned were derived 
within the Department of Medical Oncology from biopsies of small 
cell lung tumours (or their metastases). The 7S RNA probe was 
used as a loading control.
From blot (a) it is clear that CALU-3 (Lane 1) overexpresses 
mRNA from the TOPO Ila gene when compared to the other cell 
lines. It does not overexpress RNA from either the TOPO lip or 
TOPO I genes.
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and 7 (LS274 and LS310) were derived from pre- and post-treatment (4 cycles 
of therapy as for LS263 but without verapamil) biopsies respectively. 
Although there appears to be some drop in TOPO I la  expression in LS310, 
there is a slight imbalance in loading between the two samples which may 
account for this result. LSI 12 (Lane 8) was developed from a very advanced 
tumour and is seen to express high levels of all three topoisomerases. 
LS112ST is a more adherent derivative of LSI 12 and appears to show lower 
levels of topoisomerase expression.
Western Blot and Immunofluorescence Analysis of TOPO I la  Expression
Having found increased expression of TOPO I la  mRNA, 
Western blotting was used to detect topoisomerase I la  protein expression in 
CALU-3. Figure 4.2 shows the high levels of topoisomerase I la  protein seen 
in CALU-3 (lane 2). Densitometric analysis of this autoradiograph showed 
CALU-3 to express 10-15 times more protein than either L-DAN or 
SK-MES-1. Therefore, overexpression of TOPO Ila  mRNA appears to lead 
to enhanced production of the enzyme in CALU-3. Immunofluorescence was 
also used to examine topoisomerase Ila  enzyme levels in the three cell lines. 
This technique detects subcellular localisation of the topoisomerase I la  
protein and its cell to cell distribution in a cell population. As can be seen in 
Figure 4.3, topoisomerase Ila  is detected in CALU-3 cells only (panel b). 
Figure 4.3 also shows the nucleoplasmic localisation of topoisomerase II a  and 
the heterogeneous nature of expression amongst this population of cells. Very 
high expression of the protein is seen in the mitotic cell in panel (b), which 
correlates with the upregulation of topoisomerase I la  protein known to occur 
at the G2/M phase of the cell cycle (Kaufmann et a l 1991; Prosperi et al.y 
1994; Prosperi etal. , 1992).
Biochemical Assays for Topoisomerase II
In order to prove that the topoisomerase II enzyme produced in 
CALU-3 had catalytic activity, decatenation assays were performed using a kit 
supplied by TopoGEN (see section 2.2.11 for details). This assay uses the 
ability of topoisomerase II to decatenate kinetoplast DNA to minicircles (via 
DNA breakage and strand passage) as a measurement of the enzymes' activity 
in that sample. It does not, however, distinguish between the alpha and beta 
forms of topoisomerase II. The same extracts were used in these assays and 
the Western analysis (Figure 4.2). Figure 4.4 shows the results of one such
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Figure 4.2
Detection of topoisomerase I la  expression by Western blot
analysis.
L anel: L-DAN, Lane 2: CALU-3, Lane 3: SK-MES-1
Molecular mass of topoisomerase IIa= 170kD
Fifty microgrammes of nuclear extract were run per lane. 
Molecular mass standards in kiloDaltons are shown to the right of 
the autoradiograph. A polyclonal antibody from Cambridge 
Research Biochemicals was used to detect topoisomerase I la  
expression.
The CALU-3 extract (Lane 2) is seen to contain higher levels of 
topoisomerase Ila  than either of the other two cell extracts. Thus 
amplification of the TOPO Ila gene, and enhanced mRNA level in 
CALU-3 appear to lead to a greater production of the enzyme.
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Figure 4.3
Detection of TOPO Ila gene expression by 
immunofluorescence.
(a): L-DAN, (b): CALU-3, (c): SK-MES-1
Nuclei are counterstained with propidium iodide (pseudocoloured 
red), topoisomerase Ila  detected with FITC (pseudocoloured 
green). A polyclonal antibody from TopoGEN was used to detect 
topoisomerase Ila.
As can be seen from panel (b), topoisomerase Ila expression 
(green signal) is only detectable in CALU-3, where there is known 
amplification of this gene. Expression of topoisomerase Ila  is 
found within the entire nucleoplasm of the cell and is also 
heterogeneous within a cell population.
The cell with the strongest green signal in panel (b) is undergoing 
mitosis, as indicated by the condensed nature of the DNA. This 
correlates with the fact that topoisomerase Ila  expression is 
upregulated at the G2/M phase of the cell cycle.
L-DAN
CALU-3
SK-MES-1
Figure 4.4
Decatenation of kinetoplast DNA by cellular extracts from 
(a): L-DAN, (b): CALU-3 and (c): SK-MES-1.
Serial dilutions of crude nuclear extracts were assayed for 
topoisomerase II activity:
Lanel: 0/*g, Lane 2: 5/*g, Lane 3: 2.5/*g, Lane 4: 1.25/*g, 
Lane 5: 0.625/*g, Lane 6: 0.312/*g, Lane 7: 0.156/*g,
Lane 8: 0.078/* g, Lane 9: 0.039jig
Topoisomerase II activity decatenates kinetoplast DNA to 
monomer minicircles (m). In the absence of cellular extract, 
kinetoplast DNA (k) remains in the well of the gel (Lane 1).
By comparing the three gels it can be seen that CALU-3 displays at 
least a four-fold increase in topoisomerase II activity since 
monomeric kDNA can be seen down to a protein concentration of 
0.156/*g. L-DAN and SK-MES-1 show minicircle formation down 
to a protein concentration of 0.625/* g.
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assay, with CALU-3 extract shown in panel (b). From this figure it is clear 
that decatenation activity (production of minicircles) occurs with lower 
concentrations of cell extract in CALU-3 (0.078/<g) when compared with 
L-DAN or SK-MES-1 (0.625^g). Therefore, CALU-3 has at least eight-fold 
more topoisomerase II activity than either L-DAN or SK-MES-1. These other 
two cell lines have almost equivalent topoisomerase II activity.
Since the TOPO I la  gene is amplified in CALU-3, it is 
possible that the gene may contain alterations rendering the protein insensitive 
to topoisomerase II inhibiting drugs (Takano et al., 1992). To investigate this, 
decatenation assays were performed in the presence of the topoisomerase II 
interactive drug VP16. This drug stabilises the cleavable complex formed by 
topoisomerase II during its catalytic cycle thus inhibiting dissociation of the 
enzyme from the DNA. Therefore, when VP16 is added to a decatenation 
reaction, decatenation of kinetoplast DNA will be inhibited. If the 
topoisomerase II enzyme produced by CALU-3 is altered in a way which 
disturbs the binding of drug to enzyme then decatenation would not be 
affected. Figure 4.5 shows the affect of varying concentrations of VP16 on 
decatenation reactions containing L-DAN (panel a), CALU-3 (panel b) and 
SK-MES-1 (panel c) crude nuclear extract. A lower protein concentration was 
used per reaction for CALU-3 as for the other two cell lines because of the 
enhanced topoisomerase II activity seen in CALU-3. From lane 3 onwards the 
amount of minicircle DNA produced from the kinetoplast DNA is seen to be 
reduced in all three cell lines. In lane 5 of panels (a), (b) and (c) the reaction 
appears to have been almost completely inhibited. Therefore, VP16 is still 
capable of inhibiting topoisomerase II activity in all three cell lines, including 
CALU-3.
Band Depletion Assay
As well as using extracts from the cell lines to study topoisomerase II 
activity, a whole cell approach, the band depletion assay, was also used to 
study interaction of topoisomerase II with VP16. By using antibodies against 
topoisomerase I la  at the Western blotting step, interactions between this 
isozyme only and VP 16 can be studied. The band depletion assay involves 
treating living cells in culture with varying concentrations of VP16 (described 
in section 2.2.10.3), making extracts from these cells and analysing the 
extracts using Western blotting. When cells are treated with drugs such as 
VP16, the catalytic cycle of topoisomerase Ila  is disturbed. Normally during 
the strand passage/religation reaction, where VP16 acts, the topoisomerase I la
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Figure 4.5
Inhibition of topoisomerase II activity by VP 16.
(a): L-DAN, (b): CALU-3, (c): SK-MES
Crude nuclear extracts from the above three cell lines were assayed 
for decatenation activity in the presence of increasing 
concentrations of VP16.
Lane 1: no drug, no nuclear extract,
Lane 2: no drug, DMSO diluant control, Lane 3: lOpiM VP16, 
Lane 4: lOOpiM VP16, Lane 5: 200//MVP16 
k= kinetoplast DNA, m=monomer minicircles
2.5/* g of protein was used in assays (a) and (c). 1.25/*g protein 
was used in assay (b) due to the increased topoisomerase II activity 
seen in CALU-3.
From this figure it can be seen that VP16 is capable of inhibiting 
topoisomerase II activity in L-DNA, CALU-3 and SK-MES-1.
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molecule is free to dissociate from the DNA. Once cells are treated, however, 
the drug stabilises these protein/DNA interactions and large complexes of 
drug, protein and DNA are formed (as in the decatenation inhibition reactions 
above). If a protein extract is then made from these cells, detection of the 
topoisomerase Ila  is prevented since the complex cannot be resolved on a 
polyacrylamide gel. Figure 4.6 depicts this technique diagrammatically, with 
concentration of VP16 increasing from left to right. Theoretically, therefore, 
little topoisomerase Ila  should be detected at high drug concentrations. 
Figure 4.7 shows an autoradiograph developed from a band depletion assay. 
The highest concentration of drug was used in samples run in lanes 2, 6 and 
10, where a visible depletion in the amount of topoisomerase I la  can be seen 
compared to no drug controls (lanes 1, 5 and 9) in L-DAN, CALU-3 and SK- 
MES-1. Thus the topoisomerase I la  enzyme from each cell line is still able to 
be trapped by VP16 on genomic DNA.
Flow Cytometry
Flow cytometry was used as a method to investigate both 
normal cellular proliferation of L-DAN, CALU-3 and SK-MES-1 and the cell 
cycle regulation of topoisomerase Ila, nm23Hl/H2 and erbB2 expression in 
these cell lines. The cell cycle analysis was performed using 
bromodeoxyuridine (BrdUrd), which incorporates into DNA during 
replication. Therefore, this technique detects those cells which have been 
through S phase. Figure 4.8 shows the results from a FACS experiment after 
cells have been incubated with BrdUrd for 4 hours. The left-hand panels, (a) 
L-DAN, (c) CALU-3 and (e) SK-MES-1, show FACS printouts in which cells 
in G0/G1, G l-S and G2/M phases can be distinguished by the amount of 
BrdUrd incorporation (FITC fluorescence), together with intensity of PI 
staining. FITC fluorescence is measured along the LFL1 axis and FL3 
measures PI fluorescence. Thus cells in box 1 can be said to be in GO or G1 
with a 2n DNA content and cells in box 4 are in G2 or M phase with a 4n 
DNA content, since these cells have been through S phase. Cells in box 2 are 
progressing into S phase from G1 and cells in box 3 are progressing through S 
phase. Table 4.1 shows the percentages of cells in the different stages of the 
cell cycle for L-DAN, CALU-3 and SK-MES-1 calculated from this 
experiment. From this data there appears to be strong agreement between 
duplicate samples and little difference in the distribution between the cell 
cycle phases in the three cell lines.
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Figure 4.6
Diagramatic explanation of the band depletion assay
Three situations are outlined in this diagram. On the far left is an 
untreated cell, where the topoisomerase II enzyme is free to bind to 
and dissociate from the DNA. When Western analysis for 
topoisomerase Ila  is performed using protein extract from this cell, 
a large amount of topoisomerase Ila  is detected.
The middle panel depicts the situation where cells have been 
incubated with fairly low concentrations of drug. The drug has 
bound to the topoisomerase Ila/DNA complexes, but there is still 
some topoisomerase Ila  free in the nucleus. It is this free 
topoisomerase II which is detected following Western analysis.
The final diagram depicts the results when using high 
concentrations of drug, Most of the topoisomerase Ila  is bound in 
stable drug/DNA complexes and unable to be resolved upon 
Western analysis. Thus very little topoisomerase Ila is detectable 
on the Western blot.
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Figure 4.7
Band depletion assay of topoisomerase I la  using whole cell 
lysates, analysed by Western blot
Cells were incubated with decreasing amounts of VP16 for 2 hours 
at 37°C and then lysed in protein lysis buffer. Samples were 
resolved on a 6% polyacrylamide gel (see Section 2.2.10.3).
Lanes 1-4: L-DAN, Lanes 5-8: CALU-3,
Lanes 9-12: SK-MES-1
Cells in lanes 1,5 and 9 were not treated with drug, those in lanes 
2,6 and 10 were treated with 5 x 10^M  VP 16, those in lanes 3,7 
and 11 were treated with 5 x lO'^M VP16 and those in lanes 4, 8 
and 12 were treated with 5 x lO^M  VP16.
Molecular mass standards in kiloDaltons are shown to the right of 
the autoradiograph. A polyclonal antibody from Cambridge 
Research Biochemicals was used to detect topoisomerase Ila.
From the autoradiograph it can be seen that cells treated with 
higher concentrations of VP 16 show a decrease in the amount of 
topoisomerase I la  detected on the Western. This depletion of band 
intensity is caused by the topoisomerase enzyme becoming trapped 
in a DNA/drug/enzyme complex which is unable to migrate in a 
polyacrylamide gel due to its large molecular size.
L-DAN, CALU-3 and SK-MES-1 all show a depletion in the 
amount of topoisomerase Ila  detected when cells are challenged 
with VP 16. Therefore the enzyme from each cell line is still able 
to be trapped by VP16 on genomic DNA.
-2 0 6
- 1 1 0
- 7 0
-  43
-  28
1 2 3 4 5 6 7 8 9 1011 12
Figure 4.8
Cell cycle analysis using bromodeoxyuridine incorporation.
(a) & (b): L-DAN, (c) & (d): CALU-3, (d) & (e): SK-MES-1
Nuclei were stained with PI (visualised in red in panels b, d and f)- 
BrdUrd was detected with a mouse anti-BrdUrd antibody. The 
secondary anti-mouse antibody was conjugated to FITC (visualised 
in green in panels b, d and f).
LFL1: Log FITC value 
FL3: PI value
Box 1: G0/G1 phase 
Box 2: Gl-S phase 
Box 3: S phase 
Box 4: G2/M phase
Panels (a), (c) and (e) show FACS results for cell cycle analysis 
after a four hour BrdUrd incubation period.
Panels (b), (d) and (f) show the same FACS samples as in (a), (c) 
and (e) analysed by fluorescence microscopy.
From panels (a), (c) and (e) it can be seen that all three cell lines 
undergo a routine cell cycle, with cells observed at all different 
phases. Panels (b), (d) and (f) show that green fluorescence is 
observed in a proportion of the cells from L-DAN, CALU-3 and 
SK-MES-1 when analysed by fluorescence microscopy, indicating 
BrdUrd incorporation and therefore cells in S phase.
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Table 4.1
Percentage of cells in the different stages of the cell cycle
% G0/G1 % Gl/S % S % G2/M
L-DAN (1) 47.3% 4.3% 40.9% 2.3%
L-DAN (2) 43.5% 3.8% 45.8% 3.0%
CALU-3 (1) 57.2% 4.2% 29.0% 5.5%
CALU-3 (2) 47.8% 6.4% 37.7% 9.2%
SK-MES-1
(1)
39.9% 4.3% 41.2% 8.9%
SK-MES-1
(2)
43.5% 4.0% 41.2% 10.1%
In Figure 4.8, the right-hand panels, (b) L-DAN, (d) CALU-3 
and (0 SK-MES-1 show the same BrdUrd FACS samples from (a), (c) and (e) 
analysed by fluorescence microscopy. By using this type of analysis, FITC 
and PI fluorescence can be visualised (green signal and red signal 
respectively). Therefore, this can be used as a control for the FACS printouts 
since the fluorescence can actually be seen down the microscope. Panels (b), 
(d) and (0  clearly show the different intensities of FITC fluorescence in 
L-DAN, CALU-3 and SK-MES-1 indicating differential incorporation of 
BrdUrd. Differences in PI fluorescence are more difficult to see since these 
images merge both PI and FITC signals. Thus, from Figure 4.8 it appears that 
L-DAN, CALU-3 and SK-MES-1 undergo a routine cell cycle with cells 
observed in all stages of the cycle.
Figure 4.9 shows the results of FACS analysis of 
topoisomerase Ila  expression in L-DAN (a and b), CALU-3 (c and d) and 
SK-MES-1 (e and 0- From panels (a) and (e), it can be seen that there are low 
levels of topoisomerase Ila  expression in L-DAN and SK-MES-1, with the 
highest peak of expression (high level of FITC fluorescence) seen in box 4. 
This equates with the G2/M phase of the cell cycle which is where highest 
expression of topoisomerase Ila  has been observed previously (Kaufmann et 
al., 1991; Prosperi et al., 1994; Prosperi et al., 1992). Panel (c) shows the 
very high level of topoisomerase I la  observed in CALU-3, in which the 
highest peak of topoisomerase I la  expression still appears to be in G2/M. 
Panels (b), (d) and (f) also show the levels of topoisomerase I la  expression in 
L-DAN, CALU-3 and SK-MES-1, shown by green signal. Again, low 
numbers of topoisomerase I la  expressing cells are visible in L-DAN and 
SK-MES-1 with a higher number of expressing cells visible in CALU-3. 
Table 4.2 shows the number of cells in different stages of the cell cycle, 
calculated from the experiment shown in panels (a), (c) and (e) in Figure 4.9. 
All the figures shown in this table have been adjusted against a no primary 
antibody control experiment which was performed in parallel. Table 4.3 
shows percentages for each cell cycle stage calculated from the data presented 
in Table 4.2. From Table 4.3 it can be seen that although the percentages are 
markedly higher for CALU-3, there is still a rise in the percentage of cells 
expressing topoisomerase Ila  from G1 to G2/M. Therefore, it appears that 
CALU-3 still has cell cycle regulation of topoisomerase Ila  expression.
FACS analysis was also performed using the antibody against 
nm23Hl/H2 proteins. The results from this experiment are shown in Figure 
4.10. Panels (a), (c) and (e) show FACS printouts of nm23Hl/H2 expression 
for L-DAN, CALU-3 and SK-MES-1 respectively. Panels (b), (d) and (f)
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Figure 4.9
Cell cycle regulation of topoisomerase IIa expression by FACS.
(a) & (b): L-DAN, (c) & (d): CALU-3, (e) & (£): SK-MES-1
Nuclei were stained with PI (visualised in red in panels b, d and f).
Topoisomerase Ila protein was detected with a polyclonal 
antibody from CRB and the secondary antibody was conjugated to 
FITC (visualised in green in panels b, d and f).
FL1: FITC value 
FL3: PI value
Panel (a): Box 1: Gl, topoisomerase Ila  negative
Box 3: G1, topoisomerase II a  positive 
Box 2: G2, topoisomerase Ila  negative 
Box 4: G2, topoisomerase Ila  positive
Panels (c) & (e): Box 1: Gl, topoisomerase Ila  negative
Box 2: Gl,
Box 3: G2,
Box 4: G2,
Panels (a), (c) and (e) show FACS results of topoisomerase Ila  
expression in L-DAN, CALU-3 and SK-MES-1 respectively.
Panels (b), (d) and (f) show the same FACS samples as in (a), (c) 
and (e) analysed by fluorescence microscopy.
From panels (a), (c) and (e) it can be seen that all three cell lines 
express topoisomerase Ila  in the Gl and G2/M stages of the cell 
cycle (boxes 3 and 4 in a, boxes 2 and 4 in c and e). Panels (c) and 
(d) show high expression of topoisomerase Ila in CALU-3.

Table 4.2
Number of cells in different stages of the cell cycle in a 
topoisomerase I la  FACS experiment (polyclonal antibody)
G1 total cell 
no.
G1 Topo Ila  
+ve cells
G2/M total 
cell no.
G2/M Topo 
I la  +ve cells
L-D AN (a) 36270 1057 3151 494
L-DAN (b) 26634 122 3060 488
C ALU-3 (a) 10597 4362 4268 3191
CALU-3 (b) 8957 5242 3956 3248
SK-MES-1
(a)
2903 155 420 136
SK-MES-1
(b)
1634 55 372 95
All numbers listed have been corrected against a no primary antibody control 
experiment
Table 4.3
Percentage of cells positive for topoisomerase I la  expression in 
G1 and G2/M (polyclonal antibody)
% G1 positive cells % G2 positive cells
L-DAN (a) 3% 15%
L-DAN (b) 0.5% 15%
C ALU-3 (a) 41% 74%
C ALU-3 (b) 58% 82%
SK-MES-1 (a) 5% 32%
SK-MES-1 (b) 3% 25%
Figure 4.10
FACS analysis of nm23Hl/H2 expression.
(a) & (b): L-DAN, (c) & (d): CALU-3, (d) & (e): SK-MES-1
Nuclei were stained with PI (visualised in red in panels b, d and f).
Nm23Hl and H2 proteins were detected with a polyclonal 
antibody from CRB and the secondary antibody was conjugated to 
F1TC (visualised in green in panels b, d and f).
FL1: FITC value 
FL3: PI value
Box 1: Gl, nm23Hl/H2 negative 
Box 2: Gl, nm23Hl/H2 positive 
Box 3: G2, nm23Hl/H2 negative 
Box 4: G2, nm23Hl/H2 positive
Panels (a), (c) and (e) show FACS results of nm23Hl/H2 
expression in L-DAN, CALU-3 and SK-MES-1 respectively.
Panels (b), (d) and (f) show results of a FACS experiment using 
peptide-blocked anti-nm23Hl/H2 antibody.
From panels (a), (c) and (e) it can be seen that all three cell lines 
express nm23Hl and H2. There does not appear to be any cell 
cycle regulation of these proteins in L-DAN, CALU-3 or SK- 
MES-1.
Panels (b), (d) and (f) show that when blocked primary antibody is 
used, very little expression of the nm23 proteins is observed.
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show a parallel experiment in which peptide-blocked primary antibody was 
used, and shows that there was very little nm23Hl/H2 expression detectable. 
From the results shown in (a), (c) and (e) it can be seen that all three cell lines 
express the nm23 proteins, and that there does not appear to be any cell cycle 
regulation of nm23. When the anti-erbB2 antibody was used in FACS 
analysis, expression was observed only in CALU-3 and also did not appear to 
be cell cycle regulated (data not shown).
Investigation into the methylation status of the TOPO I la  and TOPO IIB 
genes
Changes in the methylation status of genes are known to have 
an effect on gene expression reviewed in Baylin et al., 1991. Alterations in 
methylation state are also thought to play a role in the organisation of DNA 
structure, with heavily methylated regions being apparently inaccessible to the 
transcription machinery and thus not being expressed, and under methylated 
regions of DNA being much more loosely organised and thus more open to 
transcription (Antequera et al., 1990; Tazi & Bird, 1990). Hypermethylation 
of DNA has been found in lung and colon carcinomas, particularly in regions 
of chromosomes where loss of heterozygosity occurs (Makos et al., 1992). It 
is thought that DNA methylation inhibits the expression of genes (Cedar,
1988), and thus hypomethylation of genes could result in overexpression. 
Hypomethylation of genes has been observed in colon carcinomas, with 
increased hypomethylation in metastatic tumours (Feinberg & Vogelstein, 
1983; Goelz & Vogelstein, 1985). Therefore, the methylation state of DNA 
may play a role in the tumorigenic process. Figure 4.11 shows the 
autoradiographs resulting from an investigation of hypomethylation of the 
TOPO II genes. A number of different tumour types were analysed, including 
the NSCLC cell lines L-DAN (lanes 15 & 16) and CALU-3 (lanes 17 & 18). 
In this study, the restriction enzymes Mspl and Hpall were utilised. MspI will 
cleave DNA irrespective of its' methylation status. Hpall, on the other hand, 
will only cleave its' restriction site if it is not methylated. Since Mspl and 
Hpall enzymes have the same restriction site, hypomethylated DNA would 
produce identical restriction fragments with both enzymes. From the data 
shown in Figure 4.11, however, there does not appear to be any evidence for 
hypomethylation of either the TOPO I la  or TOPO II p genes in any of the 
samples analysed.
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Figure 4.11
Investigation into the methylation status of TOPO I la  and lip  
genes, using Southern analysis.
The same blot was probed with SP1 (TOPO Ila) and 
SP12 (TOPO IIP) probes
Lanes 1 & 2: R3E2, Lanes 3 & 4: Sample of lung tumour DNA, 
Lanes 5 & 6: LS274, Lanes 7 & 8: LS310,
Lanes 9 & 10: LS112, Lanes 11 & 12: LS112ST,
Lanes 13 & 14: LS112Adr, Lanes 15 & 16: CALU-3, 
Lanes 17 & 18: L-DAN
DNA loaded in odd-numbered lanes was digested with Hpall 
DNA loaded in even-numbered lanes was digested with Mspl
R3E2 is a cell line derived from normal bowel. LS274, LS310, 
LSI 12, LS112ST and LS112Adr are all small cell lung tumour cell 
lines. CALU-3 and L-DAN are both non-small cell lung tumour 
cell lines.
The restriction enzyme Hpall will not cleave DNA if its' cleavage 
site is methylated. The Mspl restriction enzyme will cleave DNA 
irrespective of its methylation status. Therefore, hypomethylation 
of the TOPO Ila  or Up genes, which could result in enhanced 
transcription levels, would be evident by production of identically 
sized restriction fragments as in Mspl digests in the Hpall digests.
There does not appear to be any evidence for hypomethylation in 
any of the samples analysed.
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Expression of Other Loci on 17q
As mentioned previously, CALU-3 has a number of genes co- 
amplified on chromosome 17 including ERBB2, TOPO Ila  and RARa. All of 
these genes have been implicated in the process of carcinogenesis. ERBB2 
amplification has been linked with poor prognosis in a variety of tumour 
types, including breast and ovarian (Hynes, 1993; Perren, 1991; Slamon et al.,
1989), TOPO Ila  expression levels are thought to play a role in sensitivity of 
cells to topoisomerase II inhibitors (Davies etal., 1988; Fry etal., 1991; Nitiss 
et al., 1992) and translocation of the RARa gene is commonly found in acute 
promyelocytic leukaemia (Chang et al., 1991; Dong et al., 1993; Kastner et 
al., 1992). The expression of NM23H1 was also investigated since there is 
evidence that this protein may influence the metastatic potential of tumour 
cells (Hennessy et al. , 1991; Leone et al., 1993a; Leone et al., 1993b; Wang 
etal., 1993).
In order to investigate ERBB2 expression in CALU-3, 
immunofluorescence analysis was performed using a monoclonal antibody 
against the erbB2 protein. Results from this experiment are shown in Figure 
4.12. No expression of erbB2 was detected in either L-DAN or SK-MES-1. 
CALU-3, however, was found to express erbB2 in the cell membrane of every 
cell in the population. This high expression therefore correlates with the gene 
amplification seen in this cell line. Expression analysis of the RARa gene 
was carried out using Western analysis. Figure 4.13 shows the results of a 
Western detected with a polyclonal antibody against the retinoic acid receptor 
alpha protein. No overexpression of this protein was detected in CALU-3, 
shown in lane 2, when compared to expression levels in L-DAN (lane 1) and 
SK-MES-1 (lane 3).
Although NM23H1 is known to be outside the region of 
amplification in CALU-3, expression of this gene is of interest because of its 
proposed role in anti-metastasis. Both nm23Hl and H2 proteins were 
detected by the antibody used in this analysis. Figure 4.14 shows the results 
of a Western blot where one half was probed with anti-nm23 antibody (a) and 
the other half with peptide-blocked anti-nm23 antibody (b). The blot in panel 
(a) shows the two bands expected for nm23Hl and H2 at 17 and 18.5 kD 
respectively. When detected with peptide-blocked primary antibody these 
bands are abolished (panel b). Figure 4.15 shows immunofluorescence 
detection of nm23Hl and H2 using the same antibody as in Western analysis. 
Panels (a), (c) and (e) show nm23 expression to be cytoplasmic and in every
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Figure 4.12
Detection of ERBB2 gene expression by immunofluorescence.
(a): L-DAN, (b): CALU-3, (c): SK-MES-1
Nuclei are counterstained with propidium iodide (pseudocoloured 
red), erbB2 protein detected with FITC (pseudocoloured green). 
ERBB2 expression was detected using the monoclonal antibody 
NCL-CB11 from Novocastra.
As can be seen from panel (b), ERBB2 expression (green signal) 
was only detectable in CALU-3, where this gene is amplified. 
Expression of ERBB2 was detected only in the cell membrane and 
in every cell of the population.
L-DAN
CALU-3
SK-MES-1
Figure 4.13
Detection of retinoic acid receptor alpha (RARa) expression by
Western blot analysis.
Lanel: L-DAN, Lane 2; CALU-3, Lane 3: SK-MES-1.
M=Markers
Molecular mass of RARa= 45kD
Whole cell lysates from 1 x 10^ cells were loaded per lane. 
Molecular mass standards in kiloDaltons are shown to the right of 
the autoradiograph. RARa was detected using a polyclonal 
antibody from Affinity BioReagents.
Despite the fact that CALU-3 has an amplified RARa gene, there 
is no evidence of overexpression of that gene when compared to 
expression levels in L-DAN and SK-MES-1.
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Figure 4.14
Detection of nm23Hl/H2 expression by Western blot analysis.
(a): blot incubated with anti-nm23Hl/H2 antibody.
(b): blot incubated with peptide blocked anti-nm23Hl/H2
antibody
L anel: L-DAN, Lane 2: CALU-3, Lane 3: SK-MES-1.
Molecular mass of nm23Hl= 17kD 
Molecular mass of nm23 H2= 18.5kD
Whole cell lysates from 1 x 1 0 ^  cells were loaded per lane. 
Molecular mass standards in kiloDaltons are shown to the right of 
the autoradiograph. A polyclonal antibody against both nm23Hl 
and nm23H2 was used from Cambridge Research Biochemicals.
Both nm23Hl and nm23H2 are detected by the primary antibody, 
as observed in image (a). When a complementary peptide is used 
to block primary antibody binding these bands are abolished, as. 
observed in image (b).
As shown by Southern analysis, the NM23H1 gene is not amplified 
in CALU-3, thus expression of this protein is similar among the 
three cell lines.
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Figure 4.15
Detection of NM23H1/H2 gene expression by 
immunofluorescence.
(a), (c) and (e): L-DAN, CALU-3 and SK-MES-1 reacted with
anti-nm23Hl/H2 antibody
(b), (d) and (f): L-DAN, CALU-3 and SK-MES-1 reacted with
peptide-blocked anti-nm23Hl/H2 antibody
Nuclei are counterstained with propidium iodide (pseudocoloured 
red), nm23Hl/H2 proteins detected with FITC (pseudocoloured 
green). Nm23Hl/H2 was detected using a polyclonal antibody 
from Cambridge Research Biochemicals.
NM23H1/H2 expression (green) was detectable in the cytoplasm 
of all cells in L-DAN, CALU-3 and SK-MES-1 (panels a,c and e). 
No expression was detected when peptide-blocked primary 
antibody was used (panels b,d and f).
f t
L-DAN
CALU-3
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cell in L-DAN, CALU-3 and SK-MES-1. Again, with peptide-blocked 
primary antibody all signal was abolished.
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4.3 Discussion
The expression data shown here for CALU-3 demonstrate that 
this cell line has high expression of topoisomerase Ila  both at the mRNA and 
protein level (Figures 4.1, 4.2 and 4.3). Although the Northern gel was 
underloaded for L-DAN, CALU-3 and SK-MES-1, it is still clear that CALU- 
3 expresses the TOPO Ila  gene very highly when loading and expression 
levels of all the other cell lines are compared. It is difficult to comment on the 
expression of the topoisomerase genes in L-DAN due to the concentration of 
RNA loaded for this sample, although a faint band of TOPO Ila  expression 
can be seen in panel (a). The TOPO I la  and II p genes have an approximate 
75% overall homology at the nucleotide level (Jenkins et al, 1992; Austin et 
al., 1993) thus there is a possibility that probes may cross-hybridise on 
Southerns and Northerns. This is an important issue at the RNA level since, 
as shown in Figure 4.1, the messages for TOPO Ila  and lip genes are the 
same size (6.5kb). The same cDNA clones (SP1 and SP12) were initially used 
by Chung et a l  in 1989. This group used oligos from the most distinct part of 
HeLa topoisomerase I la  and the putative topoisomerase lip  sequence in 
competition hybridisation experiments. They found that the signal from each 
oligo was only competed out I by unlabelled identical oligo, thus implying 
that the oligos derived from the cDNA clones were specific for the TOPO I la  
and lip genes (Chung e ta l,  1989). Also, if the signals from panels (a) and (b) 
are compared, it can be seen that CALU-3 has a much lower mRNA signal for 
TOPO Up than for Ila . If this were cross-hybridisation of signal, one would 
perhaps expect a similar intensity between the two probes. The difference in 
expression of the two genes is also shown in lanes 6 and 7 (LS274 and LS310, 
respectively), where with the TOPO I la  probe LS274 has greater expression 
than LS310 but with the TOPO Up probe, the two cell lines appear to show a 
very similar level of expression. To avoid the problem of cross-hybridisation, 
but still study mRNA levels in these cell lines, RNase protection assays could 
be performed. Such assays for TOPO Ila  and TOPO Up have recently been 
described (Jenkins et al., 1992), with distinct sizes of protected fragments 
isolated for topoisomerase I la -  and topoisomerase lip-specific probes. None 
of the NSCLC cell lines showed high expression of TOPO I. Previous work 
on the SCLC cell lines was performed in the Department of Medical 
Oncology by Dr. N. Keith and Dr. J. Plumb (unpublished). The data obtained 
here was found to agree with this previous work.
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From densitometric analysis of the Western blot shown in 
Figure 4.2, CALU-3 was found to express approximately 10-15 fold more 
topoisomerase I la  than either L-DAN or SK-MES-1. Thus the high TOPO 
Ha mRNA level in CALU-3 appears to correlate with a greater production of 
enzyme. Immunofluorescence analysis shows that the topoisomerase I la  
enzyme level is not high in all CALU-3 cells, but that more positive cells are 
present in CALU-3 than either L-DAN or SK-MES-1. A very high level of 
the enzyme was detected in a mitotic cell, which agrees with many previous 
studies on the regulation of topoisomerase II during the cell cycle (Heck et al., 
1988; Kaufmann et al., 1991; Prosperi et al., 1994; Prosperi et al., 1992; 
Woessner et al. , 1991). The intense topoisomerase I la  signal in this cell 
looks to be associated with the metaphase chromosomes, unlike the other 
interphase cells where topoisomerase Ila  expression appears to be speckled 
throughout the nucleoplasm. Localisation of topoisomerase I la  to metaphase 
chromosomes has been observed previously (Boy de la Tour & Laemmli, 
1988; Eamshaw & Heck, 1985; Gasseretal., 1986; Saitoh eta l., 1994) with 
immunopositivity observed along the entire length of the chromatid in 
expanded chromosomes (Eamshaw & Heck, 1985; Gasser et al., 1986). In 
fact, topoisomerase Ila  has been proposed to be the most abundant non­
histone protein in the metaphase scaffold representing 1-2% of the total 
protein mass in metaphase chromosomes. The lower levels of topoisomerase 
Ha expression detected in L-DAN and SK-MES-1 by Western blot analysis 
were confirmed by immunofluorescence. However, due to the settings for 
digital image analysis required to maintain optimal visualisation conditions of 
topoisomerase Ila  in CALU-3, topoisomerase Ila  expression in these other 
two cell lines was almost undetectable.
Biochemical assays have shown CALU-3 to possess an 
approximate eight-fold increase in topoisomerase II activity when compared 
to the two cell lines without amplification of TOPO Ila  (Figure 4.4). This 
figure was deduced through independent analysis of the original negatives by 
at least two individuals and was taken as the protein concentration required to 
initiate decatenation. It cannot definitely be said that the increased activity 
observed in these assays is due to an increase in TOPO I la  gene copy number 
since the biochemical assays do not distinguish between the topoisomerase II a  
and lip isozymes. More detail is given on the topoisomerase II p isozyme in 
Chapter 5, which concentrates on TOPO lip expression and attempted 
detection of the 180kD protein.
Both the VP 16 inhibition of catalytic assays and use of the 
band depletion assay show that the topoisomerase II enzyme produced by
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CALU-3 and the other two cell lines is still sensitive to drug interaction. The 
catalytic assays show an in vitro approach to investigation of topoisomerase II 
activity, using a crude nuclear extract. However, as mentioned previously, it 
is not known whether the topoisomerase Up isozyme is also a target for VP16 
in these assays. The band depletion assay enables an in vivo study of 
topoisomerase ll/drug interactions since it is performed in whole cells. Also, 
this assay allows one to distinguish between the alpha and beta isoforms by 
using Western analysis to investigate the treated cell extracts. Thus, from the 
band depletion assay and resultant Western, it can be said that topoisomerase 
Da from all three cell lines is capable of forming stabilised cleavable 
complexes in the presence of VP16.
Cell cycle analysis of L-DAN, CALU-3 and SK-MES-1 was 
performed by flow cytometry following bromodeoxyuridine (BrdUrd) 
incorporation. From the results shown in Table 4.1 there do not appear to be 
any major differences between the percentages of cells at any particular stage 
of the cell cycle in the three cell lines. These results will, of course, depend 
on how confluent the cells were when the experiment was carried out. 
However, it is clear from Figure 4.8 that cells from L-DAN, CALU-3 and 
SK-MES-1 all undergo a normal cell cycle in as much as cells are seen 
progressing from G0/G1 (boxes 1 and 2), through S phase (box 3) and into G2 
(box 4). It appears from the topoisomerase I la  FACS experiment that 
CALU-3 still retains some cell cycle regulation of topoisomerase I la  
expression, since the percentage of topoisomerase I la  positive cells increases 
by 30-40% between G l and G2/M (Table 4.3). Much lower levels of 
expression were detected in L-DAN and SK-MES-1. Experiments using a 
monoclonal antibody against topoisomerase I la  were also performed (Tables 
4.4 and 4.5). Using this antibody, topoisomerase I la  expression was only 
detectable in CALU-3. This suggests that the monoclonal antibody was not 
sensitive enough to detect the topoisomerase I la  expression in L-DAN and 
SK-MES-1. It is not known whether the topoisomerase I la  positive cells 
detected in G0/G1 in CALU-3 (Figure 4.9, panel c) are expressing 
topoisomerase Ila  de novo at this stage of the cycle, or whether these are cells 
which are still expressing topoisomerase Ila  from G2/M. One way of finding 
the answer to this would be to carry out topoisomerase I la  FACS analysis 
using cells treated with hydroxyurea. Hydroxyurea causes cells to block after 
the G l phase of the cell cycle. Therefore, if this expression is caused by 
detection of topoisomerase I la  still present in cells from G2/M, the 
hydroxyurea treated cells would probably be negative for topoisomerase I la  
expression, since most of the topoisomerase I la  enzyme would degrade during
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Table 4.4
Number of cells in different stages of the cell cycle in a 
topoisomerase I la  FACS experiment (monoclonal antibody)
G l total cell 
no.
G l Topo Ila  
+ve cells
G2/M total 
cell no.
G2/M Topo 
I la  +ve cells
L-DAN - ND - ND
CALU-3 (a) 11861 4284 3991 2804
CALU-3 (b) 13229 6154 3483 2567
SK-MES-1 - ND - ND
All numbers listed have been corrected against a no primary antibody control 
experiment
Table 4.5
Percentage of cells positive for topoisomerase I la  expression in 
Gl and G2/M (monoclonal antibody)
% G l positive cells % G2/M positive cells
L-DAN ND ND
CALU-3 (a) 36% 70%
CALU-3 (b) 46% 73%
SK-MES-1 ND ND
ND: Not Detected
the blocking procedure. If expression was de novo at G l, topoisomerase I la  
expression would still be detected. Ideally, further repetitions of the 
topoisomerase I la  FACS experiments already performed, plus additional ones 
as outlined above, are required in order to have a full understanding of the cell
cycle regulation of topoisomerase Ila  expression in CALU-3.
Using a basic method for detecting the methylation status of
DNA, there was no evidence for hypomethylation of the TOPO Ila  or TOPO 
Dp genes in CALU-3, or any of the other samples analysed, as was shown in 
Figure 4.11. This would indicate that there are no gross changes to the 
chromatin structure around these genes in CALU-3, thus loosening of the 
chromatin scaffold, often associated with under methylated regions of DNA, 
(Tazi & Bird, 1990) , does not appear to play a role in the overexpression of 
the TOPO I la  gene in this cell line.
Using immunofluorescence, the erbB2 protein was detectable 
in CALU-3, where the gene is known to be amplified (Figure 4.12). 
Expression of this protein was visualised in the membrane of every cell. 
Expression of erbB2 has been observed in both the cytoplasm and membranes 
of cells (Gullick et al., 1987; Ramachandra et al., 1990; Winstanley et al., 
1991), although a recent report has suggested that membranous staining is the 
more prognostically relevant of the two when expression of erbB2 is studied 
in breast cancer (Tetu & Brisson, 1994). It has already been proposed that the 
ERBB2 gene is the driving force for the amplicon in CALU-3 since studies of 
gene amplification in breast cancer have shown that the ERBB2 gene is 
frequently found to be amplified alone, without involvement of the TOPO I la  
gene (Keith et al., 1993; Smith et al., 1993) . The overexpression of erbB2 
would give the tumour an obvious growth advantage since each cell would 
possess a higher number of growth factor receptors than a normal cell and 
thus, depending on growth conditions, could grow and divide at a greater rate. 
Overexpression of topoisomerase I la  enzyme may also be important. Calf 
thymus DNA topoisomerase II has been found to mediate illegitimate 
recombination in an in vitro situation between two phage X DNA molecules 
(Bae et al., 1988) and putative topoisomerase II DNA-binding sites have been 
found at points of DNA insertion, deletion and translocation (Negrini et al., 
1993; Sperry et al., 1989). Therefore, cells expressing large amounts of 
topoisomerase I la  may display more of a tendency to undergo such 
cytogenetic changes due to an increase in the number of topoisomerase II 
molecules free to bind to these sites in the nucleus. There was no detectable 
expression of erbB2 in either L-DAN or SK-MES. This could be due to lack 
of expression of this protein by these cell lines, or low levels of expression
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which are not detectable by this technique To clarify this point, Western blot 
analysis could be performed using whole cell extracts from L-DAN and SK- 
MES-1.
As mentioned previously, the NM23H1 and RARa genes are 
also situated around the region of the amplicon on chromosome 17 in 
CALU-3. From the results in Chapter 3 it was shown that the RARa gene is 
amplified (CALU-3 having at least 8 copies), although apparently not as 
highly as TOPO Ila  or ERBB2 genes. The NM23H1 gene was found to be 
outside the region of amplification (5 copies found in CALU-3). Western 
analysis of the retinoic acid receptor alpha (Figure 4.13) has shown the protein 
not to be overexpressed in CALU-3 in comparison to L-DAN and SK-MES-1. 
This result was repeated in 3 other Western experiments. Although this may 
seem unusual, there are cases where genes are amplified and no expression is 
detected. For example, in the l lq  amplicon, which has been reported in a 
variety of human tumours including breast and squamous cell carcinomas (see 
(Lammie & Peters, 1991) for review), the INT2 and HSTF1 genes are 
commonly within the amplicon but are not reported to be overexpressed (Fantl 
etal., 1990; Lafage etal., 1990; Tsuda etal., 1989). Also the ERBA1 gene 
has been reported to be co-amplified with ERBB2 in breast tumours with there 
being no evidence for subsequent overexpression (van de Vijver et al., 1987). 
Another suggestion to explain the apparent lack of overexpression in CALU-3 
is that the expression seen may be very high for this cell line, since the RARa 
expression level was not known previous to the occurrence of the gene 
amplification. The two fainter bands in Figure 4.13 are presumed to be 
degradation products from the main 45kD retinoic acid receptor alpha protein. 
Immunofluorescence was attempted using the same antibody as for Western 
analysis, but no specific signal could be obtained (data not shown).
The nm23Hl/H2 proteins were detected in L-DAN, CALU-3 
and SK-MES-1 by flow cytometry (Figure 4.10), Western analysis (Figure 
4.14) and immunofluorescence (Figure 4.15). By immunofluorescence 
analysis, expression was observed to be cytoplasmic. This pattern of 
expression has been previously reported for nm23Hl and H2 (Igawa et al., 
1994; Lacombe et al., 1991; Simpson et al., 1994; Yamaguchi et al., 1994). 
The minor bands detected in Figure 4.14 are assumed to be non-specific 
binding of the secondary antibody, since they are also present in the peptide- 
blocked primary antibody control (panel b). Specific detection of the nm23 
proteins was confirmed using a blocking peptide, to which the antibody had 
initially been raised. This was successful in blocking primary antibody signal 
in both Western and immunofluorescence analysis. No investigation has been
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performed into whether this expression correlates with the metastatic potential 
of these cell lines.
From Chapter 3 it is known that CALU-3 has amplification of 
TOPO Ila, ERBB2, RARa and G-CSF genes. It was also discovered that 
L-DAN has three copies of both TOPO Ila  and ERBB2 and SK-MES-1 has 
two copies of each of these genes. Expression analysis of TOPO I la  and 
ERBB2 has shown these genes to be overexpressed in CALU-3 when 
compared to L-DAN and SK-MES-1. No alterations were found in the 
activity or drug binding capability of the topoisomerase I la  enzymes in any of 
the cell lines. CALU-3 has previously been found to be 35-52-fold more 
sensitive to VP16 than either L-DAN or SK-MES-1, and 12-25-fold more 
sensitive to doxorubicin (Merry et al., 1987). Therefore, it is proposed that 
expression of the amplified TOPO I la  gene sequences in CALU-3 cause 
enhanced production of topoisomerase II alpha enzyme and this plays a major 
role in the sensitivity of CALU-3 to topoisomerase II inhibitors. This finding 
may be of importance in a clinical situation since tumours which are found to 
carry such a gene amplification may, therefore, respond preferentially to 
treatment with topoisomerase II inhibitory drugs (Keith et al., 1993; Smith et 
al., 1993).
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CHAPTER 5
EXPRESSION ANALYSIS OF 
TOPOISOMERASE Up
5.1 Introduction
This chapter will deal with expression analysis of the 
topoisomerase II beta enzyme in L-DAN, CALU-3 and SK-MES-1. The beta 
isoform of topoisomerase II was initially described by Drake et al. in 1987 
when they purified topoisomerase II from amsacrine-resistant P388 leukaemia 
cells (Drake et al., 1987). After performing SDS-polyacrylamide gel 
electrophoresis with their purified topoisomerase II, two bands were noticed at 
170 (pl70) and 180kD (pl80). When antibodies were raised to these specific 
proteins, each antibody was found only to react to the protein it was raised 
against. Other data was also obtained which led the authors to conclude that 
there were two forms of topoisomerase II, including the finding that each 
protein had catalytic activity, each produced distinct proteolytic fragments 
upon digestion with Staphylococcus V8 protease and the relative levels of the 
pl70 and pl80 forms between amsacrine-resistant P388 and amsacrine- 
sensitive P388 cells were found to be consistently different. In 1989 the same 
group isolated pl70 and pl80 proteins from U937 cells and proceeded to 
study the biochemical and pharmacological properties of each isozyme (Drake 
et al., 1989). In this study it was discovered that the isozymes could be 
distinguished in a number of ways. The optimal salt concentration for 
catalytic activity was found to be higher for the pl80 enzyme than for pl70. 
Thermal stability of the two proteins was found to be very different with the 
half life of pl80 shown to be half of that for pl70 and the drug sensitivity of 
the two isozymes differed in that higher concentrations of both teniposide and 
merbarone were required for inhibition of catalytic activity in reactions with 
pl80. Investigations into drug-induced cleavage sites found that p l70 
appeared to prefer A-T-rich binding sites, whereas pl80 appeared to prefer 
G-C rich sites. Finally, when expression of the two isozymes during the cell 
cycle was investigated, it was discovered that pl70 levels were highest during 
logarithmic growth and dropped as cells reached the plateau stage of growth 
(as described in Chapter 4). Expression of pl80 appeared to be the opposite to 
this, with low expression during logarithmic growth and higher expression as 
the plateau phase was reached. Therefore, it appeared that the initial proposal
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of the existence of two topoisomerase II proteins was correct, although there 
was still no genetic data showing the existence of two genes for topoisomerase 
II.
However, in 1989 the first publication appeared reporting the 
characterisation of two human TOPO II cDNA clones (Chung et al., 1989). 
The cDNAs described in this paper are the same ones which were used for the 
Southern and Northern blotting previously described in Chapters 3 and 4. By 
screening a cDNA library made from a nitrogen mustard-resistant human 
Burkitt lymphoma cell line (Raji-HN2) previously used by Tan et al. in 1988, 
two classes of TOPO II clones were pulled out. One member of the first class 
was found to be identical to part of a HeLa cell TOPO II cDNA (SP1), 
whereas members of the second class (SP11 and SP12) displayed a 75% 
nucleotide and 92% predicted peptide similarity to the first two-thirds of this 
HeLa TOPO II clone, leading to the suspicion that they were cDNAs from 
different genes. When antibodies were raised against peptides specific to each 
cDNA, SPl-peptide antibodies were found only to recognise the pl70 form of 
topoisomerase II and SP11-peptide antibodies to only recognise the pl80 
form. Hybridisation of oligos from the SP1 and SP11 cDNAs to Northern 
blots resulted in the detection of a 6.5 kb mRNA for each class, although 
when competition experiments were performed, hybridisation of oligo from 
one class was not competed out by oligo specific for the other, ruling out the 
possibility that the probes were detecting the same message. Therefore, this 
paper provided both genetic and immunological evidence for the existence of 
two TOPO II genes. It was also in this paper that the suggestion was made to 
adopt the terms I la  (pl70) and II p (pl80) for the two topoisomerase II 
isozymes. In 1990, another group reported the finding of a novel 
topoisomerase II homologue from HeLa cells (Austin & Fisher, 1990), again 
finding 60-70% nucleotide and peptide sequence homology with a region of 
HeLa cell TOPO II cDNA. It was later published that this clone encoded a C- 
terminal segment from the TOPO lip gene (Austin et al., 1993).
The TOPO II gene had already been localised to chromosome 
17q21-22 (Tsai-Plugfelder et al., 1988), although confirmation that this was 
the TOPO Ila gene had to wait until the beginning of 1992 when Tan et al. 
reported the mapping of the TOPO I la  and IIp genes using the SP1 and SP12 
cDNA clones (Tan et al., 1992). It was then confirmed that the human 
genome possessed two genes for topoisomerase II, one of which was located 
on 17q21-22 and the other on chromosome 3. Further mapping of the TOPO 
HP gene localised it to chromosome 3p24 (Jenkins et al., 1992). It has 
subsequently been reported that there are two differentially spliced forms of
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topoisomerase II p expressed in human cells, with the p-2 form containing a 
sequence which would encode an extra 5 amino acids in the topoisomerase II p 
protein. However, in all cases it appeared that the p~l form was the major 
form expressed, with consistently higher levels of p-1 RNA seen than p-2
(Davies et al. , 1993).
Analysis of topoisomerase II expression in normal human
lymphocytes has shown that topoisomerase lip expression is higher than 
topoisomerase I la  expression in non-cycling cells, and that levels of both 
isoforms rose between Gl and G2-M following phytohaemoagglutinin 
stimulation of the lymphocytes (Prosperi et al., 1994). Other studies 
commenting on differential expression of the topoisomerase I la  and IIp 
enzymes in tumour cells during the cell cycle have also reported a higher level 
of topoisomerase II beta in resting cells when compared to topoisomerase II 
alpha expression (Kimura et al. , 1994; Negri et al. , 1992; Prosperi et al., 1992; 
Woessner et al., 1991). A study of the patterns of TOPO Ila  and TOPO lip 
gene expression in various differentiated tissues in mice also found expression 
of the beta gene in tissues with no proliferating cells (Capranico et al., 1992). 
However, topoisomerase II p expression has been difficult to analyse because 
of the instability of the beta protein (Drake et al. , 1989; Negri et al. , 1993).
As well as cell cycle regulation, a number of groups have 
investigated the subcellular localisation of the two isoforms in cells. As 
presented in Chapter 4, topoisomerase II alpha is localised to the nucleoplasm 
of cells. Topoisomerase II p expression was initially observed only in the 
nucleoli of cells (Negri et al., 1992; Zini et al. , 1992), although a more recent 
study has suggested that the beta isozyme may be present in both the nucleoli 
and the nucleoplasm (Petrov et al., 1993). Investigations of topoisomerase II 
expression in Xenopus oocytes also found topoisomerase II expression in both 
nucleoli and nucleoplasm, although this work was performed using a 
polyclonal antibody which recognised both 170 and 180kD proteins, which 
may explain this result (Fischer et al., 1994). The discovery that the two 
isoforms appear to be expressed in different locations has led to the proposal 
that they may play different roles within the cell, with the beta isoform 
possibly involved in the regulation of transcription of the ribosomal genes.
The analysis of topoisomerase II p expression detailed in this 
chapter has been undertaken using a variety of techniques in an attempt to 
overcome the major problem associated with the detection of this protein, that 
being degradation. The mouse monoclonal antibody used, 8F8 (kindly 
provided by Dr. Astaldi Ricotti), has been characterised previously in various 
analyses of topoisomerase II beta expression (Negri etal., 1992; Negri etal.,
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1993; Prosperi et a l 1994; Prosperi et a l 1992; Zini et al., 1992). The 
NSCLC cell lines CALU-3, L-DAN and SK-MES-1 were also used in this 
analysis.
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5.2 Results
This chapter deals with expression of the beta isozyme of 
topoisomerase II. This protein has been notoriously difficult to isolate, as was 
hinted at in the previous chapter. The main factor for successful detection of 
the intact, 180kD topoisomerase lip protein by Western blotting appears to be 
the time taken from preparation of the cell lysates to loading the Western. 
Therefore, in an attempt to detect the 180kD topoisomerase lip protein a 
number of different protocols and antibodies have been tried. However, the 
only antibody which routinely detected a signal in the cell lines used was a 
mouse monoclonal against topoisomerase Up, 8F8, (Negri et al. , 1992), kindly 
given to us by Dr. Giulia Astaldi Ricotti from Pavia, Italy.
Dot Blot Analysis for Topoisomerase IIP
Dot blotting was initially used to see if the antibody would 
detect any topoisomerase lip signal from the three cell lines. Figure 5.1 
shows the results of two identical dot blots, of which one was incubated in the 
anti-topoisomerase lip  primary antibody (panel a) and a control one in which 
the primary antibody was omitted (panel b). Doubling dilutions of nuclear 
extract were applied to the filter from 50pig (darkest signal) down to 0.39pig 
for each cell line. As can be seen from panel (a), topoisomerase lip  protein 
was detected in L-DAN (lane 1), CALU-3 (lane 2) and SK-MES-1 (lane 3) 
down to a protein concentration of 0.78/<g. Very little background from the 
secondary antibody was observed (panel b). The lanes marked here are the 
same as in panel (a). From Figure 5.1, panel (a), it appears that L-DAN and 
SK-MES-1 express very similar amounts of topoisomerase II p protein, with 
CALU-3 expressing slightly less. It is not clear from this data whether it is 
the intact or degraded form of topoisomerase II p which is being detected.
Western Blot Analysis for Topoisomerase IIB
The same anti-topoisomerase lip antibody was subsequently 
used in Western analysis in an attempt to detect the intact 180kD 
topoisomerase lip protein. Figure 5.2 shows the results of Western blots for 
both topoisomerase IIa  and topoisomerase lip enzymes. Following 
incubation of the filter with anti-topoisomerase Ila  antibodies, CALU-3 (lane 
2 ) can be seen to overexpress the 170kD topoisomerase I la  protein when
87
Figure 5.1
Detection of topoisomerase lip using dot blot analysis.
(a): Dot blot using a mouse monoclonal primary antibody 8F8 
against the topoisomerase IIp enzyme 
(b): Control dot blot without using primary antibody
L anel: L-DAN, Lane 2: CALU-3, Lane 3: SK-MES-1
The first dot at the top of the filter corresponds to 50pig of sample. 
Successive dilutions of sample were then performed down to a 
protein concentration of 0.39pig.
Panel (a) shows the results when the dot blot filter was incubated 
with a mouse monoclonal primary antibody against the 
topoisomerase II beta enzyme. Panel (b) shows an identical filter 
strip which was exposed only to the secondary antibody.
Thus, expression of topoisomerase lip was observed in all three 
cell lines, down to a protein concentration of approximately 
O.ISptg. L-DAN (lane 1) and SK-MES-1 (lane 3) show very 
similar amounts of topoisomerase lip expression, whereas 
CALU-3 (lane 2) appears to express slightly less. Very little 
background was observed on the control filter.
a  b
•  • •
•  • •
I •  • •
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Figure 5.2
Detection of topoisomerase lip using Western analysis.
Lane 1: L-DAN, Lane 2: CALU-3, Lane 3: SK-MES-1 
Lane 4: L-DAN, Lane 5: CALU-3, Lane 6: SK-MES-1
Lysate from 10^ cells was loaded per lane for each cell line.
Topoisomerase Ila (170kD) was detected using a rabbit polyclonal 
from Cambridge Research Biologicals. 
Topoisomerase IIp (180/150kD) was detected using 8F8.
Incubation with antibody against topoisomerase Ila shows the 
same results as observed previously, with very high expression of 
the 170kD protein being seen in CALU-3 (lane 2).
Incubation with the anti-topoisomerase II p antibody detects a 
smaller band of approximately 150kD in size. Expression of this 
protein appears to be highest in L-DAN (lane 4).
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compared to L-DAN (lane 1) and SK-MES-1 (lane 3), as was previously 
shown in Section 4.2. Incubation with the topoisomerase Up antibody 
resulted in the detection of a 150kD band in all three cell lines (right hand 
panel, lanes 4, 5 and 6). This was assumed to be the degradation product from 
the topoisomerase lip enzyme which is commonly observed in Western 
analysis of cell extracts (see section 5.1), unless extracts are handled 
extremely quickly following preparation. In lanes 4 and 5 (L-DAN and 
CALU-3, respectively) a faint band can be seen at approximately 170-180kD 
which could be the intact topoisomerase II p protein. Signal in lane 6 (SK- 
MES-1) is very weak, thus making it difficult to compare expression in the 
three cell lines.
Band Depletion Assay
Using cell lysates prepared for Western analysis, which may 
have been freeze-thawed once or twice previously, only the 150kD 
degradation product of the topoisomerase II p enzyme could be detected. For 
this reason it was decided to incubate a filter from a band depletion assay with 
the topoisomerase II p antibody. In this technique, the cell lysates are prepared 
directly from cells growing in culture (some of which have been drug treated) 
and these are immediately loaded onto a Western gel using a microsyringe 
(see Section 2.2.10.3 and 4.2). Therefore, handling of the extracts is 
extremely quick which may be beneficial when attempting to detect the 
topoisomerase lip protein.
Figure 5.3 shows the autoradiographs resulting from 
topoisomerase I la  (lower panel) and topoisomerase Up (upper panel) 
detection of a band depletion assay filter. Results of the topoisomerase I la  
blot have been presented in more detail in Chapter 4. The topoisomerase II p 
signal detected in CALU-3 (upper panel, lanes 5-8) appears to mimic that seen 
with topoisomerase I la  in as much as at the highest concentration of VP 16 
there is a depletion in the amount of topoisomerase lip. However, this is the 
only lane in CALU-3 where this effect is observed and it is not seen in either 
L-DAN (upper panel, lanes 1-4) or SK-MES-1 (upper panel, lanes 9-12). 
Since the two isozymes are very similar in protein sequence (see Chapter 1) 
there is the possibility that the signal observed in the topoisomerase II p 
autoradiograph could be caused by anti-beta antibody cross-reaction with the 
alpha isozyme. This is unlikely, however, since the relative band intensities 
between the two autoradiographs are different. For example, of the
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Figure 5.3
Band depletion assay of topoisomerase lip  using whole cell 
lysates, analysed by Western blot.
Cells were incubated with decreasing amounts of VP 16 for 2 hours 
at 37°C and then lysed in protein lysis buffer. Samples were 
resolved on a 6% polyacrylamide gel (see Section 2.2.10.3).
Lanes 1-4: L-DAN, Lanes 5-8: CALU-3,
Lanes 9-12: SK-MES-1
Cells in lanes 1,5 and 9 were not treated with drug, those in lanes 
2,6 and 10 were treated with 5 x 10^M  VP16, those in lanes 3,7 
and 11 were treated with 5 x 10’^ M VP16 and those in lanes 4, 8 
and 12 were treated with 5 x 10“^ M VP16.
The mouse monoclonal antibody 8F8 was used to detect 
topoisomerase lip. A rabbit polyclonal from Cambridge Research 
Biologicals was used to detect topoisomerase Ila.
This figure shows a re-probing of the band depletion Western from 
Figure 4.7 (also shown here) with the topoisomerase IIp antibody.
L-DAN and CALU-3 show similar levels of topoisomerase II p 
expression with SK-MES-1 appearing to have a slightly lower 
level. Incubation of the cells with VP 16 does not appear to have 
an effect on the topoisomerase Up levels, unlike the results shown 
for topoisomerase Ila (see Chapter 4).
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SK-MES-1 samples, lanes 10 and 11 in the topoisomerase lip results appear 
more intense than either lanes 9 or 12. This is clearly different to the results 
from the topoisomerase Ila  band depletion since the strongest signals in this 
case are observed in lanes 9 and 12. The smaller band visible just below the 
main topoisomerase lip band in the upper panel is assumed to be the 150kD 
degradation product, previously observed in Western analysis (see Figure 5.2). 
Therefore, the data presented here shows the presence of intact topoisomerase 
II p protein in all three cell lines, but does not show any convincing evidence 
to suggest that the II p isozyme is a target for VP16-directed topoisomerase 
inhibition.
Immunofluorescence Analysis of TOPO IIB Expression
Immunofluorescence analysis was performed using 8F8 in 
order to see the cell to cell distribution and subcellular localisation of the 
topoisomerase Up protein. Figure 5.4 shows the results of 
immunofluorescence analysis with L-DAN (a), CALU-3 (b) and SK-MES-1 
(c). Topoisomerase II beta expression (yellow signal) was observed in every 
cell in all three cell lines. Beta expression has previously been reported to be 
largely confined to the nucleolus (Negri et al. , 1992), and the data presented in 
Figure 5.4 confirms this. Immunofluorescence is only semi-quantitative and 
due to the intense localised fluorescence pattern obtained when analysing 
expression of the topoisomerase lip protein, any difference in expression 
levels between the three cell lines is difficult to assess. Therefore, expression 
of topoisomerase lip differs from topoisomerase I la  expression in that beta 
expression appears to be common to every cell in a population and also 
appears to be localised within a specific nuclear compartment. Again, it is not 
possible to distinguish whether or not the protein detected using this technique 
is the 180- or 150 kD form.
In order to confirm the localisation of topoisomerase II p to the 
nucleolus, an anti-nucleolar antibody was obtained from ImmunoConcepts 
(see Section 2.1.6). Figure 5.5 shows the results of a co-localisation 
experiment with the nucleolar control antibody shown in green and 
topoisomerase II beta expression shown in red. Co-localisation of these 
signals is apparent where the two colours overlap, creating a yellow signal. 
This result was observed in L-DAN (a), CALU-3 (b) and SK-MES-1 (c). 
Therefore, topoisomerase lip  expression appears to co-localise with nucleolar 
proteins.
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Figure 5.4
Detection of TOPO 11(3 gene expression by
immunofluorescence.
(a): L-DAN, (b): CALU-3, (c): SK-MES-1
Nuclei are counterstained with propidium iodide (pseudocoloured 
red), topoisomerase II(3 detected with FITC (pseudocoloured 
green). The mouse monoclonal antibody 8F8 was used to detect 
topoisomerase II p.
Topoisomerase 11(3 was observed in every cell of the population in 
all three cell lines. Expression of this enzyme appears to be 
restricted to the nucleoli.
L-DAN
CALU-3
SK-MES-1
Figure 5.5
Co-localisation of topoisomerase lip  with a nucleolar control
antibody.
(a): L-DAN, (b): CALU-3, (c): SK-MES-1
Nuclei are counterstained with propidium iodide (pseudocoloured 
blue), topoisomerase Up was detected with Cy^ (pseudocoloured 
red), nucleolar control was detected with FITC (pseudocoloured 
green).
The mouse monoclonal antibody 8F8 was used to detect 
topoisomerase Up and an anti-human nucleolus antibody from 
ImmunoConcepts (c/o Alpha Laboratories) was used to detect 
nucleoli.
Topoisomerase lip expression was again observed in every cell of 
the population in all three cell lines, as was the nucleolar signal. 
Co-localisation of the two signals is apparent when a yellow signal 
is seen, caused by overlap of the green and red colours used for 
visualisation.
5.3 Discussion
The data presented in this chapter show the expression of topoisomerase II p in 
L-DAN, CALU-3 and SK-MES-1. Various techniques of both protein 
isolation and detection were used in an attempt to detect the intact 180kD 
topoisomerase Up enzyme. The major problem in isolating this protein is that 
it appears to be extremely unstable, degrading very quickly following 
extraction to produce a 150kD protein (Drake et al., 1989; Negri eta l., 1993). 
The antibody used for all the analyses was 8F8, a mouse monoclonal antibody 
kindly supplied by Dr. Astaldi Ricotti, Pavia, Italy. This antibody was one of 
six anti-topoisomerase lip monoclonal antibodies produced by this group and 
was first reported in 1992 in a paper by Negri et al. (Negri et al., 1992). This 
antibody has previously been shown in Western analysis to detect a single 
band in extracts from both human and bovine cells, and has also been shown 
not to cross-react with purified topoisomerase Ila  protein (Negri etal., 1993).
Due to the problems often encountered in the detection of the 
intact topoisomerase Up it was decided to use dot blotting as the initial 
method of detection. Although this technique does not give any idea of 
specificity of the antibody, since the size of any protein detected is not known, 
it does enable one to see that the antibody being used is recognising a protein. 
The autoradiograph in Figure 5.1 shows that 8F8 is recognising a protein in all 
three cell lines, and its' detection is linked to protein concentration. The blot 
incubated with secondary antibody alone shows that there was minimal 
background in this experiment, and the signal obtained in the first panel was 
as a result of incubation with the anti-topoisomerase II p antibody.
To ensure that the anti-topoisomerase Up antibody was 
detecting the topoisomerase lip protein, a Western was run of L-DAN, 
CALU-3 and SK-MES-1 whole cell extracts. One half of this Western blot 
was incubated with anti-topoisomerase I la  antibody, and the other with anti- 
topoisomerase Up antibody. The results shown in Figure 5.2 clearly show a 
different signal is obtained in the topoisomerase II p detected filter (lanes 4, 5 
and 6) as opposed to the I la  filter (lanes 1,2 and 3), thus there does not appear 
to be any cross-reaction of the anti-topoisomerase lip antibody with 
topoisomerase Ila. Unfortunately in this Western, only the 150kD 
degradation product of topoisomerase lip has been detected, which has also 
been reported on a number of occasions (Negri et al., 1992; Zini et al., 1992). 
It is difficult to compare levels of topoisomerase II p expression by the levels 
of this 150kD protein since the beta isozyme may have different stabilities in
90
the different cell lines. The level of the 150kD protein in lane 6 (SK-MES-1) 
is very low. This may be a result of interference in either primary antibody 
incubation or detection by air bubbles which may block the signal. In lanes 4 
and 5, (L-DAN and CALU-3, respectively), a very faint band can be seen 
above the 150kD band. This may be the intact topoisomerase II p protein. 
There may be various reasons for the degradation of the topoisomerase II p 
protein. Cells from 6-well plates were lysed directly into Western loading 
buffer and extracts were usually prepared in advance and kept at -20°C until 
required. It is not known what effect the storage at -20°C might have on this 
protein. Also, if Western gels were run overnight at room temperature this 
may affect the 180kD protein.
Therefore, to have some chance of detecting the beta enzyme, 
it appears that the cell extracts must be prepared very quickly and immediately 
loaded onto the Western gel. One technique which was already being used in 
which these criteria were met was the band depletion assay (previously 
described in Chapter 4). In this assay there is a very quick turn-around from 
cells in culture to lysates and on to the gel. It was therefore decided to re- 
incubate a filter from such an assay with the 8F8 antibody. This experiment 
would also show any effects of VP16 treatment of cells on topoisomerase II p 
levels, if it was successful. The resulting autoradiograph from the 
topoisomerase lip experiment (upper panel) is shown in Figure 5.3, together 
with the original result of the topoisomerase I la  experiment (lower panel). 
The anti-topoisomerase II p antibody detected two bands on the filter. It was 
assumed that the larger protein detected here was the intact 180kD 
topoisomerase lip protein and the smaller, fainter band was the 150kD 
degradation product. The relative signal intensities between the 
topoisomerase Ila  and topoisomerase lip bands is obviously very different. In 
the beta detected filter, there appears to be little evidence for any effect of 
VP16 on the levels of topoisomerase II p detected, unlike the results seen for 
topoisomerase I la . This result may have been expected since it was 
previously reported that the beta isozyme was less sensitive to topoisomerase 
II inhibitors (Drake et al., 1989). However, there does appear to be a 
depletion in the amount of topoisomerase II beta in lane 6 (CALU-3), in 
which the cells were treated with the highest concentration of VP16. Since 
this effect is not seen in the other two cell lines, it could be that the 
topoisomerase Up in CALU-3 is more sensitive to VP16 than that present in 
L-DAN or SK-MES-1. In order to prove this, more repetitions of this 
experiment would be required.
91
From the levels of the 180kD band detected in this experiment, 
there appears to be little difference in expression of topoisomerase II p 
between L-DAN and CALU-3, with SK-MES-1 perhaps expressing slightly 
less. It could be proposed from this result that there is differing stability of the 
topoisomerase lip protein in the different cell lines since varying amounts of 
degradation of the 180kD protein can be seen on this autoradiograph. More 
intense bands of the 150kD product can be seen in the L-DAN and SK-MES-1 
samples than for CALU-3. This could, of course, also be due to treatment of 
cells before extracts were made. For example, CALU-3 may have been the 
first cells lysed, followed by L-DAN and then SK-MES-1.
Immunofluorescence analysis was used as a method of 
detecting the topoisomerase II p protein without worrying about degradation 
since the treatment of cells for immunofluorescence preserves the protein. 
Data shown in Figures 5.4 and 5.5 show topoisomerase II p expression to be 
localised strictly to the nucleolus, as has been shown previously for this 
antibody (Negri et al., 1992; Zini et al., 1992). However, there does appear to 
be some controversy around the localisation of the topoisomerase lip enzyme 
since a recent study found it to be in the nucleoplasm as well as the nucleolus 
(Petrov et al., 1993). One explanation for this difference could be the use of 
polyclonal antibodies which whilst being specific for each isozyme on a 
Western blot, may cross-react with the related protein when that protein is still 
in its natural state.
Expression of the beta isozyme appears very different to that of 
topoisomerase II a , since topoisomerase lip is expressed in every cell in all 
three cell lines. Since the signal is so intense in the cells, it is very difficult to 
quantify this result, although the results of Western blotting do not appear to 
show any major differences between L-DAN, CALU-3 and SK-MES-1. From 
Figure 5.5 it can be seen that the beta enzyme co-localises with a nucleolar 
control antibody. The anti-nucleolar antibody has not yet been fully 
characterised, thus it is not known what its1 protein target is.
The finding that topoisomerase Up expression is localised to 
nucleoli, and appears to be differentially regulated to topoisomerase I la  has 
led to suggestions that the two isozymes may perform different functions 
within the cell. It has been proposed that topoisomerase Ila  is more involved 
with DNA replication since its expression is upregulated during cell 
proliferation, whereas topoisomerase II p is involved with DNA transcription, 
particularly of ribosomal genes, since its expression appears to be higher at the 
plateau stage of the cell cycle. As mentioned previously, it was discovered 
that topoisomerase II p bound preferentially to G-C-rich regions of DNA
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(Drake et al., 1989). This is of interest since certain genes have been found to 
exhibit G-C-rich promoter regions (Kozasa et al., 1988). It may be that 
topoisomerase II p plays a role in the transcriptional regulation of these genes. 
There is also evidence that nucleolar DNA itself is G-C-rich, and may 
therefore lend itself to preferential binding of topoisomerase lip (Willems et 
al., 1968). The discovery of the second topoisomerase II could also be 
extremely useful for cancer therapy since, although it appears to be slightly 
more resistant to the effects of current topoisomerase II inhibitors, it could be 
a target for therapy in its own right where there is low expression of 
topoisomerase Ila. This could be extremely valuable in cases of relapsed 
tumours where cells have become resistant by reducing expression of 
topoisomerase Ila, or are expressing a mutant topoisomerase II a.
In order to quantify TOPO II p expression levels in the three 
cell lines which have been studied, RNase protection assays could be 
performed, and the Northern analysis could be repeated. With respect to 
protein analysis of the topoisomerase II beta enzyme, it should be pointed out 
that much of the data which has so far been accumulated on this enzyme has 
been through the use of only a couple of different antibodies, one from the 
Italian group of Dr. Astaldi Riccotti, and the other from Dr. Fred Drake. 
Therefore, perhaps detection of the topoisomerase II p protein would be easier 
and more reliable if there were more anti-topoisomerase Up antibodies 
available.
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CHAPTER 6
INVESTIGATION INTO THE 
VP16-RESISTANCE OF A CALU-3 CLONE.
6.1 Introduction
As mentioned in previous chapters, topoisomerase II is the 
target for a number of anti-tumour agents including mAMSA and VP16. In 
section 4.1, details were given as to how both changes in the expression of 
topoisomerase II and alterations in the molecule itself can lead to resistance or 
sensitivity of cells to topoisomerase II-targeting agents. Numerous studies, 
using both human and rodent cell lines, have found that a low or reduced level 
of topoisomerase II expression correlates with drug resistance (Davies et al., 
1988; de Jong etal., 1993; Friche etal., 1992; Lefevre et a l . , 1991; Long et 
al., 1991; Per et a l . , 1987; Potmesil et al., 1988; Ritke et al., 1994; Tan et a l., 
1989; Webb et al., 1991; Zwelling et al., 1990b). With the exception of the 
study of normal and leukaemic lymphocytes by Potmesil etal., all the above 
analyses were performed using drug-resistant cell lines derived in vitro. 
Despite most of these drug resistant cell lines being selected with one drug 
(commonly mAMSA, doxorubicin, mitoxantrone, VP16 or VM26), a cross- 
resistance to one or other of these drugs, or other topoisomerase II inhibitors 
can also be found (Cole et al., 1991; de Jong et al., 1993; Lefevre et al., 1991; 
Long et al., 1991; Per et al., 1987; Schneider et al., 1994; Webb et al., 1991). 
Cross-resistance to Vinca alkaloids, such as vincristine and vinblastine, has 
also been observed in topoisomerase II inhibitor-resistant cell lines (Gupta, 
1983; Hill & Bellamy, 1984; Per et al., 1987). Thus cells can be resistant to a 
number of different agents that are not necessarily related by structure or 
mechanism of action, which suggests that reduced topoisomerase II levels are 
not solely responsible for this drug resistance.
This kind of broad cross-resistance is termed multidrug 
resistance, or MDR. The commonest feature of cells which exhibit the MDR 
phenotype is amplification and overexpression of the gene encoding a 170kD 
plasma membrane protein known as P-glycoprotein, which is also associated 
with a decreased accumulation of drug within the cell. Overexpression of P- 
glycoprotein has also been found in conjunction with altered topoisomerase II 
levels (Kamath et al., 1992). In humans, two MDR genes have been 
discovered, MDR1 and MDR3 (also known as MDR2) (Nooter & Herweijer,
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1991; Schinkel et a l . , 1991; Van der Bliek et al., 1988). It appears, however, 
that only the MDR1 gene is involved in multidrug resistance (Gros et al., 
1986a; Ueda et al., 1987; Van der Bliek et al., 1988). The P-glycoprotein 
molecule was shown to have a strong homology with bacterial transport 
proteins (Chen et al., 1986; Gerlach et al., 1986; Gros et al., 1986b). 
Structural analysis of the protein showed that it consisted of two homologous 
halves, each containing a hydrophobic domain with six transmembrane 
regions and a hydrophilic domain (Chen et al., 1986; Gerlach et al., 1986). It 
was also noted that each segment contained a consensus site for ATP-binding. 
It was therefore proposed that P-glycoprotein functioned as an energy- 
dependent drug efflux pump, with the transmembrane domains forming a 
channel in the cell membrane through which suitable substrates are actively 
pumped out of the cell. This model for P-glycoprotein function also 
accounted for the observed decrease in accumulation of drug that was 
observed in multidrug resistant cells (Endicott & Ling, 1989; Riehm & 
Biedler, 1972; Siroinak etal., 1986).
A somewhat controversial issue is whether expression of the 
MDR phenotype is of relevance in an in vivo situation. Numerous studies 
have been undertaken to analyse P-glycoprotein expression in both 
haematological and solid tumours (reviewed in Roninson, 1992). A study of 
P-glycoprotein expression in acute lymphoblastic leukaemia (ALL) showed 
that the remission rate for MDR-positive patients was approximately half of 
that for MDR-negative patients (Goasguen et al., 1993). Also, of those MDR- 
positive patients that achieved a first remission, 81% relapsed compared to 
37% of MDR-negative patients. Therefore, P-glycoprotein expression would 
appear to be prognostically significant in ALL. Increased transcription levels 
of the MDR1 gene have also been found in high-grade, poorly differentiated 
bladder cancers (Clifford et al., 1994). In this study, an association was made 
between high MDR1 gene expression and poor survival. Various studies 
have shown a correlation between expression of the protein and poor response 
to chemotherapy, or shorter progression-free survival in breast tumours (Lonn 
et al., 1993; Verrelle et al., 1991). Studies of other kinds of tumours, 
however, have found no evidence for involvement of P-glycoprotein in drug 
resistance (Lai et al., 1989; Shin et al., 1992). It would therefore appear that 
the significance of P-glycoprotein in tumours depends on the type and origin 
of the tumour analysed, and also the technique used to analyse expression 
(Holmes & West, 1994; Schlaifer et al., 1990).
Following the discovery of P-glycoprotein, a number of cell 
lines were described which appeared to have the MDR phenotype, but in
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which no MDR gene expression could be detected (Baas et al., 1990; Beck et 
al., 1987; Cole et al., 1989; Danks et al., 1987; Mirski et al., 1987; Zwelling 
et al., 1990b). Such cell lines, lacking P-glycoprotein expression but still 
exhibiting resistance to a number of natural product antitumour drugs, except 
the Vinca alkaloids, were classified as "atypical" MDR cell lines. Included in 
this classification are drug resistant cell lines in which no decrease in drug 
accumulation is observed, but alterations in topoisomerase II are commonly 
found (Beck et al., 1993a; Beck et al., 1993b). A study of drug resistance 
associated membrane proteins in human leukaemic HL60-adriamycin resistant 
cells (HL60/Adr), lacking expression of MDR genes, discovered a 190kD, 
ATP-binding protein which was not present in either HL60-vincristine 
resistant or HL60-sensitive cells (McGrath et al., 1989). In a further study of 
resistance associated membrane proteins in HL60/Adr (Marquardt et al., 
1990), numerous antisera were raised against synthetic peptides from different 
sequence domains of the P-glycoprotein molecule. All of the antisera reacted 
with P-glycoprotein (pl70) in the vincristine resistant HL60 cell line, whereas 
in HL60/Adr only 1 antiserum reacted with a 190kD protein (pl90). As 
observed previously, the protein was also found to be capable of binding ATP 
(Marquardt et al., 1990). These results indicated that a minor sequence 
homology existed between the 190kD protein and P-glycoprotein.
Differential hybridisation of cDNA prepared from total mRNA 
from the previously characterised H69AR human lung cancer cell line (Cole et 
al., 1989; Mirski et al., 1987) and parental H69 cells, found one cDNA which 
was 100- to 200-fold overexpressed in H69AR cells (Cole et al., 1992). This 
overexpression was found to be caused by gene amplification, with the 
amplification being lost in reverted drug resistant cells. A further association 
between the overexpressed gene and drug resistance was made when 
overexpression of the gene was discovered in a drug resistant HeLa cell line, 
which lacked P-glycoprotein expression (Cole et al., 1992). The protein 
coded for by this gene was designated MRP (multidrug resistance-associated 
protein) and was found to be a member of the ATP-binding cassette 
superfamily of transport systems (Hyde et al., 1990), which also includes P- 
glycoprotein. The gene for MRP was mapped to the short arm of 
chromosome 16 (Cole et al., 1992). Fluorescence in situ hybridisation 
analysis of H69AR and HT1080/DT4 chromosomes, (HT1080/DT was 
previously characterised in Zwelling et al., (1990b)), localised the amplified 
MRP gene to homogeneously staining regions on numerous chromosomes in 
both cell lines, with hybridisation of MRP also found on double minutes in
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H69AR (Slovak et al., 1993). Therefore, further evidence was provided for 
the involvement of MRP in drug resistance of certain tumour types.
Following the cloning of the gene for MRP, it was deduced that 
the gene encoded a 190kD membrane bound glycoprotein (Krishnamachary & 
Center, 1993) which confirmed the earlier reports of the pl90 protein found in 
HL60/Adr cells (Marquardt et al., 1990). Transfection studies using the 
complete coding sequence of the MRP gene showed that the level of drug 
resistance in transfected cells was proportional to the level of 190kD protein 
expressed (Grant et al., 1994). Transfectants were also shown to be resistant 
to vincristine and VP16, as was previously seen in "atypical” MDR cell lines. 
Another study investigated MRP expression levels in doxorubicin resistant 
non-small cell lung cancer cell lines (Barrand et al., 1994) and also found that 
the most resistant cells exhibited the highest levels of MRP protein 
expression, with loss of MRP expression in revertant cell lines. It is also of 
interest to note that the MRP phenotype can be found in conjunction with 
changes to topoisomerase II expression (Cole et al., 1991; de Jong et al., 
1993; Friche etal., 1992; Schneiders al., 1994).
Very recent data, generated using stable MRP transfectants and 
immunohistochemistry, has shown that the multidrug resistance-associated 
protein is plasma membrane bound and is possibly a drug efflux pump (Hens 
et al., 1994; Zaman et al., 1994), similar to P-glycoprotein. It would therefore 
be assumed to act in a similar way to P-glycoprotein by actively pumping 
drugs out of the cell. Differences have been found, however, in the substrates 
which can interact with the two molecules, since MRP-transfected cells do not 
appear to be resistant to taxol, whereas MDR1-transfected cells are (Mickisch 
et al., 1991; Zaman et al., 1994). Also, cyclosporin A is seen to reverse P- 
glycoprotein mediated drug resistance but is not capable of reversing MRP 
mediated resistance (Zaman et al., 1994). Very little data has been generated 
concerning the relevance of MRP expression in the clinic. One study 
performed to investigate MRP RNA expression levels in acute and chronic 
leukaemias (Burger et al., 1994) found a high frequency of MRP 
overexpression in chronic lymphocytic leukaemia samples, but only 
occasional high expression in acute cases. No samples were found with 
amplification of the gene.
The work presented in the following section has involved the 
characterisation of a VP16-resistant cell line derived from a CALU-3 sensitive 
clone. The resistant cell line, CALU-3/lO'^M VP16 was derived as outlined 
in section 2.2.1. The ID50 values for parental CALU-3 clone 4 and CALU- 
3/10"^M VP16 are shown in the table below (from Dr. J. Plumb, Medical
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Oncology, Glasgow). The table shows results from a representative 
experiment, where each cell line was tested in triplicate.
Cell Line ID 50 (pM)
VP 16 Doxorubicin Vincristine Cisplatin
CALU-3 
Clone 4
0.26 ±0.02 0.0062 ± 0.0004 0.0107 ±0.004 0.40 ±0.03
CALU-3 
10-5M VP16
2.1 ±0.1 
(8x)
0.52 ±0.08 
(84x)
0.69 ±0.04 
(65x)
0.58 ±0.05 
(1.5x)
Therefore, it can be seen that CALU-3/lO'^M is resistant to VP16 and cross- 
resistant to doxorubicin and vincristine. As has been previously mentioned, 
there could be at least three possible causes for this drug resistance, these 
being alterations to topoisomerase II, overexpression of P-glycoprotein or 
overexpression of MRP. Investigations were therefore carried out to analyse 
each of these possibilities using both the parental CALU-3 clone 4 cell line 
and CALU-3/lO^M VP16 resistant cell line. Biochemical assays were 
performed to check topoisomerase II activity in the two cell lines. Flow 
cytometry was carried out for P-glycoprotein expression, and Western 
analysis was performed to analyse MRP expression levels.
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6.2 Results
This chapter has involved the use of various techniques in an 
attempt to discover the cause of drug resistance in a VP16-resistant CALU-3 
clone. Three successively more VP16 resistant CALU-3 cell lines were 
derived from CALU-3 clone 4, a VP16 sensitive clone. The first, CALU- 
3/10^M  VP16 was resistant to IjaM VP16. The second, CALU-3/9xlO"^M 
VP16 was resistant to 9]aM  VP16. The final cell line, CALU-3/10“^ M VP16 
was resistant to \0piM VP16. Investigations were performed to analyse the 
expression levels of topoisomerase Ila, P-glycoprotein and the multidrug 
resistance-associated protein, MRP using the parental CALU-3 clone 4 cell 
line and the derived, drug resistant CALU-3/10‘^ M VP16 cell line.
Western Blotting Detection of Topoisomerase I la
It is known from the results shown in Chapter 4 that CALU-3 
has high expression of the topoisomerase I la  enzyme. Therefore, it was of 
interest to see if the levels of topoisomerase Ila  protein were reduced in the 
derived drug resistant cell line, CALU-3/10'^M VP16 since this is a known 
mechanism of resistance against topoisomerase II targeting agents. Figure 6.1 
shows the result from a Western blot of CALU-3 clone 4 and CALU-3/10"^M 
VP16 crude protein extracts incubated with anti-topoisomerase I la  antibody 
from CRB. From Figure 6.1 there does not appear to any major difference in 
topoisomerase I la  protein levels between the CALU-3 clone 4 (lane 1) and 
CALU-3/10"^M VP16 (lane 2). The smaller band observed at around 130kD 
is presumed to be a degradation product from the topoisomerase I la  protein.
Biochemical Assays for Topoisomerase II
Even though there does not appear to be any difference in 
topoisomerase Ila  protein levels between the parental and drug-resistant 
CALU-3 cell lines, the VP16 resistance could be caused by a mutation of the 
topoisomerase II molecule (Bugg et al., 1991; Per et al., 1987). If this was the 
case, the topoisomerase II from CALU-3/10_^ M VP16 may have altered 
catalytic activity, as was shown in the above studies. Biochemical assays 
were performed to test this theory using the same crude nuclear extracts as 
used for the Western in Figure 6.1 in the TopoGEN assay system, as detailed 
in section 2.2.11. The results of these assays are shown in Figure 6.2. Panel
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Figure 6.1
Detection of topoisomerase I la  in CALU-3 clone 4 and 
CALU-3/lO'^M VP16 using Western analysis.
Lane I: CALU-3 clone 4, Lane 2: CALU-VP16
50/* g of crude extract was loaded per lane for each cell line.
Topoisomerase Ila (170kD) was detected using a rabbit polyclonal 
from Cambridge Research Biologicals.
Molecular mass standards are shown in kilodaltons on the right of
the figure.
Incubation with antibody against topoisomerase Ila  shows 
approximately the same levels of topoisomerase Ila are observed 
in the parental CALU-3 clone 4 cell line (lane 1) and 
CALU-3/10-5M VP16 line (lane 2).
The smaller band is a degradation product from the p i70 protein.
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Figure 6.2
Decatenation of kinetoplast DNA by cellular extracts from 
A: CALU-3 clone 4, B: CALU-3/10-5M VP 16.
Serial dilutions of crude nuclear extracts were assayed for 
topoisomerase II activity:
Lane I: 0//g, Lane2: 5//g, Lane3: 2.5pig, Lane4: 1.25//g, 
Lane 5: 0.625//g, Lane 6: 0.312//g, Lane 7: 0.156//g,
Lane 8: 0.078//g, Lane 9: 0.039pig,
Lane 10: Fully decatenated kinetoplast DNA
Topoisomerase II activity decatenates kinetoplast DNA to 
monomer minicircles (m). In the absence of cellular extract, 
kinetoplast DNA (k) remains in the well of the gel (Lane 1).
Topoisomerase II activity can be observed down to 0.039//g of 
protein in both CALU-3 clone 4 extract and CALU-3/IO-^m  VP16 
extract. Therefore, there does not appear to be any difference in 
topoisomerase II activities between the parental and resistant cell 
lines.
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A shows the catalytic activity in CALU-3 clone 4 and panel B shows the 
catalytic activity in the CALU-3/10'^M VP16 clone. In both the CALU-3 
samples, topoisomerase II activity can be observed down to a protein 
concentration of 0.039/^g (lane 9, panels A and B). Therefore there does not 
appear to be any difference in the catalytic activity of topoisomerase II 
between CALU-3 clone 4 and CALU-3/10'^M VP16.
Since there is no difference in topoisomerase II activity 
between the parental and resistant CALU-3 cell lines, the possibility of 
mutation of topoisomerase II was investigated which can also render a cell 
insensitive to topoisomerase II inhibitors (Takano et al., 1992). This was 
achieved by attempting to inhibit the topoisomerase II activity in 
CALU-3/10"^M VP16 by the addition of VP16 to biochemical assay 
reactions. The same assay was shown in Chapter 4 with the three cell lines, 
CALU-3, L-DNA and SK-MES-1. Figure 6.3 shows the results of the 
inhibition assay with CALU-3/lO'^M VP16. Formation of monomer 
minicircles, indicative of topoisomerase II catalytic activity, can be seen to be 
inhibited in reactions containing 100 and 200piM VP16 (lanes 4 and 5). A 
small amount of topoisomerase II activity remains, however, when cells are 
treated with 50piM VP16 (lane 3). Therefore, the topoisomerase II in the 
CALU-3/10"^M VP16 cell line is sensitive to inhibition by VP16, thus neither 
reduction in topoisomerase II expression nor alterations to the topoisomerase 
II molecule appear to be responsible for the VP16 drug resistance in 
CALU-3/ 10*5 M VP16.
Flow Cytometry
As mentioned in section 6.1, there are two major proteins 
which have been implicated in the development of drug resistance in vitro, 
these being P-glycoprotein and MRP. The level of P-glycoprotein was 
measured in both CALU-3 clone 4 and CALU-3/lO'^M VP16. As a control, 
the A2780 and A2680/Adr cell lines were analysed since it is known that 
A2780/Adr overexpresses P-glycoprotein (Rogan et al. , 1984; Sugawara et al., 
1988; Van der Bliek et al., 1988). Figure 6.4 shows the results of flow 
cytometry using A2780 and A2780/Adr with MRK16 and JSB1, independent 
anti-P-glycoprotein antibodies. Panels (A) and (B) show the results of 
incubation of A2780 cells with MRK16 and JSB1 antibodies, respectively. 
Panels (C) and (D) show results of incubation of A2780/Adr cells with 
MRK16 and JSB1 antibodies, respectively. Empty peaks correspond to 
isotype control samples, and coloured peaks correspond to incubation with
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Figure 6.3
Inhibition of topoisomerase II activity by VP 16
Crude nuclear extract from the CALU-3/10"^M VP16 resistant cell 
line was assayed for decatenation activity in the presence of 
increasing concentrations of VP 16.
Lane 1: no drug, no nuclear extract 
Lane 2: no drug, DMSO diluant control, Lane 3: 50yM  VP16, 
Lane 4: lOOjiM VP16, Lane 5: 200//MVP16 
k=kinetoplast DNA, m=monomer minicircles
1.25pig of protein was used in each reaction
From this figure it can be seen that VP16 is capable of inhibiting 
topoisomerase II activity in CALU-3/10'^M VP16.
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Figure 6.4
Flow cytometry graphs of P-glycoprotein status in 
A&B:  A2780, C & D: A2780/Adr
Samples shown in plots A & C were analysed using the JSB1 
antibody against P-glycoprotein
Samples shown in plots B & D were analysed using the MRK16 
antibody against P-glycoprotein
Empty peaks indicate isotype control samples 
Coloured peaks indicate samples incubated with 
anti-P-glycoprotein primary antibody
X-axis: FTTC fluorescence level 
Y-axis: Cell number
Plots A and B (A2780) show that there is very little positivity for 
P-glycoprotein in this cell line since the coloured peak only shifts 
very slightly along the X-axis from the control peak, indicating low 
FITC fluorescence.
Plots C and D (A2780/Adr) show the high expression of 
P-glycoprotein which has previously been characterised in this cell 
line. This is shown by a large shift of the coloured peak along the 
X-axis from the control peak, indicating high levels of FITC 
fluorescence.
Therefore, P-glycoprotein expression is seen in the A2780/Adr 
resistant cell line using the two independent antibodies.
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anti-P-glycoprotein antibodies. FITC fluorescence is shown along the x-axis 
in all four panels. With A2780 cells, the control peak and the MRK16/JSB1 
peaks are almost super-imposed on one another, thus there is very little P- 
glycoprotein expression in this cell line. With A2780/Adr, however, there is a 
large shift of both the MRK16/JSB1 peaks to the right of the isotype control 
peaks. Thus, the levels of FITC fluorescence are much higher in this cell line, 
indicating a high level of P-glycoprotein expression.
Figure 6.5 shows the same experiment performed using CALU- 
3 clone 4 and CALU-3/10"^M VP16 cells. Panels (A) and (B) show results of 
JSB1 and MRK16 incubation of CALU-3 clone 4 cells. Again, empty peaks 
show isotype control samples and coloured peaks show results obtained with 
anti-P-glycoprotein antibodies. Therefore, the same results are seen with 
CALU-3 clone 4 cells as was seen with A2780 cells, indicating that there is 
little expression of P-glycoprotein in this cell line. Panels (C) and (D) show 
the results of incubation of CA LU^/IO ^M  VP16 cells with JSB1 and 
MRK16 antibodies. It would therefore appear from these results that, as 
observed in the parental clone 4 line, CALU-3/10"^M VP16 cells do not 
express P-glycoprotein.
Western Analysis for MRP
Since from the above experiments it appeared that P- 
glycoprotein was not responsible for the drug resistance in CALU-3/lO'^M 
VP16 it was decided to investigate the expression of the "atypical” drug 
resistance protein, MRP. Two independent experiments were performed to 
analyse MRP expression in the parental and drug resistant cell lines. One 
Western blot was incubated with the polyclonal rabbit anti serum against MRP, 
ASPKE, obtained from Dr. Melvin Center in Kansas. A different blot was 
sent to Dr. Susan Cole's laboratory in Canada and was incubated with their 
monoclonal antibody against MRP, QCRL-1. The results of this Western 
analysis are shown in Figure 6.6. Panel (A) shows the autoradiograph 
resulting from incubation of the Western blot with the ASPKE antibody. A 
band of approximately 190kD can clearly be seen in lanes 1 and 4, with a 
fainter band visible in lane 3. Protein samples from CALU-3 clone 4 and 
CALU-3/10-5M VP16 are present in lanes 3 and 4, respectively, of this 
Western blot. Therefore, it would appear that CALU-3/lO'^M VP16 has 
increased expression of the MRP protein compared to the parental clone. 
Lane 1 contains a sample of protein extract from the NSCLC cell line, L-
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Figure 6.5
Flow cytometry graphs of P-glycoprotein status in 
A&B: CALU-3 clone 4, C & D: CALU-3/10s M VP 16
Samples shown in plots A & C were analysed using the JSB1 
antibody against P-glycoprotein
Samples shown in plots B & D were analysed using the MRK16 
antibody against P-glycoprotein
Empty peaks indicate isotype control samples 
Coloured peaks indicate samples incubated with 
anti-P-glycoprotein primary antibody
X-axis: FITC fluorescence level 
Y-axis: Cell number
These plots show that there is very little P-glycoprotein detectable 
in either CALU-3 (plots A and B) or the CALU-3/10-5M VP16 
resistant cell line (plots C and D) since only a slight difference in 
X-axis position is observed between the two peaks.
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Figure 6.6
Detection of MRP (pl90) using Western analysis.
Blot A: Incubated with ASPKE, polyclonal antiserum against 
MRP, kindly provided by Dr. Melvin Center.
Lane 1: L-DAN, Lane 2: SK-MES-1, Lane 3: CALU-3 clone 4, 
Lane 4: CALU-3/10-5M VP16
Blot B: Incubated with QCRL-1, a monoclonal antibody against 
MRP. Incubation kindly performed by Dr. Susan Cole.
Lanel: L-DAN, Lane 2: SK-MES-1,
Lane 3: CALU-3 (heterozygous population),
Lane 4: CALU-3 clone 4, Lane 5: CALU-3/10-5M VP16
50pig of crude extract was loaded per lane for each cell line.
Molecular mass standards are shown in kilodaltons on the right of
each panel
Blots A and B both show higher levels of MRP expression in 
C A L U -3 /1 0 -5 m  VP16 (Blot A, lane 4  and Blot B, lane 5 )  than in 
the parental CALU-3 clone 4  cell line (Blot A, lane 3 and Blot B, 
lane 4 ) . Therefore, high expression of this protein may be the 
cause of the drug resistance in CALU-3/lO'^M VP16.
High expression of MRP is also seen in L-DAN (Lane 1 in both 
blots).
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DAN, which also appears to have high levels of expression of MRP. No MRP 
expression is detectable in SK-MES-1 (lane 2).
The result of independent analysis of a different Western blot 
by Dr. Susan Cole with a monoclonal antibody against MRP is shown in 
Figure 6.6, panel (B). Using this antibody, a band of approximately 190kD 
can be seen in all lanes on the Western blot. Protein samples from CALU-3 
clone 4 and CALU-3/10"^M VP16 are in lanes 4 and 5, respectively, on this 
blot. Lane 3 contains protein extract from the heterozygous CALU-3 
population. Thus, low levels of MRP expression are seen in both the overall 
CALU-3 population, and in the CALU-3 clone 4 cells. The level of MRP 
expression in CALU-3/10'^M VP16 cell line appears to be higher than in 
either of the other two CALU-3 populations. Therefore, these results repeat 
the findings shown with the ASPKE antiserum. Interestingly, this blot again 
shows the high level of expression of MRP in L-DAN (lane 1) and MRP 
expression is also detectable in SK-MES-1 (lane 2).
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6.3 Discussion
There are several mechanisms of drug resistance in both cell 
lines and tumours, as previously described in section 6.1. The aim of this 
section of work has been to deduce the mechanism of drug resistance in a cell 
line, CALU-3/10"^M VP16, which displays an 8-fold resistance to VP16 
when compared to the VP16-sensitive parental cell line, CALU-3 clone 4, as 
well as being highly cross resistant to doxorubicin and vincristine. The 
mechanisms of resistance that were analysed were possible alterations to 
topoisomerase II, with respect to genetic changes, expression levels and 
mutations to the molecule itself, overexpression of P-glycoprotein and 
overexpression of the multidrug resistance-associated protein, MRP.
The data presented in this chapter has revealed that the drug 
resistant, non-small cell lung adenocarcinoma cell line CALU-3/lO'^M VP16 
does not appear to have any change in expression of, or alteration to 
topoisomerase II when compared to the sensitive, parental CALU-3 clone 4. 
This has been shown by Western blotting (Figure 6.1) and biochemical assays 
(Figures 6.2 and 6.3). In the Western blotting data, however, only the 
topoisomerase IIa  isoform has been detected and by biochemical assay it is 
not possible to distinguish activity of the two topoisomerase II isoforms. 
Therefore, it should not be ruled out that changes may have occurred to 
topoisomerase IIp. The finding that topoisomerase IIa , at least, does not 
appear to be affected in CALU-3/10"^M was quite a surprising result, as it 
was assumed that since the parental CALU-3 clone 4 cell line overexpressed 
topoisomerase Ila , the favoured mechanism of creating a drug resistance 
when challenged with a topoisomerase II inhibitor would be to reduce the 
expression of topoisomerase II.
Following this finding, alternative mechanisms which can also 
result in topoisomerase II inhibitor drug resistance were investigated. The 
possibility that the drug resistance in CALU-3/10‘^ M VP16 was caused by 
overexpression of P-glycoprotein was ruled out by flow cytometry analysis 
performed using two independent monoclonal antibodies, JSB1 and MRK16 
(Figure 6.5). These antibodies are truly independent as they each recognise 
different epitopes of the P-glycoprotein molecule (JSB1 recognises an internal 
epitope and MRK16 recognises an external epitope). Since a positive result 
was obtained with the control cell line, A2780/Adr, an adriamycin resistant 
ovarian carcinoma cell line which is known to overexpress P-glycoprotein 
(Rogan et al., 1984; Sugawara et al., 1988; Van der Bliek et al., 1988), this
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proves that the experiment had worked and that the negative results observed 
with CALU-3 clone 4 and CALU-3/ 10"^M VP16 were true negatives.
Studies of P-glycoprotein expression in lung tumours and lung 
tumour cell lines have found no correlation between MDR1 gene expression 
and in vitro drug sensitivity of cells (Lai et al., 1989; Shin et al., 1992). Both 
of these papers showed a low level of MDR1 mRNA in all samples which 
were analysed, including any normal samples. Out of 114 lung tumours and 
cell lines analysed in both these studies, only 3 samples displayed low levels 
of MDR1 gene amplification (Shin et al., 1992). Even clinical trials involving 
the use of modulators of P-glycoprotein mediated multidrug resistance show 
that very little effect of these agents is seen in solid tumour types (see Raderer 
& Scheithauer, 1993 for review). This leads one to propose that another 
mechanism may be responsible for the drug resistance seen in these tumours.
Since CALU-3/ 10'^M VP16 did not express P-glycoprotein, it 
was decided to analyse the multidrug resistance-associated protein (MRP) 
levels in this cell line. MRP has previously been found to be overexpressed in 
a number of lung tumour cell lines (Baas et al., 1990; Cole et al., 1992; 
Marquardt et al., 1990; Mirski et al., 1987) and so was a good candidate to be 
involved in the resistance of the CALU-3 line. Initial investigations into MRP 
expression were performed using the ASPKE polyclonal antiserum against the 
MRP protein from Dr. Melvin Center in Kansas (Figure 6.6, panel A). This 
was the first evidence that MRP was overexpressed in CALU-3/10'^M VP16 
as compared to CALU-3 clone 4. Following this initial result, a protein blot 
was sent to Dr. Susan Cole, one of the first people to characterise an MRP- 
expressing cell line (Cole et al., 1992; Cole et al., 1991), where the blot was 
probed with a monoclonal antibody against MRP, QCRL-1 (Figure 6.6, panel 
B). This antibody, again, showed elevated levels of MRP in the VP16 
resistant CALU-3 cell line when compared to CALU-3 clone 4. Therefore, it 
is proposed that overexpression of MRP plays a role in the drug resistance 
observed in CALU-3/10“^ M VP16.
Further work remains to be performed with CALU-3/lO'^M 
VP16 to investigate whether the MRP gene is amplified in this cell line. 
Various FISH studies could be carried out to confirm this, including whole 
chromosome 16 paint analysis (since the MRP gene has been located to 
chromosome 16p (Cole et al., 1992)) and single copy gene analysis, providing 
a cosmid probe for MRP could be found. Initial FISH studies with a plasmid 
carrying a full length cDNA for MRP, pJ3-MRP (kindly provided by Drs. 
P.Borst and G. Zaman), have proved unsuccessful.
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It should be noted that proteins other than MRP have also been 
found to be associated with drug resistance in studies using non-P- 
glycoprotein mediated multidrug resistant cell lines (Scheper et al., 1993). 
This study found overexpression of a 1 lOkD protein (pi 10) in a drug resistant 
cell line which was known not to express P-glycoprotein. Expression of p i 10 
was reduced in revertants from the drug resistant cell line. Thus, there would 
appear to be the possibility that multidrug resistance, at least in in vitro 
derived cell lines, may be caused by a variety of proteins which could all be 
related.
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CHAPTER 7
GENERAL DISCUSSION
The work presented in this thesis has involved the 
characterisation of an amplicon on chromosome 17 in the non-small cell lung 
adenocarcinoma cell line CALU-3. It has been shown that the TOPO IIa, 
ERBB2, RARa and G-CSF genes, and the cosmid C05123 from an unknown 
locus are all contained within an amplified region which is present on three 
separate chromosomes in CALU-3. The PKCa, NM23H1 and NF1 genes 
were also analysed and shown to be outside the region of amplification in 
CALU-3. Co-localisation studies demonstrated that the TOPO Ila , ERBB2, 
RARa, NM23H1, NF1 and C05123 gene cosmids all remained associated 
with chromosome 17-specific sequences. This is an important point since 
previous studies have observed that amplified sequences can remain at the 
original locus and can also be translocated to unrelated chromosomes (Roelofs 
et al., 1992). These chromosomal translocation events are associated with the 
mechanism of amplification. In addition, both amplified and non-amplified 
genes were also found to co-localise to the same regions. Such co-localisation 
studies have also been important in providing structural detail of the amplicon. 
Much of the previous data concerning structural data of amplicons has been 
derived from in vitro selected drug resistant cell lines where the amplification 
of certain genes has been generated by exposure to particular drugs. This 
includes studies on amplified DHFR genes (Trask & Hamlin, 1989) and CAD 
gene amplification (Smith et al., 1990). Both of these studies show a 
laddering effect of the amplified genes, indicative of amplification occurring 
via sister chromatid exchange, as discussed in Chapter 3. In comparison with 
these studies, the work presented in this thesis has involved the structural 
analysis of a "naturally" occurring amplicon, for which there has been no 
selective pressure applied. Therefore, it is interesting to note that small 
ladders of signal are detected for the amplified genes within the amplicon in 
CALU-3. This pattern of hybridisation of the single copy genes in CALU-3, 
together with the data showing association of the amplified genes with 
chromosome 17 centromere sequences, implies that the amplification in 
CALU-3 may have been brought about by initial sister chromatid exchange. 
The information gathered concerning the amplicon in CALU-3 is also 
extremely valuable since it is likely that such an amplicon exists in certain 
breast tumours (Keith et al., 1993; Murphy et a l, in press; Smith et a l, 1993),
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thus knowledge of the amplification of other genes from the 17q region may 
have an effect on the clinical treatment of these tumours.
In terms of analysing the structure of the amplicon in CALU-3, 
a recent technique has been developed which involves the micro-dissection of 
amplified regions and the production of microclone libraries (Guan et al., 
1992; Ray et al., 1994; Zhang et al., 1993). This approach would be useful 
for analysing the organisation of genes within the amplicon. For example, a 
recent study has successfully cloned and obtained a structure for amplified 
DNA sequences from double-minute chromosomes (Fakharzadeh et al., 
1993), with three genes found to be located on the circular double minute 
chromosome, arranged in two identical inverted repeats. Microdissection can 
also be used to generate probes for use in FISH. Recently, studies have used 
microdissected homogeneously staining regions in breast tumour cell lines as 
probes on normal metaphase chromosomes to deduce the origin of the 
amplified sequences (Guan et al., 1994). Interestingly, microdissected probes 
generated from a single homogeneously staining region in a drug resistant cell 
line were found to hybridise to at least four different chromosomal locations 
on a normal metaphase spread (Ray et al., 1994). This work emphasises the 
genuine complexity of gene amplification. Thus, if the 17q amplicon was 
microdissected from CALU-3 and hybridised back onto normal chromosomes, 
it would be interesting to see if all the sequences within the amplicon originate 
from chromosome 17q, and if they did, whether the genes amplified in 
CALU-3 were from a contiguous section of the chromosome.
The data presented in Chapter 3 indicates that ERBB2 is 
amplified to a greater extent than TOPO II a , which is in turn amplified more 
highly than RARa and C05123. The exact copy numbers of these genes were 
not able to be calculated, however, a computer programme has now been 
made available to the department which will hopefully enable such data to be 
generated through ratioing of the fluorescent signals. Differences in the level 
of amplification of ERBB2 and TOPO Ila  have also been noted in breast 
tumour samples (Keith etal., 1993; Smith etal., 1993). The study by Smith et 
al. found ERBB2 amplification to be higher than TOPO I la  amplification in 
three tumours which demonstrated co-amplification of these genes. In 
contrast, however, three tumours analysed by Keith et al. were found to have 
varying levels of ERBB2 and TOPO Ila  gene co-amplification, with two of 
these tumours exhibiting higher amplification of TOPO Ila  than ERBB2. 
Therefore, it may be that these variations in levels of gene amplification result 
from selective pressure in the tumours for the expression of particular genes. 
Thus, in different tumours there may be different selections applied. For there
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to be any selective pressure, however, the respective genes must be expressed 
within the tumour.
Expression analyses carried out in Chapter 4 have 
demonstrated that amplification of both the TOPO Ila  and ERBB2 genes 
leads to high expression of their protein products. This is an important aspect 
of the CALU-3 amplicon since previous studies have shown that genes within 
other multi-locus amplicons can be amplified as "silent partners", with no 
expression of the genes detected. This has been observed in the case of INT2 
and HSTF1 genes in the 1 lq amplicon (Fantl et al., 1990; Lafage et al., 1990; 
Tsuda et al., 1989) and the ERBA1 gene, co-amplified with ERBB2 in certain 
breast tumours (van de Vijver et al., 1987). Therefore, as suggested 
previously, it may be that expression of TOPO I la  and ERBB2 genes was 
selected for during the process of tumour evolution of CALU-3. It was also 
noted that the topoisomerase II a  encoded by CALU-3 is still capable of being 
stabilised in a drug/enzyme/DNA complex, and that the overall topoisomerase 
II content of CALU-3 has catalytic activity. Therefore, it appears that despite 
the high levels of amplification of the TOPO Ila  gene, there are no mutations 
of the enzyme. Bow cytometric analysis has revealed that although the 
topoisomerase I la  protein is present at high levels in CALU-3, the expression 
of the enzyme still appears to be cell cycle regulated. This is interesting since 
it is not known what the result of constitutive topoisomerase I la  expression 
would be on a mammalian cell. It may be that if expression of TOPO Ila  was 
deregulated that this would perhaps be toxic to the cell in some way.
Most of the work presented on topoisomerase II in this thesis 
has concentrated on the I la  isoform. This is mainly due to the lack of 
reagents available for detection of the topoisomerase II p isoform. Alternative 
methods could be used for the analysis of topoisomerase lip expression, such 
as RNase protection assays (Jenkins et al., 1992). This isozyme of 
topoisomerase II may well play a role in drug resistance as, interestingly, loss 
of the 3p region (the location of the TOPO lip gene) has been noted in both 
tumours and derived drug-resistant cell lines (Patel & Fisher, 1993; Yokota et 
al., 1987). Therefore, the approaches detailed in this thesis using molecular 
cytogenetic techniques would prove very valuable in investigations of possible 
loss of heterozygosity of the TOPO lip locus in tumours and cell lines.
From the data presented in Chapter 6 it is clear that drug 
resistance can be produced by a variety of mechanisms, including the 
expression of certain drug efflux pumps and/or alterations to the 
topoisomerase Ila  molecule. The detection of MRP overexpression in the 
CALU-3/lCL^M VP16 resistant line was unexpected. Since no alteration in
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topoisomerase I la  level was detected, this demonstrates that the phenotype of 
these cells is stable, even in the presence of topoisomerase II-targeting drugs. 
Therefore, it may be that in particular tumour types, upregulation of the MRP 
gene is the mechanism of choice when cells are challenged with certain anti- 
tumour agents. In fact, it appears that drug resistant lung tumour cell lines 
often express MRP (Barrand et al., 1994; Cole et al., 1992; Zaman et al., 
1993) and not P-glycoprotein. Since multidrug resistance usually appears to 
involve more than one mechanism, comparative genome hybridisation would 
be an extremely interesting approach to use with the sensitive parental and 
VP16-resistant CALU-3 cell lines described in Chapter 6. CGH is a powerful 
new molecular cytogenetic approach which involves the hybridisation of 
mixed tumour and normal DNA, each labelled with a different fluorochrome, 
to normal metaphase spreads. Gains or losses of sequences from the tumour 
can then be visualised by ratioing the different fluorochromes along each of 
the normal chromosomes. For example, a region of amplification would 
appear as an over-representation of the fluorochrome which the tumour DNA 
was labelled with. The opposite would obviously be seen in the case of gene 
deletions. This technique has been used for the analysis of genome-wide 
amplifications and deletions in a number of different tumour types (du Manoir 
etal., 1993; Kallioniemi etal., 1994; Kallioniemi etal., 1992a; Suijkerbuijk et 
al., 1994). The use of this technique would highlight any other, perhaps 
novel, regions of the genome in CALU-3/10'^M VP16 where genetic 
alteration may have resulted in an effect on drug resistance.
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